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Abstract
Total chemical synthesis is an essential tool for the validation of natural product
structures and the discovery and elaboration of novel therapeutic scaffolds.
Chapter 1 (Part I) surveys existing treatments for trypanosomatid neglected
tropical diseases, and the synthesis of a novel class of antiparasitic cyclic
depsipeptides is reported (Chapter 2) alongside a full NMR assignment and
structure calculation using NMR-derived distance restraints. The synthetic
peptides exhibit activity profiles in agreement with published results, and a
series of ester-to-amide substitution analogues also synthesized show similar
low micromolar potency. Chapter 3 describes the synthesis of lassomycin,
a tuberculocidal lasso peptide reported to exhibit a unique unthreaded
topology. The naturally occurring peptide was synthesized alongside C-
terminally amidated and truncated analogues, but none were biologically
active. Given clear differences observed in the two-dimensional NMR data
for synthetic lassomycin, it is suggested that the reported natural product in
fact exists in the threaded form. The chemical synthesis of whole proteins is
addressed in Part II, and current progress in the field is reviewed (Chapter 4).
Work towards the total chemical synthesis of acyl carrier protein using a two
fragment approach is described in Chapter 5. The N-terminal fragment was
synthesized using the sulfonamide linker, and while the C-terminal fragment
presented difficulties due to extremely low solubility, solubilization using
backbone protection was demonstrated. The development of a modified
Dawson linker for the synthesis of peptide N-acylureas without overacylation
is also described. Finally, Part III details the synthesis of tumor targeting
peptides used for imaging and inhibition of cancer cell growth, and which
cause tumor size reduction in vivo. A novel web utility used for the automated
assignment of peptide mass spectra throughout this thesis is also presented.
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Preface
The following thesis details a number of synthetic projects in peptide
chemistry, covering a range of peptide target sizes and applications in
biological research. Chapters 2 and 3 describe the total synthesis of a range
of newly discovered peptide natural products possessing potent and selective
antimicrobial activity. The usefulness of chemical synthesis in the elucidation
of structure-activity relationships is demonstrated, in addition to its role in
confirming (or disproving) published structural characterization for natural
products. The compounds presented in Chapter 2 are active against the
causative agents of a number of the so-called ‘neglected tropical diseases’,
and a concise review of existing treatments is given in Chapter 1. The peptide
described in Chapter 3 possesses a unique three-dimensional structure and is
active against Mycobacterium tuberculosis.
Chapter 5 is concerned with the total chemical synthesis of a 77-amino
acid protein involved in the biosynthesis of fatty acid natural products. A
selection of illustrative examples of published chemical syntheses of whole
proteins – representing an overview of the state of the art in the field –
are reviewed in Chapter 4. Peptide thioesters are essential intermediates
used in protein chemical synthesis, and a novel linker that can be used
for the microwave-assisted synthesis of peptide thioester equivalents is also
presented in Chapter 5.
The synthesis and fluorescent labelling of two tumor targeting peptides is
described in Chapter 6. Their use in cancer cell imaging, and their in vitro and
in vivo effectiveness against cancer cells and tumor xenografts respectively is
also reported. Finally, Appendix C details the synthesis and investigation into
sequence-activity relationships of a gene product found to be a regulator of
root growth in Arabidopsis. The effects of the synthetic peptide on root length
are documented. A number of publications arising as a result of the work
described are also summarized.
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Part I
Total synthesis of antimicrobial
peptide natural products

Chapter 1
Current and future therapies for
neglected tropical diseases
T he neglected tropical diseases are a group of 13 disabling chronicconditions that constitute the most common infections worldwide,affecting billions of people living below the poverty line.9 Thefollowing chapter summarizes their occurrence, geographical distri-
bution and current treatments, focusing specifically on those resulting from
trypanosomatid infection: Chagas disease, human African trypanosomiasis
(HAT) and leishmaniasis. The chapter concludes with an outlook towards
future therapies and the elucidation of novel parasitic drug targets. The
total synthesis and characterization of a series of compounds active against a
number of NTDs and malaria is described in Chapter 2.
1.1 Occurrence and geographical distribution
Neglected tropical diseases (NTDs) affect some of the poorest communities
in the world, up to 2.7 billion people who live on less than $2 a day.9 It
is estimated that NTDs cause over 500 000 deaths per year, and although
this number is small compared to that for other tropical diseases such as
malaria, their resulting contribution to severe disability and poverty means that
they constitute a significant burden on healthcare services worldwide. The
regions in which Chagas disease, HAT and leishmaniasis occur are summarized
on the map shown in Figure 1.1. Other diseases which come under the
NTD umbrella include three soil-transmitted helminth infections (ascariasis,
3
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hookworm infection, and trichuriasis), lymphatic filariasis, onchocerciasis,
dracunculiasis, schistosomiasis, Buruli ulcer, leprosy, and trachoma.9
Figure 1.1: Geographic distribution of Chagas disease, human African
trypanosomiasis (HAT) and leishmaniasis. Adapted from Cavalli et al.10
NTDs occur primarily in rural or poor urban areas of low-income countries
in sub-Saharan Africa, Asia, and Latin America.9 Because of this they receive
comparatively little attention from the pharmaceutical industry, due to the fact
that they offer little or no commercial incentive for drug development.11 It is
estimated that a central-nervous-system disorder or cancer drug has a 13-fold
greater chance of being brought to market than one for a neglected disease.12
Consequently for many NTDs treatment options are severely limited, and
current front-line treatments often have undesirable toxic side effects or
problems with antimicrobial resistance. A new generation of therapies is
therefore needed to tackle the growing problem, which will be discussed in
this chapter.
1.2 Symptoms and disease vectors
A description of the primary symptoms of Chagas disease, HAT and
leishmaniasis – and their associated vectors – is shown in Figure 1.2. All
three diseases result from infection by parasites of the order trypanosomatida.
4
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Figure 1.2: Summary of disease vectors and symptoms for the NTDs Chagas disease,
African trypanosomiasis and leishmaniasis.13
5
Total Synthesis of Bioactive Peptides and Whole Proteins
HAT (or sleeping sickness) is caused by infection with either of the
parasites Trypanosoma brucei gambiense or Trypanosoma brucei rhodesiense,
the former a chronic form of the disease present in western and central Africa,
and the latter an acute form found in eastern and southern Africa.14 HAT is
transmitted through the bite of an infected tsetse fly, and causes progressive
neurological damage upon crossing of the blood-brain barrier by the parasite,
leading to coma, severe organ failure, and eventually death if left untreated.13,14
Chagas disease is endemic to Latin America and is caused by the species
Trypanosoma cruzi, carried by the triatomine (or ‘kissing bug’).15 The parasite
is transmitted when the insect defecates on the victim’s skin whilst taking a
blood meal. T. cruzi can enter the host through broken skin, such as cuts,
abrasions or the insect bite, or it can penetrate the soft skin of the eyes and
mouth. The initial acute infection often presents with only relatively mild
symptoms, such as swelling of lymph nodes and tissues, conjunctivitis and
skin lesions. The chronic infection can persist unnoticed for more than 30
years, and can lead to complications such as abnormal heart rhythm, heart
failure, digestive problems and sudden cardiac death. Chagas disease affects
10–12 million people, and is responsible for over 15 000 deaths yearly.15
Leishmaniasis is most commonly caused by the parasites Leishmania
donovani and L. infantum/L. chagasi, transmitted by the bite of an infected
female phlebotomine sand fly.16 The disease typically occurs in two forms:
cutaneous, which causes skin ulcerations lasting months to years and often
resulting in severe scarring, and visceral, which affects internal organs,
especially the spleen, liver, and bone marrow. If left untreated, severe
visceral leishmaniasis is often fatal. It is estimated that 2 million new cases of
leishmaniasis occur each year.16
1.3 Existing treatments
Existing drugs for NTDs often suffer from severe toxic side effects. In
addition, many are increasingly ineffective due to the problem of antimicrobial
resistance. Figure 1.3 shows the current front-line treatments for HAT, Chagas
disease and leishmaniasis.
Benznidazole (2) and nifurtimox (1), first used to treat Chagas disease
in 1974 and 1970 respectively, are nitroheterocyclic prodrugs that undergo
activation by nitroreductases (NTRs) within the parasite.18 This results in
6
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Figure 1.3: Structures of widely used or recently introduced therapies for Chagas
disease, HAT and leishmaniasis. Current drugs carry risks of severe adverse effects,
problems with antimicrobial resistance and/or a lack of efficacy in the later disease
stages.10,17
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the production of reactive moieties, potentially producing a cytotoxic effect
through the promotion of DNA damage and/or induction of oxidative stress,
although the nature and extent of these processes are not fully understood.
Cases resistant to treatment with nitroheterocyclic therapies are commonly
reported, and resistant parasites can be selected in the laboratory.19 It is
suggested that benznidazole resistance in T. cruzi arises due to a number of
mechanisms, one of which involves mutations in the gene which encodes the
nitroreductase TcNTR.20
Eflornithine (5), the front-line therapy against HAT (first used in 1991),
is an ornithine analogue that targets parasitic ornithine decarboxylase
(ODC).21 Inhibition of ODC causes a reduction in polyamine biosynthesis
and diminished production of trypanothione (8, Figure 1.4), the redox active
metabolite occurring exclusively in trypanosomatids and essential for their
survival.22 Interestingly, nifurtimox/eflornithine combination therapy has been
found to be effective against the Gambian form of HAT (T. b. gambiense),
resulting in cure rates of ∼97%, and has consequently been added to the
WHO Essential Medicines List.23 Eflornithine resistance resulting from the
loss of a single amino acid transporter gene has been demonstrated.21
NH2
O
H
N
SH
O
N
H
O
H
N
HN
N
H
O
H
N
O
SH
N
H
O
NH2
O
HO
O
HO
8
Figure 1.4: Trypanothione (8) consists of two glutathione molecules joined by a
spermidine linker (shown in red). Trypanosomatids have evolved a unique thiol-
redox system centred on 8.22
Pentamidine (3, 1939) is the front-line treatment for early-stage T. b.
gambiense infection, but cannot cross the blood-brain barrier, and so is
ineffective once the parasite has entered the central nervous system.24
Melarsoprol (4, 1949), the only available treatment in the late stage of infection
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by the T. b. rhodesiense subspecies, acts by inhibiting parasite glycolysis.24,25
However, 4 exhibits considerable toxicity, killing 5% of HAT patients receiving
this treatment.21 Cross-resistance to pentamidine and melarsoprol was first
observed over 60 years ago, and has been linked to genetic changes in T.
brucei transport proteins and aquaglyceroporins.26
Amphotericin B (6, 1990) is used for the treatment of visceral leishmaniasis,
and while drug toxicity can be reduced by administration as a colloidal
dispersion, this option is more expensive.27,28 Miltefosine (7, 2002) is also
used to treat visceral leishmaniasis, although its associated teratogenicity
means that pregnancy must be avoided until at least two months after
treatment.29 The mechanism of action is not fully understood for either 6
or 7.29,30 While pore formation leading to depolarization of the membrane
is assumed to be responsible for the cytotoxicity of amphotericin B, auto-
oxidation and subsequent formation of free radicals may also play a part.30
It is suspected that miltefosine and other alkyl-lysophospholipids can trigger
programmed cell death (apoptosis), although the way that this occurs is not
currently understood.29
Miltefosine is highly vulnerable to resistance due to its long half-life, and
it is suggested that this arises due to suppression of oxidative stress-induced
apoptosis.31 Resistance to amphotericin B in Leishmania donovani may arise
from alteration of parasitic membrane composition and fluidity, in addition to
upregulation of the thiol metabolic pathway and overexpression of drug efflux
machinery.30
1.4 Target validation and future therapies
There are very few validated molecular targets for parasitic diseases.32 As
can be seen from the previous section, the mechanism of action is not
well understood for any of the drugs currently available for the treatment of
trypanosomatid infections. The only exception is the ornithine decarboxylase
inhibitor eflornithine (5), described previously.32 Continued research into the
validation of targets for existing antiparasitic drugs is therefore required, in
addition to the discovery of new targets. Phenotypic screening can be used
to ascertain the importance of a given molecular target for cell survival. This
information can then be used to guide the selection of targets to use in target-
based approaches, such as enzyme inhibition assays.
9
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N-Myristoyltransferase (NMT) is an example of an enzyme found to be
essential for survival in T. brucei, as elucidated through RNA interference
(RNAi) studies.33 NMT is responsible for myristoylation of the N-terminal
glycine of a number of different peptides.32 Brand et al. used high throughput
screening followed by binding optimization to identify NMT inhibitors with
nanomolar potency.34,35 The lead molecule in the study (9, IC50 = 2 nM) was
found to cure rodent models of peripheral HAT infection. A crystal structure
of 9 bound to NMT is shown in Figure 1.5.
Figure 1.5: X-ray crystal structure of 9 bound to N-myristoyltransferase (NMT), PDB
ID: 2WSA.34,36
Many other potential enzyme targets exist in trypanosomatida, such as
inositol-3-phosphate synthase, glucose-6-phosphate dehydrogenase, Long
chain fatty acyl-CoA synthetase, and the cysteine peptidases, histone
deacetylases and topoisomerases.11 The sterol 14-α-demethylase inhibitors
posaconazole and E1224 (a prodrug of ravuconazole) are active against Chagas
disease and are currently in clinical trials.32,37 In vivo efficacy was recently
reported for a selective inhibitor of the kinetoplastid proteasome.38 Other
10
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possible targets include parasite surface glycoconjugates, and pathways such
as apoptosis, cAMP signalling, glycolysis and lipid biosynthesis.11
Antimicrobial peptides (AMPs) have also been shown to be active against
NTD-causing parasites, either through direct membrane or capsid interactions
leading to membrane disruption, or by involvement in immunoregulatory
processes such as angiogenesis, cell proliferation, cytokine regulation,
leukocyte chemotaxis, degranulation of mast cells, stimulation of phagocytosis
and even modulation of gene expression.39 AMPs offer promise due to
their broad spectrum of activity and limited probability of inducing pathogen
resistance.
1.5 Conclusions and future work
It can be seen that sustained effort towards the discovery of improved drugs
for NTDs is vitally important in the face of increasing resistance to current
therapies. While this necessarily involves the improvement of available drugs
and the elucidation of their mechanisms of action (many of which are poorly
understood), a significant drive to elucidate new molecular targets in parasites
is also necessary. The next chapter details the total synthesis of a number
of newly discovered compounds found to be active against T. brucei and T.
cruzi, in addition to Plasmodium falciparum – a causative agent of malaria.
Investigations into the relationship between their molecular structure and
activity are also described.
11

Chapter 2
Synthesis of the ‘chaiyaphumine’
series of antiparasitic natural
products
V ector-borne protozoan infections constitute a major burden onhealthcare services throughout the world. As discussed inChapter 1, neglected tropical diseases represent a significantproportion of this burden. In addition, malaria – caused by
protozoan parasites belonging to the genus Plasmodium – accounts for more
than 1 million deaths per year worldwide.40 Living organisms are a rich
source of privileged molecular scaffolds for use in the search for bioactive
candidates as leads in pharmaceutical development.41,42 Numerous peptide
natural products are produced by organisms such as fungi and bacteria, and
these often offer promising leads in drug research.
The following chapter details the total synthesis of a newly discovered
class of cyclic peptide natural products found to possess biological activity
against the parasitic agents responsible for Chagas disease, human African
trypanosomiasis and malaria. The synthesis of a series of more stable
analogues that retain biological activity is also described.
2.1 Introduction
A suite of novel cyclic depsipeptides, termed ‘chaiyaphumines’, was recently
isolated from Xenorhabdus sp. by Grundmann et al.43 A number of members
13
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were found to be active against T. brucei, T. cruzi, and P. falciparum,
the causative agents of HAT, Chagas disease and malaria respectively (see
Chapter 1). In order to confirm their structure and investigate the relationship
between chaiyaphumine structure and antiparasitic activity, a total synthesis
of the previously discovered compounds was proposed.
The general structures of the chaiyaphumines isolated are summarized in
Figure 2.1. The sequence contains D-alanine and D-phenylalanine, in addition
to an ester bond between the C-terminus and threonine side chain hydroxyl
group. The N-terminus is acylated with a carbonyl fragment bearing an R-
group which depends on the compound (shown).
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Figure 2.1: Isolated chaiyaphumine structures.43
Due to the absence of reactive side chain functionality, it was decided that
a solution-phase cyclization approach would be the most straightforward for
the total synthesis of the chaiyaphumines. This would involve formation of
the ester bond in solution between the threonine side chain and C-terminus
of the fully deprotected peptide. A similar approach was used in the total
synthesis of the natural product lassomycin, described in Chapter 3. In order
to elucidate the importance of the potentially labile ester bond, the synthesis
of a set of analogues where the ester bond has been replaced by an amide
linkage was also proposed and is described below.44
A retrosynthesis is given in Scheme 2.1. Routes to both the natural
structures (10a–d) and amide-linked analogues (11a–d) are shown. The
required sequence is synthesized via SPPS followed by installation of a range
of N-terminal capping groups via acylation with the appropriate acid chloride
or acetic anhydride. Following global deprotection and cleavage from the
14
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resin, a final solution-phase cyclization step furnishes the target peptide. The
synthesis and characterization of the chaiyaphumine ester and amide-linked
analogue series is described in the following sections.
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Scheme 2.1: Retrosynthetic route for chaiyaphumines and chaiyaphumine analogues
(Nu = NH2 or OH, R = H or CH3 respectively, P = protecting group). R’ variesacross the range of chaiyaphumines isolated (see text).
2.2 Synthesis of chaiyaphumine ester series
The synthetic route used for chaiyaphumines 10a–d is shown in Scheme 2.2.
Due to the presence of a proline residue close to the C-terminus, the sterically
hindered 2-chlorotrityl linker was used to prevent diketopiperazine formation
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early in the synthesis. The required sequence was synthesized via SPPS
followed by installation of the appropriate N-terminal capping group via
acylation with either 2-phenylacetyl, butyryl or propionyl chloride, or acetic
anhydride. Cleavage from the resin and global deprotection was carried out
using 95% TFA to give linear precursors 12a–d, as confirmed by LCMS.
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Scheme 2.2: Synthesis of chaiyaphumines 10a–d. Reagents and conditions: (i) Fmoc-Trp(Boc)-OH (1.0 equiv) and DIPEA
(5.0 equiv), DMF, RT, 2 × 1 h; (ii) MeOH, RT, 15 min; (iii) Fmoc SPPS (see Experimental section); (iv) RCH2COCl or (CH3CO)2Ofor 10d (5.0 equiv), DIPEA (10 equiv), DMF, RT, 2 × 1 h; (v) TFA (95%, water), TIPS, RT, 3–4 h; (vi) PyBOP® (3.0 equiv) and
DIPEA (6.0 equiv) or EDCI/DMAP/HOBt for 10b (see text), DMF, RT, 5 h (high dilution).
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The cyclization step was carried out in solution at high dilution using a
final peptide concentration of 0.003 M. The required total volume of DMF
was calculated for each peptide, and a fifth of this was taken to dissolve the
crude linear precursor. This solution was added dropwise over a period of
2 h to a stirred solution of PyBOP® (3.0 equiv) and DIPEA (6.0 equiv) in the
remaining volume of DMF, and the reaction mixture was stirred for a further
3 h. Removal of the solvent under vacuum, followed by reversed-phase HPLC
purification of the crude residue yielded chaiyaphumines 10a–d. Peptides
10a and 10c were obtained in high purity by this method, as confirmed by
analytical HPLC and ESI-MS (see below).
Peptide 10d proved impossible to separate from the tripyrrolidinophos-
phine oxide by-product produced during amide bond formation using PyBOP®
during the cyclization step (m/z = 258.2), due to their coelution during
HPLC purification. The cyclization was therefore repeated using the coupling
reagent HATU, although this resulted in a second impurity (m/z = 784.4) that
also proved impossible to remove from the final product (see chromatogram
for 10d in Figure 2.2). The by-product was hypothesized to result from
capping of the linear peptide by HATU (due to the initial large excess of
the activator under the conditions used), thus preventing cyclization. While
the synthesis of 10b also initially produced a similarly impure product,
subsequent optimization of the reaction and cleavage conditions, using
syringe pump control with EDCI/DMAP/HOBt activation (as described in the
Experimental section) significantly improved product quality.45 Optimization
of the synthesis of 10d using alternative conditions for ester formation is
ongoing. ESI-MS and analytical HPLC data for synthetic chaiyaphumines 10a–
d are shown in Figure 2.2.
2.3 Comparison with naturally isolated material
In order to compare the synthetic material with the natural product, a co-
injection of 10a with its naturally isolated counterpart was performed under the
conditions described previously (Helge Bode, Goethe Universita¨t Frankfurt).43
A slight difference in retention time was observed for synthetic and natural
chaiyaphumine (Figure 2.3), and in order to confirm the absolute configuration
of the amino acids in both compounds, the advanced Marfey’s method
was used as described previously (chromatograms shown in Figure 2.4–
18
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Figure 2.2: ESI-MS data (left) and HPLC traces (right) for synthetic chaiyaphumines
10a–d. Labelled MS peaks are for [M + H]+ ion. Absorbance recorded at
220 nm, gradient 0-100% B over 30 or 10 min as indicated for 10b (A = 5:95:0.05
MeCN/H2O/TFA; B = 95:5:0.03 MeCN/H2O/TFA). The chromatogram for 10dexhibits a double peak (see text).
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Figure 2.8).46–48 No difference in the amino acid configuration was observed
however. It is therefore suggested that the differences in retention time and
NMR data (below) might be the result of proline cis/trans isomerisation as
observed by Zhou et al. for proline-containing xenoamicines, which naturally
exhibit two distinct peaks for each mass.49
Figure 2.3: HPLC/MS of extracted ion chromatograms (EIC m/z 721.3 [M + H]+) for
analysis of natural (top) and synthetic (middle) chaiyaphumine 10a, and co-injection
of both (bottom). Conditions as previously described.43
20
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Figure 2.4: Advanced Marfey’s analysis of synthetic 10a and naturally isolated
chaiyaphumine for the amino acid tryptophan (EIC m/z 499.0 [M + H]+).
21
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Figure 2.5: Advanced Marfey’s analysis of synthetic 10a and naturally isolated
chaiyaphumine for the amino acid proline (EIC m/z 410.0 [M + H]+).
22
Chapter 2. Synthesis of the antiparasitic chaiyaphumines
Figure 2.6: Advanced Marfey’s analysis of synthetic 10a and naturally isolated
chaiyaphumine for the amino acid alanine (EIC m/z 384.0 [M + H]+).
23
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Figure 2.7: Advanced Marfey’s analysis of synthetic 10a and naturally isolated
chaiyaphumine for the amino acid phenylalanine (EIC m/z 460.0 [M + H]+).
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Figure 2.8: Advanced Marfey’s analysis of synthetic 10a and naturally isolated
chaiyaphumine for the amino acid threonine (EIC m/z 414.0 [M + H]+).
25
Total Synthesis of Bioactive Peptides and Whole Proteins
2.4 Synthesis of amide-linked chaiyaphumine
analogues
With a successful synthetic route to the chaiyaphumines in hand, it was
decided that a series of more stable lactam analogues should be synthesized
in order to evaluate their biological activity alongside the natural products.44
A synthesis of the proposed derivatives, in which the ester bond has been
replaced by an amide linkage that is less susceptible to hydrolysis, is
outlined in Scheme 2.3. The synthetic route used previously for 10a–d
(Scheme 2.2) was repeated, instead incorporating the non-proteinogenic L-
diaminopropionic acid (Dpr) in place of threonine. N-terminal acylation,
cleavage and cyclization steps were then carried out as previously described,
furnishing chaiyaphumine lactam analogues 11a–d, confirmed by analytical
HPLC and ESI-MS (Figure 2.9).
Some dimerization was observed during the synthesis of peptide 11b,
and cyclic dimeric by-product 20 (Figure 2.10) was observed in certain HPLC
fractions. Figure 2.10 illustrates how singly-charged (monomeric) 11b is
impossible to distinguish from the doubly-charged (dimeric) 20 by m/z value
alone (also the case for singly-charged 20 and singly-charged dimeric species
formed from 11b during ESI-MS analysis, shown). It was possible to confirm
the charge state of the molecular ion peak in each case, however, by inspection
of the isotopic envelope observed at high resolution to determine∆m. A similar
analysis was carried out on all peptides synthesized to ensure dimers were not
present in the final products. A reduction in dimer formation was observed
when additions of the linear precursor peptides were carried out under syringe
pump control in order to reduce addition rates and increase reaction mixture
dilution.50
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Scheme 2.3: Synthesis of amide-linked chaiyaphumine analogues 11a–d. SPPS
and solution-phase cyclization were carried out as in the previous synthesis, instead
incorporating L-diaminopropionic acid in place of threonine (resin loading and initial
peptide elongation steps not shown). Reagents and conditions: (i) RCH2COCl or(CH3CO)2O for 11d (5.0 equiv), DIPEA (10 equiv), DMF, RT, 2 × 1 h; (ii) TFA (95%,water), TIPS, RT, 3–4 h; (iii) PyBOP® (3.0 equiv) and DIPEA (6.0 equiv), DMF, RT, 5 h
(high dilution, see text).
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Figure 2.9: ESI-MS data (left) and HPLC traces (right) for amide-linked chaiyaphumine
analogues 11a–d. Labelled MS peaks are for [M + H]+ ion. Absorbance recorded
at 220 nm, gradient 0-100% B over 30 min (A = 5:95:0.05 MeCN/H2O/TFA; B =95:5:0.03 MeCN/H2O/TFA).
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Figure 2.10: Low resolution ESI-MS analysis of fractions obtained during HPLC
purification of crude peptide 11b. Both the target peptide and covalent dimer 20
are observed, but cannot be distinguished by their m/z values alone at this resolution.
Determination of the charge state of the molecular ion species present in each fraction
enabled assignment to either the monomeric or dimeric peptide (see text).
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2.5 Biological testing
Synthetic chaiyaphumines 10a and 10c, and analogues 11a–d were screened
for antiparasitic activity against Trypanosoma brucei rhodesiense, Trypanosoma
cruzi, Plasmodium falciparum and Leishmania donovani (Marcel Kaiser, Swiss
Tropical and Public Health Institute). Cytotoxic activity was determined against
mammalian L6 cells. The bioactivity data are summarized in Table 2.1.
30
Table 2.1: Antiparasitic activity and cytotoxicity data for chaiyaphumines 10a and 10c and amide-linked analogues 11a–d.
Literature values for the naturally isolated peptides published previously are shown in brackets.43
Compound IC50 /µMT. b. rhodesiense T. cruzi P. falciparum L. donovania L6
10 a 7.96 (5.11) 9.01 (56.4) 2.96 (0.61) >10 >10 (92.25)
c 60.9 (77.58) 90.0 (98.94) 21.6 (15.4) >100 >100 (>151)
11 a 61.4 76.7 2.87 >100 >100
b 7.00 8.67 4.7 >10 >10
c 5.93 8.18 >5 >10 >10
d 63.1 79.5 >50 >100 >100
Refb 0.01 (0.01) 1.91 (1.73) 0.004 (0.006) 0.127 0.016 (0.02)
a Axenic amastigotes.
b Melarsoprol (T. b. rhodesiense), benznidazole (T. cruzi), chloroquine (P. falciparum),
miltefosine (L. donovani) or podophyllotoxin (mammalian L6 cells).
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Synthetic peptides 10a and 10c had similar activity profiles to those of the
naturally isolated versions published by Grundmann et al.43 Propionyl deriva-
tive 10c exhibited negligible inhibitory activity against T. brucei (60.9 µM) and
cruzi (90.0 µM), and only weak activity against P. falciparum (21.6 µM), as
previously described. Phenylacetyl chaiyaphumine 10a displayed the inverse
profile, with activity against T. brucei (7.96 µM), cruzi (9.01 µM) and P.
falciparum (2.96 µM), in agreement with published results except for T.
cruzi, against which the naturally isolated peptide showed negligible activity
(56.4 µM).
Interestingly, the opposite appears to be true for amide-linked chaiya-
phumine analogues 11a–d. While alkyl derivatives 11b and 11c exhibit
antiparasitic activity (5-9 µM), phenylacetyl derivative 11a exhibits negligible
activity against all parasites (>60 µM), with the exception of P. falciparum
(2.87 µM). Reducing alkyl chain length, as in the case of 11d, appears to have
a deleterious effect on activity (>50 µM). This difference in activity profile
observed for the amide variants may suggest that the lability of the ester bond
present in 10a is important for its biological activity, and that some form of ring-
opening and linearization may occur in its mechanism of action. Furthermore,
the fact that analogue 11a appears to contradict this trend, exhibiting activity
against P. falciparum when 10c does not, may point to a different target for
this compound in P. falciparum than in Trypanosoma.
The differing activity profile may also be a result of possible decreased cell
permeability of the amide analogues. The replacement of an ester bond with a
primary amide necessarily introduces a hydrogen bond donor into the peptide
structure, which can negatively affect cell permeability.51 The effect of this
modification will of course depend on whether the peptides in question act on
cell-surface or intracellular targets. The introduction of a methyl group onto
the Dpr side chain/Trp C-terminal amide nitrogen of amides 11a–d would
remove hydrogen bonding potential, and would be useful for investigating the
effect of hydrogen bonding ability on biological activity (see below).52
None of the synthetic peptides showed any appreciable inhibitory activity
against Leishmania donovani at the concentrations tested. Significant
cytotoxicity against mammalian L6 cells was not observed for any of the
peptides tested.
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2.6 NMR characterization
2.6.1 Spectral assignment
Structural characterization of 10a was carried out using NMR spectroscopy.
2D 1H-1H COSY, 1H-13C HSQC, 1H-13C HMBC and 1H-1H NOESY NMR data
were collected and are given in Appendix A. Distinctive resonances such as
those belonging to the Trp indole NH (10.79 ppm), and the and Ala and Thr
methyl groups were assigned first. The characteristic couplings between CH2
protons in the Pro spin system, in addition to the benzyl CH2 protons, were
also identified from the COSY spectrum. Proton and carbon assignments
within amino acid side chain spin systems were then carried out as far as
possible by using COSY and HSQC data. HMBC data was then used to
assist in the identification of remaining resonances, and to assign amino acid
connectivity. A full assignment is given in Table 2.2, alongside the literature
assignment of the natural isolate. Shift differences (Figure 2.11) were observed
between the two compounds, but this is assumed to be due to putative proline
cis/trans isomerisation (as discussed above).
2.6.2 Structure determination
Structural modelling using the NOESY NMR data was carried out using ARIA
(Ambiguous Restraints for Iterative Assignment).53 ARIA iteratively reassigns
ambiguously assigned NOESY cross-peaks during the structure calculation,
thus allowing automatic assignment of overlapping signals (such as phenyl
group aromatic resonances). The software uses CNS (Crystallography &
NMR System)54,55 for structure refinement against NOE-derived distance
restraints using a modified version of the PARALLHDG force field.56 Typical
simulation runs involve a combination of simulated annealing from a
high initial temperature using fast torsion angle dynamics followed by
conventional Cartesian dynamics structure refinement.57 Peak reassignment
occurs following each iteration.
Peak picking and assignment of the 1H-1H NOESY spectrum was carried
out using the CCPN (Collaborative Computing Project for NMR) software.58
Initial distance restraints were then calculated using the software, and restraint
and peak lists were exported to ARIA using the inbuilt interface. Due to
the presence of D-amino acid residues, the N-terminal phenylacetyl capping
33
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Table 2.2: NMR spectroscopic data for chaiyaphumine 10a, 600 MHz (1H) and
150 MHz (13C) in d6-DMSO.
Synthetic peptide 10a Peptide 10a literaturea
δ 13C /ppm δ 1H /ppm, mult (J /Hz) δ 13C /ppm δ 1H /ppm, mult (J /Hz)
C=O 168.5 169.4
NH 7.96, d (6.7) 8.06, d (10.1)
α 55.0 4.35, t (6.8) 54.9 4.57, m
β 69.0 5.08, quint (6.6) 71.3 5.31, m
γ 15.0 0.99, d (6.5) 15.5 0.66, d (6.5)
C=O 170.8 172.3
NH 8.96, d (7.4) 7.90, d (9.9)
α 57.3 4.23, ddd (11.3, 7.4, 4.7) 56.6 4.64, m
β1 35.9 3.00, dd (14.0, 4.7) 35.7 3.20, m
β2 2.89, dd (14.0, 11.3) 3.08, dd (14.2, 9.7)
Ar 1 137.6 137.5
Ar 2 128.8 7.24-7.27, m 128.4b 7.26, m
Ar 3 128.2 or 128.1c 7.21-7.29, m 128.5b 7.27, m
Ar 4 126.4c 7.13-7.17, m 126.6d 7.18, m
C=O 170.4 172.7
NH 7.25-7.31, m 8.23, d (6.7)
α 47.1 4.41, quint (6.6) 47.4 4.54, m
β 17.7 1.20, d (6.6) 15.9 1.36, d (7.0)
C=O 170.3 170.1
α 61.4 3.97, dd (8.8, 5.4) 60.8 4.27, dd (8.9, 2.3)
β1 28.4 1.92-1.99, m 28.8 1.89, m
β2 1.33, dq (12.2, 6.1) 1.46, m
γ1 24.4 1.79-1.87, m 23.2 1.62, m
γ2 1.79-1.87, m 1.03, m
δ1 46.7 3.67-3.72, m 46.7 3.73, m
δ2 3.48-3.53, m 3.46, m
C=O 171.2 170.5
NH 7.58, d (9.9) 6.9, d (8.1)
α 55.4 4.58-4.63, m 53.0 4.39, m
β1 27.9 2.94-2.97, m 26.9 3.21, m
β2 2.94-2.97, m 2.96, dd (14.5, 11.5)
Indole 1 10.79, d (2.1) 10.81, d (1.9)
Indole 2 122.9 7.01, d (2.1) 124.0 7.23, m
Indole 3 109.9 109.9
Indole 3a 127.2 126.9
Indole 4 118.10 7.50 , d (8.0) 118.0 7.54, d (7.9)
Indole 5 118.07 6.97, ddd (8.0, 7.0, 1.0) 118.5 6.97, t (7.4)
Indole 6 120.9 7.05, ddd (8.0, 7.0, 1.2) 121.0 7.03, t (7.7)
Indole 7 111.3 7.29-7.32, m 111.4 7.31, d (8.1)
Indole 7a 136.0 136.2e
C=O 170.3 171.3
α(1/2) 40.1 3.26, d (15.7) 43.4 3.88, d (13.0)
3.36, d (15.7) 3.49, d (13.0)
134.0 136.1e
126.7c 7.19-7.27, m 128.8 7.25, m
128.2 or 128.1c 7.21-7.29, m 129.1 7.37, d (7.1)
129.2 7.12-7.16, m 136.5b 7.18, m
a Literature values for the naturally isolated compound as published previously. 43
b One peak with an integral for two carbons.
c,d,e Assignments are interchangeable (second assignment not specified for d).
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Figure 2.11: Overlay of 1H NMR spectra of 10a (black) and natural isolate43 (red).
Chemical shift differences are observed.
35
Total Synthesis of Bioactive Peptides and Whole Proteins
group and a depsipeptide bond in the structure, the ARIA run parameters and
scripts generated by default had to be heavily modified (as described in the
Experimental section).
Torsion angle dynamics simulations attempted using the default param-
eters were found to cause instabilities due to the cyclization restraint and
relatively small molecular size, which were not resolved upon decreasing
high temperature values by more than half. Simulated annealing runs
were therefore carried out using Cartesian dynamics only (with the default
simulation total time period quadrupled), and were found to be stable when
using the same high temperature value (10 000 K). An overlay of the final
converging structural ensemble is given in Figure 2.12.
Figure 2.12: Overlay of 10 lowest energy conformers of 10a following molecular
dynamics energy minimization using NOE-derived distance restraints (see text).
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2.7 Conclusions and future work
A synthetic route to the chaiyaphumines, a newly discovered class of
antiparasitic cyclic depsipeptide natural products, has been successfully
developed. Correct stereochemistry was confirmed via Marfey’s analysis, and
the synthetic peptides exhibited antiparasitic bioactivity comparable to the
naturally isolated peptides. In addition, a series of chaiyaphumine analogues
were synthesized in which the ester bond was replaced by an amide linkage,
and these exhibited a similar potency of antiparasitic action (<3 µM for 11a
against P. falciparum), although interestingly with respect to the N-terminal
capping moiety the activity profile was reversed (see above).
Future work will involve assaying stability of the synthetic chaiyaphumines
and analogues under different pH conditions and with regards to enzymatic
degradation, to demonstrate the increased stability of the amide-linked
analogues over the natural ester structures. Structure-activity studies will also
be critical in further elucidating those structural features essential for activity.
This will involve the synthesis of analogues bearing amino acid substitutions,
such as the replacement of D- with L-amino residues to evaluate the effect
of stereochemistry. In particular the role of the capping group functionality
(previously demonstrated to be important) should be probed – for example
further studies of chain length with regards to the phenyl-substituted version,
to contrast that for the aliphatic capping moiety already investigated.
Of particular interest are those modifications likely to increase hydropho-
bicity and reduce hydrogen bonding ability, potentially resulting in increased
cell permeability. Examples of this type, such as the halogenation of aromatic
side chains or the introduction of the Dpr side chain methylation discussed
in section 2.5, are given in Scheme 2.4a. These can be incorporated
during Fmoc SPPS using the appropriate commercially available building
blocks. In addition, a route to the methylated Dpr building block required
for the latter modification is proposed in Scheme 2.4b. Although some
difficulty is anticipated during cyclizations involving the relatively hindered
methylated Dpr side chain, the already demonstrated propensity of the linear
chaiyaphumines to readily undergo macrocyclizations at room temperature
suggests that this will be feasible given the correct choice of activator and
optimization of reaction conditions.
The elucidation of the mechanism of action of the chaiyaphumines is also
necessary, and the identification of protein targets of this class of antiparasitics
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Scheme 2.4: (a) Suggested modifications to the chaiyaphumine scaffold, potentially
introducing enhanced cell permeability. N-Methylation of the isopeptide bond can
be incorporated using the appropriate methylated Dpr building block (see below).
Commercially available halogenated Phe and Trp building blocks facilitate introduction
of chloro and fluoro substitutions on aromatic side chains. (b) A two-step route from
Fmoc-Dpr(Boc)-OH (21) to methylated intermediate 23 recently published by Lindahl
et al.59 23 can be Boc protected to give the methylated Dpr building block required
above.
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is vital. The work described provides access to much larger amounts of
peptidic material than was previously available, thus paving the way for target
validation studies using affinity chromatography-based techniques (in which
the active peptide is immobilized on a stationary phase followed by washing
with protein extracts to identify binders).60 Drug affinity responsive target
stability (DARTS) has also been used relatively recently to confirm or identify
a number of small molecule-protein interactions, and selects proteins based
on their induced stability with respect to proteolysis upon binding of the
ligand of interest.60 Finally, the most valuable advantage of obtaining natural
products via a chemical route is the potential for chemical modification. The
introduction of reactive electrophilic functionality into the chaiyaphumine
scaffold would allow covalent attachment to catalytic residues in the active
site of a potential target enzyme, and could be used in a target-based screen.60
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Synthesis of the lasso peptide
lassomycin
A s illustrated in Chapter 1, the pressing issue of antimicrobialresistance continues to drive the search for novel antiparasitic drugscaffolds. This is of course an equally important concern in antibioticdrug discovery, and emerging threats such as extensively drug-
resistant tuberculosis require the use of innovative approaches in the search
for potential leads.61–63
The following chapter describes the total synthesis of a peptide natural
product found to be active against drug-resistant forms of Mycobacterium
tuberculosis. The peptide is of particular interest due to the fact that it belongs
to the class of ‘lasso’ peptides, which have been found to exhibit a unique
three-dimensional fold. The use of total chemical synthesis in the elucidation
of the structure of a natural product is demonstrated. An overview of lasso
peptides is also given.
3.1 Introduction
3.1.1 Lasso peptides
Lasso peptides are a class of cyclic peptide natural products of bacterial
origin.64,65 Members of this class contain a post-translationally installed
isopeptide bond between the N-terminus and an aspartate or glutamate side
chain, resulting in a cyclic structure.65,66 Some of the known lasso peptides
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exhibit antibacterial activity and are secreted into the growth medium, where
their putative role is to defend against competing bacterial strains within the
same habitat.67
The compact cyclic structure of lasso peptides favours receptor interactions
and confers resistance to unfolding or proteolytic degradation.67,68 For this
reason it is thought that the loop region could be used for the presentation
of receptor binding epitopes – lasso peptides are therefore of interest in the
development of peptide drug scaffolds.65 In 2011 Knappe et al. demonstrated
low cytotoxicity and high stability in physiological conditions of a lasso peptide
integrin antagonist, where a tripeptide sequence in the loop region was
substituted for the integrin recognition sequence ‘RGD’.69
Only a handful of lasso peptide crystal structures have been published to
date.67,70–72 The first, published by Nar et al. in 2010, is shown in Figure 3.1.
The peptide exhibits a conformation whereby the C-terminus is ‘threaded’
through the loop and held, either by steric interactions (in the case of
the peptide shown) or disulfide bonds.66 Attempts to chemically synthesize
threaded lasso peptides have not been successful thus far,67 although the
synthesis of an interlocked peptide-containing rotaxane exhibiting a lasso
topology has been described.73
Figure 3.1: X-ray crystal structure of BI-32169 exhibiting the characteristic threaded
loop conformation common to all lasso peptides discovered to date (except one, see
text).36,67
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3.1.2 Lassomycin
Lassomycin (24) is a newly discovered lasso peptide isolated from an extract
of the Actinomycete Lentzea kentuckiensis sp. in a screen of a library
of previously unculturedI soil bacteria.74 Lassomycin was found to possess
potent and specific bactericidal activity against mycobacteria, including drug-
resistant forms of Mycobacterium tuberculosis. It was discovered that the
peptide targeted the ClpC1 ATPase, an essential enzyme in mycobacteria,
thus accounting for the specificity of 24. ClpC1 ATPase is a key component
of protein degradation together with the ClpP1P2 proteolytic complex.75 The
primary sequence and connectivity of 24, as confirmed by preliminary MS and
NMR analysis, is shown in Figure 3.2.
NRRGVLQ
D
AF
L
R
R
L G
I OMe
OHN O
Figure 3.2: Primary sequence and connectivity of amino acids in lassomycin (24).74
The peptide contains an isopeptide bond between the N-terminus and the carboxylate
side chain of Asp-8, forming an 8-residue macrolactam ring. The C-terminus is
methylated.
The reported NMR solution structure of lassomycin is shown in Figure 3.3.
Remarkably, the peptide does not appear to adopt the characteristic threaded
knot conformation reported for other homologous lasso peptides discovered
to date.65 In light of this discovery, and the potential of lasso peptides as novel
drug scaffolds in general,65,67,68 it was decided that a chemical synthesis of the
natural product should be attempted to confirm its structure and investigate its
biological activity. It was envisaged that a total synthesis would also provide
enough material for crystallization and full structural characterization via X-ray
diffraction methods.
IBacteria that do not grow (or grow very poorly) in vitro, and represent an untapped
source of secondary metabolites for drug discovery.63,74
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Figure 3.3: NMR solution structure of lassomycin (24).36,74 The proposed structure
of 24 is unique in that the C-terminus packs tightly against the N-terminal ring instead
of passing through the macrolactam.
3.2 Proposed synthetic routes and initial attempts
Two key structural features that need to be addressed during a chemical
synthesis of lassomycin (24) are the isopeptide bond between the N-terminus
and the carboxylate side chain of Asp-8, and the methylated C-terminus
(Figure 3.2). Two synthetic approaches were proposed and are outlined in the
retrosynthesis given in Scheme 3.1.
Route A involves the synthesis of the linear sequence on 2-chlorotrityl
chloride resin, followed by head-to-side-chain cyclization of the protected
peptide on resin. The side chain of Asp-8 was protected using the orthogonal
allyl ester protecting group. Treatment with methanolic anhydrous HCl was
chosen as a convenient method of simultaneously cleaving the product peptide
from the resin and generating the desired C-terminal methyl ester in the
approach reported by Turner at al.76
Synthesis of the linear sequence was carried out successfully, and aqueous
test cleavage of 29 (Scheme 3.1) using TFA generated the correct linear
Fmoc/allyl ester intermediate bearing a C-terminal acid group, as confirmed by
MALDI-TOF MS (m/z = 2146.3). Obtaining C-terminal peptide methyl esters
was found to be more problematic however, and the target peptide methyl
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Scheme 3.1: Proposed synthetic routes to Lassomycin (24). On-resin cyclization
approach A uses orthogonal protection in the form of an allyl ester protecting group,
which was found to be difficult to remove (see text). A solution-phase cyclization
strategy B was instead considered, which involves installation of the C-terminal methyl
ester at the beginning of the synthesis as opposed to via a cleavage-esterification step
at the end (as in A). (Amino acid side chain protecting groups are omitted for clarity.)
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ester was not obtained using the previously published conditions (cleavage
cocktail made up of a 3 M solution of acetyl chloride in methanol, to generate
HCl in situ).76
Removal of the allyl ester protecting group also proved to be highly
problematic, and no deprotected product was observed after 5 × 1 h
treatments with 20 equivalents of phenylsilane in the presence of a Pd(PPh3)4
catalyst (0.35 equiv) under an inert atmosphere.77 The conditions for various
(unsuccessful) deprotection attempts are summarized in Table 3.1.
Table 3.1: Summary of conditions attempted for allyl ester deprotection.77–79
Pd(0) equiv Other Solvent Duration
0.35 PhSiH3 (20 equiv) DCM 5 × 1 h1.0 PhSiH3 (20 equiv),CH3COOH (20 equiv)
DCM 2 × 2 h
2.0 CHCl3/CH3COOH/NMM(37:2:1)
Chloroform 2 × 2 h
Allyl ester group removal was not observed despite the use of stoichiomet-
ric amounts of catalyst and silane, and trialling in a number of reaction solvents.
The lack of success was assumed to arise from a difficulty in coordinating the
allyl moiety to the catalyst, presumably due to steric hindrance around the
metal centre. This effect will depend upon peptide sequence length and
folding of the peptide, and as such is likely to be highly sequence dependent.
In light of the difficulties described, alternative orthogonal protecting
groups were considered for the side chain of Asp-8, such as highly acid
sensitive,80–82 photolabile83,84 or silicon-based protection.85,86 It was decided
that these were less than ideal, however, due to their sensitivity, requirement
for specialized conditions for deprotection, or a lack of commercially available
building blocks. Instead an alternative solution-phase cyclization approach
(Route B) was proposed.
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3.3 Solution-phase cyclization strategy
Route B is outlined in Scheme 3.1. This approach involves assembly of
the side-chain-anchored linear peptide on resin, followed by cyclization of
the product in solution after global deprotection and cleavage from the
support. Due to the use of side chain anchoring, the C-terminal methyl
ester functionality can be installed at the beginning of the synthesis.
A dipeptide of aspartic acid and isoleucine methyl ester (30) was
synthesized in solution and the t-butyl group removed from the aspartate
side chain under standard acidic conditions. The dipeptide was then attached
via the deprotected side chain to Rink amide resin (0.77 mmol/g) in order
to give the required Asn-Ile-OMe C-terminal sequence upon TFA cleavage
(Scheme 3.2). The required sequence was then elongated via automated SPPS
at room temperature using PyBOP®/DIPEA activation and 2 × 1 h couplings
(3 × 1 h for Arg). Fmoc deprotection of the penultimate residue (Leu-2) was
found to be inefficient, and an additional two further deprotection steps were
incorporated into the synthesis at this point. The fully deprotected linear
peptide (25) was obtained after cleavage from the resin using 95% TFA, as
confirmed by ESI-MS (m/z = 1898.4, [M + H]+).
Cyclization of linear precursor 25 was then attempted. While peptide
macrocyclizations are often best performed under high dilution to mini-
mize unwanted oligomer formation,87 the pseudo-high dilution conditions
described by Malesevic et al. were instead utilized as a more convenient
alternative in order to minimize solvent usage.50 11.3 mL each of solutions
of 25 (0.01 M) and HATU (0.03 M) in DMF were added to a reaction flask
containing DIPEA and HOAt over a period of ∼20 h at a rate of 0.01 mL/min
(syringe pump controlled). Slow addition was used in order to keep the
effective reaction concentration low, while requiring only a relatively small
final solvent volume (34 mL). Removal of the solvent under vacuum and HPLC
purification of the crude reaction product yielded lassomycin (24) in high
purity, as confirmed by analytical HPLC and MALDI-TOF MS (Figure 3.4).
The C-terminal amide analogue (35) of lassomycin was also synthesized
(Scheme 3.3). Synthesis of the linear peptide was carried out directly on Rink
amide resin via Fmoc SPPS (without side chain anchoring). Cleavage from
the resin, solution-phase cyclization and HPLC purification to yield 35 were
carried out as previously described for the synthesis of 24. Purity and correct
molecular weight were confirmed by analytical HPLC and MALDI-TOF MS
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Scheme 3.2: Synthesis of lassomycin. The dipeptide Fmoc-Asp(OH)-Ile-OMe (34,
not shown) was preformed in solution and anchored to Rink amide resin via the
Asp side chain. The required sequence was then elongated via SPPS, before global
deprotection and cleavage from the resin. Cyclization of the linear peptide in solution
yielded the cyclic target. Reagents and conditions: (i) PyBOP® (1.0 equiv) and NMM
(3.0 equiv), DCM, RT, 18 h; SiO2, 98/2% hexane/EtOAc → 50/50% hexane/EtOAc;(ii) 40% TFA, DCM, RT, 30 min; (iii) Rink amide resin (0.79 mmol/g), 34 (3.1 equiv),
PyBOP® (3.1 equiv) and DIPEA (6.2 equiv), DMF, RT, 2 × 1 h; (iv) Fmoc SPPS (see
Experimental section); (v) TFA (95%, water), TIPS, RT, 4 h; (vi) HATU (3.0 equiv) and
DIPEA (6.0 equiv), DMF, RT, 20 h (pseudo-high dilution, see text).
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(Figure 3.4). Lassomycin(1-9) (36), a truncated analogue, was synthesized
by the same route in order to assess the effect of loss of the tail region on
biological activity (characterization shown).
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Scheme 3.3: Synthesis of lassomycin-amide (35). The peptide sequence was
synthesized via SPPS on Rink amide resin (0.79 mmol/g), before global deprotection
and cleavage from the resin. Cyclization of the linear peptide in solution yielded the
cyclic target. Reagents and conditions: (i) TFA (95%, water), TIPS, RT, 4 h; (ii) HATU
(3.0 equiv) and DIPEA (6.0 equiv), DMF, RT, 20 h (pseudo-high dilution, see text).
3.4 MS characterization and biological testing
MALDI TOF/TOF MS/MS using LIFT88 technology was used to provide
sequence information for the peptides synthesized. This technique enables the
detection of product ions resulting from fragmentation in the field free region
of the mass spectrometer, after acceleration from the ion source and as a
consequence of elevated laser power. Conservation of momentum means the
product ions will maintain the velocity of their corresponding precursor ion.
In the case of LIFT, the product ions subsequently experience an additional
voltage potential that ‘lifts’ them to an energy that enables them to pass
through the rest of the mass spectrometer and be detected. Backbone amide
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Figure 3.4: MALDI-TOF mass spectra (left) and HPLC traces (centre) for (a)
lassomycin (24), (b) lassomycin-amide (35) and (c) lassomycin(1-9) (36). Labelled
MS peaks are for [M + H]+ ion. Absorbance recorded at 220 nm, gradient 0-100% B
over 30 min (A = 5:95:0.05 MeCN/H2O/TFA; B = 95:5:0.03 MeCN/H2O/TFA).
50
Chapter 3. Synthesis of the lasso peptide lassomycin
bond cleavages are the most commonly used for peptide sequencing and
result in series of product ions extending from either the N-terminus (‘b’ ions,
retaining the carbonyl part of the amide bond) or C-terminus (‘y’ ions, retaining
the nitrogen atom).89
Product ions observed for lassomycin (in addition to linear and amide
analogues) are shown in Figure 3.5. While a complete set of product ions
were observed for the uncyclized peptide, the cyclic peptides only exhibited
fragmentation up to Asp-8 (side chain cyclized onto N-terminus). This is in
agreement with the results from MS/MS sequencing of the natural product by
Gavrish et al.,74 and is unsurprising given that for a cyclic peptide two bond
cleavages must occur in order to observe b or y ion series in the ring region.II
Figure 3.5: Summary of product ions observed via MALDI LIFT-TOF/TOF sequencing
of (a) linear (uncyclized) lassomycin (25), (b) lassomycin (24) and (c) lassomycin-
amide (35). Ions resulting from amide (CO-NH) bond cleavage are shown, with the
charge retained on either the N-terminal (‘b’ ion) or C-terminal (‘y’ ion) fragment
(charged fragment is observed).89 Asterisked ions are observed only as M-17 (loss of
ammonia).
IIA single cleavage in the ring does not divide the peptide into two fragments as they are
still attached at the branching point, hence the resulting ‘fragment’ has the same mass as the
fully intact peptide.
51
Total Synthesis of Bioactive Peptides and Whole Proteins
Ion-mobility (IM) mass spectrometry was also carried out on the synthetic
peptide. This technique involves separation of ions based on their differential
mobility through a buffer gas,90 and has been used previously to distinguish
threaded and unthreaded topoisomers in lasso peptides.91 The mobiliogram
(plot of m/z against drift time in Bins) is shown in Figure 3.6. A number
of peaks with distinct collisional cross sections were resolved belonging to
either lassomycin or a trace amount of the C-terminal acid hydrolysis product
(39). Only a single peak was observed for each species suggesting that
only one conformation is present, as opposed to distinct populations of
threaded and unthreaded peptide (or that the collisional cross section for
threaded/unthreaded ions is identical).
Figure 3.6: Mobiliogram for lassomycin (LC ES IM MS, full scan). The collisional cross
section for the lassomycin (methyl ester, 24) and trace hydrolysis product (C-terminal
acid, 39) ions in 4+ charge state are virtually identical (left-hand ellipse), whereas
the 3+ charge state ions for the two peptides have different drift times and can be
separated (right-hand ellipse). The peak at 50 Bins belongs to 39, and at 58 Bins to
24.
Peptides 24, 35 and 36 were tested against Mycobacterium tuberculosis
H37Rv in minimum inhibitory concentration (MIC) assays utilizing both solid-
agar based and liquid-media based methods (Tim Bull, St. George’s University
of London). None of the peptides showed inhibitory activity when tested, up
to concentrations of 100 µg/mL. These results were surprising, in particular
for peptide 24, given the previously reported biological activity profile for the
natural product.74 Due to the unlikely nature of spontaneous threading during
the synthesis of 24 (and 35), it is logical to assume that the peptides reported
are unthreaded. The biological data presented therefore suggests that the
unthreaded structure previously reported may not be correct.
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3.5 Investigation of effect of temperature on
peptide conformation
The structural discrepancy from the previous data may possibly be due
to unthreading of lassomycin between biological testing and NMR data
collection in the published report.74 Several examples have been documented
of lasso peptides unthreading upon heat treatment. Caulosegnin I unthreads
completely after 4 hours at 95 ◦C, while caulosegnin III unthreads and
decomposes at elevated temperatures.92 Similarly, astexin-1 unthreads when
heated to 50 ◦C for 4 hours68 and astexin-2 unthreads and decomposes after
heating at 95 ◦C for 2 hours.93 In contrast, caulosegnin II and astexin-3 show
minimal to no unthreading when heated at 95 ◦C for prolonged periods of
time.92,93 NMR data collection was carried out previously at 40 ◦C however,
at which temperature unthreading seems unlikely.
In order to further elucidate the effect of temperature on the conformational
state of lassomycin, structural characterization of synthetic peptide 24 was
carried out using two-dimensional NMR. A comparison of 1H-13C HSQC
spectra for 24 at two different temperatures is shown in Figure 3.7.
The NMR data gathered is also compared with naturally isolated labelled
[13C, 15N]lassomycin.74 No noticeable changes in chemical shift values are
observed between the spectrum of 24 at 25 ◦C and at 40 ◦C. Furthermore,
clear differences in the 1H-13C HSQC spectrum can be seen between the
synthetic (24) and naturally isolated peptide at 40 ◦C (Figure 3.7). These results
strongly suggest that the conformation of 24 does not change appreciably upon
heating, and they highlight that there are significant differences between the
conformation of synthetically prepared and naturally isolated lassomycin.
In light of this evidence, it is proposed that synthetic lassomycin (24)
either exists in the unconstrained unthreaded form, or as a threaded lasso
that does not unthread upon heating to at least 40 ◦C (the latter implying
that unthreading would also be impossible for the natural isolate, should it
exist in a threaded conformation). Given the clear conformational differences
observed between synthetic and naturally isolated peptides at the point of
NMR data collection, it seems likely that one is threaded while the other
is not. As an identical situation has already been established at the point
of biological testing, it is proposed that i) neither peptide has undergone
unthreading (or threading) upon heating during NMR data collection, or ii)
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Figure 3.7: Overlay of expanded regions of 1H-13C HSQC (heteronuclear single-
quantum correlation) NMR spectra of naturally isolated [13C, 15N]lassomycin at 40 ◦C
(green), and synthetic lassomycin (24) at 25 ◦C (blue) and 40 ◦C (red). (Full spectra
given in Appendix B.)
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one has undergone threading from an initial unthreaded state whilst the other
has undergone unthreading. For case ii) the peptide undergoing unthreading
cannot be the natural isolate, as this would imply that the synthetic peptide
(24) has undergone threading and is threaded at the point of NMR data
collection, thus paradoxically implying (given the NMR study of temperature
dependence already discussed) that a threaded lassomycin cannot unthread.
Neither scenario therefore supports the hypothesis that the naturally isolated
peptide has undergone unthreading upon heating to 40 ◦C. Furthermore, given
the general implausibility of scenario ii), taken together with the previously
discussed likelihood that synthetic peptide 24 is in fact unthreaded, it is
proposed that the previously published naturally isolated peptide exists as
a threaded lasso that does not unthread upon heating to 40 ◦C.
3.6 Crystallization screening
Crystallization of synthetic lassomycin (24) was also attempted via high-
throughput screening of 10 mg/mL peptide solution using a standard protein
crystallization buffer set on an InnovadyneTM Screenmaker 96+8 XtalTM
nanolitre scale screening robot. No crystals were obtained for any of the
conditions tested, and so a novel sparse matrix screen developed specifically
for peptide crystallization94 was investigated.
Vapour diffusion conditions in sitting-drop format were set up manually
using 1 µL of 40 mg/mL peptide solution per well, in addition to either 1 or
2 µL of the buffer solution (1:1 and 2:1). An additional 1:1 tray was also set
up to run at 4 ◦C. The complete buffer set prepared is shown in Table 3.2.
Each of the 24 solutions were used for 1:1, 2:1 and 1:1 (4 ◦C) conditions (72
conditions total).
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Table 3.2: Buffer set prepared for peptide sparse matrix crystallization screen.94
Precipitant 1 Salt/precipitant 2 Additive Buffer (0.1 M) pH
1 2.0 M NaCl - - NaOAc 4.5
2 20% 2-PrOH - 0.01 M CaCl2 ” ”3 10% (w/v) PEG 3000 0.1 M ZnCl2 - ” ”4 30% (w/v) PEG 4000 - - ” ”
5 0.8 M (NH4)2SO4 - - Na citrate 5.06 30% (v/v) MPD - - ” ”
7 30% (v/v) t-BuOH - - ” 5.5
8 20% (w/v) PEG 4000 20% (v/v) 2-PrOH - ” ”
9 20% (w/v) PEG 3350 - - ” ”
10 20% (w/v) PEG 8000 0.2 M ZnCl2 - MES 6.011 30% (v/v) Jeffamine® M-600 - - ” ”
12 30% (v/v) MPD 0.2 M Mg(OAc)2 - ” 6.513 20% (w/v) PEG 3000 0.2 M MgCl2 - ” ”14 0.1 M K2HPO4 - - HEPES 7.015 1.0 M NaOAc 0.1 M ZnSO4 - ” ”16 20% 2-PrOH 0.1 M NaCl 20% (v/v) glycerol ” 7.5
17 25% (w/v) PEG 3350 10% (v/v) 2-PrOH - ” ”
18 30% (v/v) Jeffamine® M-600 - - ” ”
19 45% (v/v) MPD 0.2 M NH4OAc - ” ”20 20% (v/v) MPD - 0.05 M NaCl Tris 8.0
21 10% (w/v) PEG 8000 - - ” ”
22 25% (w/v) PEG 3350 0.2 M NH4OAc - ” 8.523 10% 2-PrOH - 0.05 M NaCl ” ”
24 70% (v/v) MPD - - ” ”
Abbreviations: HEPES - 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, MES - 2-(N-morpholino)ethanesulfonic
acid, MPD - 2-methyl-2,4-pentanediol, PEG - poly(ethylene glycol), Tris - 2-amino-2-(hydroxymethyl)-1,3-propanediol.
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Peptide aggregates were seen in a number of wells, but no crystalline
material was observed after 1 week. The trays will be checked at monthly
intervals, and alternative protein crystallization screens will be considered.
Truncated peptide 36 or analogues from alanine scanning may also potentially
be more amenable to crystallization.
3.7 Conclusions and future work
A practical synthetic route has been developed for the synthesis of an
unthreaded version of the lasso peptide lassomycin (24). Lassomycin(1-9)
(36), in addition to lassomycin-amide (35), a C-terminal amide derivative of
24, were also prepared. A lack of biological activity for the synthetic peptides
against Mycobacterium tuberculosis suggests the structure of the synthetic
peptide does not match that of the previously published compound.74 Given
that the correct sequence was confirmed by MS analysis, it is assumed that the
peptides differ only in their threading state. Furthermore, IM data suggested
that the synthetic peptide exists only in a single conformation, and not in a
mixture of threaded and unthreaded states.
Due to threading of the peptide during chemical synthesis being unlikely,
it is suggested that the previously published natural product in fact exists in
a threaded conformation, and that the previously published unthreaded NMR
structure is incorrect. In order to rule out the possibility of unthreading of
the natural product during the NMR data collection previously reported, NMR
characterization was carried out on the synthetic peptide. The results reported
suggest that for lassomycin there is no interconversion between threaded and
unthreaded states upon heating to 40 ◦C. Furthermore, clear differences
between the NMR data presented and the previously published data support
the hypothesis that synthetic and naturally isolated lassomycin adopt different
conformations.
Together these results strongly suggest that the previously published,
naturally isolated lassomycin peptide exists in the threaded lasso conformation
observed for all other lasso peptides discovered to date. Crystallization assays
are ongoing, and an X-ray crystal structure will provide definitive evidence for
the lack of threading in the synthetic peptide.
Threaded lasso peptides remain out of the reach of chemical synthesis
techniques. Given the conclusion that lassomycin is likely to be expressed
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as a threaded lasso, the lack of cysteine residues in its sequence suggests
that stabilization of the threaded topoisomer may be due to a ‘steric lock’
formed from the bulky arginine side chains present, as opposed to disulfide
bonding.65 It is possible therefore that threaded conformations may be
accessed via replacement of Arg side chains with less sterically hindered
residues such as Ala or Gly, and that equilibrium populations of threaded and
unthreaded forms could be isolated through covalent ‘trapping’ via cyclization
or disulfide bond formation. A potential strategy could involve introduction
of Acm-protected Cys residues during SPPS, which would be deprotected
following purification and solution-phase cyclization. Threading dynamics
could then feasibly be observed in aqueous solution via disulfide trapping of
threaded and unthreaded topoisomers, which may be subsequently separated
and characterized by ion-mobility MS (Figure 3.8). Such an approach
would facilitate elucidation of the effect of peptide sequence and structural
modifications upon the threading, stability and biological activity of lasso
peptides.
Figure 3.8: Suggested strategy for the isolation of chemically synthesized
threaded lasso peptides. Equilibrium populations of threaded and unthreaded
conformations could be ‘trapped’ via disulfide formation and subsequently purified
and characterized.
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Part II
Total chemical synthesis of whole
proteins

Chapter 4
Current progress in whole protein
chemical synthesis
T he applicability of chemical synthesis to the investigation of thestructure and function of small bioactive peptide natural productshas been demonstrated thus far in Chapters 2 and 3. Chemicalsynthesis can also be invaluable in elucidating the role of much larger
biomolecules, such as proteins. The following chapter introduces the reaction
central to the field of whole protein chemical synthesis – native chemical
ligation (NCL) – which enables the application of peptide synthesis techniques
to targets which which would otherwise be inaccessible due to their size. A
selection of illustrative examples are also provided, representing the state of
the art in the field.
4.1 Introduction
Peptide chemistry has changed immeasurably since Emil Fischer’s synthesis
of glycyl-glycine in 1901.95 Bruce Merrifield’s pioneering work using Boc
chemistry and a solid support enabled peptide synthesis to become a routine
technique,96 and stepwise Fmoc SPPS has since been used to produce
peptides97 and even whole proteins98–100 of increasing length. Nevertheless,
the purification of longer synthetic peptides quickly becomes problematic due
to the increasing proportion of deletion by-products resulting from incomplete
couplings.101,102 Instead the target peptide can be synthesized in smaller
sections that are subsequently ligated in solution, thus circumventing issues
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associated with the SPPS of longer targets. Native chemical ligation (NCL) is a
well-established technique involving the reaction between a peptide bearing
an N-terminal cysteine and a second bearing a C-terminal thioester group
(Scheme 4.1). The reaction can be carried out on unprotected peptides in
aqueous buffer, and the technique has enabled the total chemical synthesis
of countless whole proteins inaccessible by SPPS alone.103–109 The various
methods available that can be used to produce the peptide thioesters required
for NCL will be discussed at the end of this chapter.
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Scheme 4.1: General mechanism for native chemical ligation (NCL).104
An area of particular interest in the field is the chemical synthesis of
proteins bearing post-translational modifications (PTMs).110 While PTMs often
play a crucial role in the biological processes associated with a particular
protein’s function, obtaining homogeneously modified protein bearing one
or more specific PTMs at one or more specific sites is often impossible by
conventional means. A post-translationally modified protein isolated from
a biological source may comprise multiple forms, each bearing different
PTMs at a number of possible sites, hence rendering the purification of a
given form in order to study the effect of a specific PTM extremely difficult.
For example, despite the area of therapeutic glycoproteins being the fastest
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growing field in the pharmaceutical industry,111 glycosylated proteins cannot
be recombinantly expressed routinely in bacterial systems such as E. coli,112,113
and the variability of glycosylation sites for recombinant protein can render
the successful purification of a desired glycoform impossible.111,114,115
By contrast, a host of covalent modifications can be incorporated
site-specifically into a target protein during a total chemical synthesis,
including labels such as fluorophores116 or NMR probes,117 or PTMs
such as phosphorylations118 or glycosylations.119 Indeed any natural or
unnatural amino acid can be inserted at the desired point during Fmoc
SPPS, given an appropriately protected building block is available or can be
chemically synthesized.120 An understanding of the relationship between PTM
occurrence and function is crucial for a given protein of interest, and total
chemical synthesis affords unparalleled control over sequence and covalent
modification, allowing access to site-specifically modified synthetic proteins.
A selection of recent examples of whole protein total chemical synthesis is
provided in the following sections, representing the state of the art in the field.
The focus of the chapter will be those targets bearing important PTMs and
for which obtaining site-specifically modified protein has proved extremely
difficult or impossible by conventional means.
4.2 Obtaining erythropoietin as a single glycoform
The glycoprotein hormone erythropoietin (EPO) is secreted by the kidneys
during decreased oxygen circulation and is responsible for triggering ery-
thropoiesis – the production of red blood cells (erythrocytes).121 Despite the
primary sequence of EPO and its glycosylation sites being highly conserved,
the oligosaccharides linked at asparagines 24, 38, and 83 are not and
exhibit considerable structural variation, resulting in a family of inseparable
EPO glycoforms.122 While a number of semisynthetic homogeneous EPO
glycoforms have been reported,123 including those by Flitsch (Macmillan et al.,
2001)124 and Kajihara (Hirano et al., 2009),125 the first total chemical synthesis
of a synthetic EPO analogue was published by Kent in 2003 (Kochendoerfer
et al.).126 While this analogue was unglycosylated, PEG-derived branched
polymer side chains were introduced at two of EPO’s four native glycosylation
sites, resulting in enhanced biological activity and lifetime in vivo. A second
fully synthetic EPO analogue was reported by Kent in 2012 (Liu et al.), where
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Asn residues at three of the native glycosylation sites were replaced with Lys,
retaining biological activity despite the lack of glycosylation.127
Kajihara (Murakami et al.) reported a fully synthetic glycosylated EPO
analogue in 2012, bearing a complex oligosaccharide at Asn-83.128 However,
the first total chemical synthesis of EPO bearing oligosaccharides at all
four native glycosylation sites (40) was completed by Danishefsky in 2012
(Wang et al.).121 The approach used is summarized in Figure 4.1a. The
protein was assembled in four fragments (I-IV) using using NCL. Alanines
79 and 125 were replaced with Cys residues allowing sequential ligations
to be carried out at those points, with subsequent conversion back to
Ala using metal-free dethiylation (MFD). MFD is carried out using the
reducing agent tris(2-carboxyethyl)phosphine (TCEP) in the presence of
the radical initiator 2,2’-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride
(VA-044).129,130 Acm protecting groups were used for those Cys residue side
chains that were to remain in the final protein.
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Figure 4.1: (a) Chemical synthesis of a single glycoform of erythropoietin (EPO, 40). (b) Tripeptide incorporating fully deprotected
glycosyl-amino acid cassette, which was ligated onto the N-terminus of fragment IV (see text). The Thz residue was subsequently
unmasked to give the required Cys residue. (c) Example oligosaccharide structure occurring at asparagine sites 24, 38 and 83 in
the naturally isolated protein121 (glycan symbol nomenclature shown131,132). Adapted from Wang et al.121
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The oligosaccharide required at position Ser-126 was first incorporated
as a fully deprotected glycosyl-amino acid cassette into a tripeptide bearing
the masked C-terminal thioester equivalent previously reported by Chen et
al.,133 while the required N-terminal cysteine was masked as a thiazolidine-4-
carboxylic acid (Thz) residue (Figure 4.1b). This tripeptide was then introduced
onto the N-terminus of fragment IV via NCL, with subsequent deprotection of
the Fmoc group and treatment with methoxyamine to unmask the thiazolidine
group. Simplified disaccharide units were coupled at the required Asn
positions using the previously reported one-flask aspartylation/deprotection
protocol, which was carried out on the Asp-containing thioester fragments.134
An example of the type of carbohydrate structure that would appear at these
sites in the naturally isolated protein is shown in Figure 4.1c. An explanation
of the standard glycan symbol nomenclature is also given.131,132
Biological activity of 40 and unglycosylated EPO was evaluated by
observing erythroid colony formation in a hematopoietic stem and progenitor
cell differentiation assay. Glycosylated 40 exhibited greater activity than the
unglycosylated protein, potentially due to the poor stability of the latter.
Furthermore, the unglycosylated form ‘did not give rise to a supportive mass
spectrum’.121 These results demonstrate the importance of glycosylation in
maintaining glycoprotein stability, and thus presumably biological activity also.
4.3 Elucidating the role of polyubiquitination
Ubiquitination is a PTM most well known as a signal for proteasomal
degradation, but is also involved in many and varied cellular processes
and has been implicated in the pathogenesis of several neurodegenerative
diseases.135,136 The modification involves either the attachment of a single
molecule of the 76 amino acid protein ubiquitin (Ub) to a protein target
(monoubiquitination), or a chain of Ub molecules (polyubiquitination). The
latter is greatly complicated by the fact that linkage of consecutive Ub
molecules in the chain can occur at any of the seven Lys residues present in the
Ub protein.137 Therefore rigorous study of the effect of ubiquitination on the
function of a given protein requires access to homogeneously ubiquitinated
analogues of the protein in question.
α-Synuclein (α-Syn) is a 140-residue intrinsically disordered protein that
plays a central role in Parkinson’s disease and several other neurodegenerative
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disorders.136 Ubiquitination is hypothesized to be involved in regulating the
formation of fibrillar α-Syn aggregates, which occurs in diseased brain tissue.
In 2013 Haj-Yahya et al. reported the semisynthesis of site-specifically mono-,
di-, and tetraubiquitinated forms of α-Syn.136 A summary of the approach is
given in Scheme 4.2.
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Recombinantly expressed fragment [A30C]α-Syn(30-140) (42) was first
ligated with synthetic thioester 41, incorporating the thiazolidine-protected
form of δ-mercaptolysine at the Lys-12 position. Deprotection of the
thiazolidine group (using methoxyamine) yielded the full α-Syn sequence
(43). Ubiquitin monomers were produced by total chemical synthesis, which
enabled the necessary site-specific attachment at defined Lys residues within
the Ub sequence. N-Methylcysteine-mediated latent thioester formation138
was proposed to produce the necessary Ub-thioesters for attachment to α-
Syn, although attempts to produce the entire tetraubiquitin molecule were
found to be problematic due to difficulties in the final thioester formation
step.
Instead two separate diubiquitin fragments were synthesized (46 and 50)
and ligated sequentially with α-Syn. Monoubiquitin thioesters 44 and 48
underwent isopeptide chemical ligation (ICL) with N-methylcysteine ‘latent’
thioesters 45 and 49, respectively, to form diubiquitin units linked at the side
chain of Lys-48. Diubiquitin thioesters 46 and 50 were obtained following
an N→S acyl shift in the presence of 4-mercaptophenylacetic acid (MPAA)
(photolysis of the 2-nitrobenzyl protecting group was required first for 45).
Sequential ligation of 46 (followed by thiazolidine deprotection) and 50
to the δ-mercaptolysine side chain of 43 was then carried out. A final
MFD step was used to convert Cys to Ala in the α-Syn sequence, and all
δ-mercaptolysine residues in the polyubiquitin section to Lys, to give site-
specifically tetraubiquitinated α-synuclein.
With a route to semisynthetic α-Syn allowing full control over the
extent and position of ubiquitination in hand, Haj-Yahya et al. were able to
characterize the biological properties of mono-, di-, and tetraubiquitinated
forms of the protein. In vitro fibrillization studies were carried out at low
concentration (5 µM) to mimic the estimated concentration in neurons.
While wild type α-Syn does not form aggregates at low concentration, the
tetraubiquitinated protein was found to form SDS-resistant high-molecular
weight species at 5 µM in vitro. Transmission electron microscopy was used
to confirm that the wild type protein only formed mature amyloid fibrils after
8 days, whereas tetraubiquitinated α-Syn formed electron-dense aggregates
at 84 h, not possessing an amyloid-like structure. Haj-Yahya et al. suggest
therefore that tetraubiquitination at this position results in the formation of
nonfibrillar aggregates but blocks α-Syn fibrillization in vitro.
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It was also demonstrated that phosphorylation at Tyr-125 of α-Syn
destabilized both di- and tetraubiquitinated forms, causing a tendency to
precipitate (unlike the wild type), suggesting the possibility for crosstalk
between these two PTMs. In addition di- and tetraubiquitinated α-Syn
were shown to undergo efficient proteasomal degradation, whereas the
single ubiquitin moiety is efficiently cleaved by deubiquitinases for the
monoubiquitinated form (thus preventing degradation). It was therefore
suggested by Haj-Yahya et al. that polyubiquitination serves as a signal for
α-Syn degradation by the proteasome. The clearly demonstrated role of
ubiquitination in the regulation ofα-Syn stability, aggregation, phosphorylation
and clearance therefore suggests that the function of α-Syn in disease may
be under the control of complex regulatory mechanisms involving crosstalk
among different PTMs.136
4.4 Exploring novel protein chain topologies
The small, disulfide-rich protein crambin was previously chemically synthe-
sized by Bang et al. in 2004 using NCL.108,109 Subsequent synthetic work by
the Kent group, in which the carboxylate of the C-terminal Asn-46 residue
was replaced with an amide, demonstrated the importance of the salt bridge
between Arg-10 and the C-terminus for correct folding and disulfide bond
formation.139 It was proposed that replacing the salt bridge by a covalent
linkage would result in a protein bearing an unusual topology lacking a
C-terminus.140 Furthermore the structure would be of particular interest
due to the threading of the linear N-terminal section through the covalent
macrolactam ring, resulting in a topology reminiscent of the lasso peptide
fold (see Chapter 3). A chemical synthesis was carried out incorporating Lys
at position 10 in place of Arg, with an amide bond installed between the
Lys side chain and the C-terminus. The approach reported is summarized in
Scheme 4.3.
Fragments 52 and 53 were used in a ‘kinetically controlled ligation’ (KCL)
whereby the N-terminal Cys of 53 reacts more rapidly with C-terminal peptide
aryl thioester 52 than the alkyl thioester C-terminus of 53. KCL reactions must
necessarily be carried out in the absence of exogenous thiol, as the presence
of a catalyst such as MPAA would cause interconversion to the more reactive
aryl thioester. The more rapid reaction of the Ala thioester (at position 15)
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Scheme 4.3: Synthesis of topological analogue of crambin (55). Intermediate
54 was assembled from fragments 52 and 53 via a kinetically controlled ligation
(KCL, see text), followed by conversion of Thz to Cys. Subsequent cyclization,
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in Figure 4.2). Fragments were synthesized using in situ neutralization Boc SPPS. R =
CH2CH2CO(Arg)4−Ala−COOH. Adapted from Mandal et al.140
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than the hindered Thr-39 thioester was also exploited in this case. The Thz
residue was converted to Cys in the same pot following the ligation reaction,
using methoxyamine at pH 4.0. The reaction mixture was diluted and the pH
adjusted to 6.8 before carrying out the intramolecular NCL reaction to form
the cyclic product. Acm protecting groups were used for side chains of Cys
residues not at ligation sites (not shown), and these were removed before
HPLC purification, folding and oxidation in a redox buffer to yield 55.
An X-ray crystal structure of the synthetic protein is shown in Figure 4.2.
While crystallization trials with 55 over a period of several months were not
initially successful, microcrystals were obtained from a quasi-racemateI of
55 and synthetic D-crambin after 4 days in 40-50% of the conditions tested.
Topologue 55 was found to share a similar fold with native crambin, with
correct disulfide bond formation. It can be seen however that introduction
of the amide bond between the C-terminus and Lys-10 results in a folded
structure where the N-terminus is threaded through a macrolactam ring and
is held in place by two disulfide bonds (as shown). The structure presented by
Mandal et al. therefore represents a previously undiscovered protein topology
made accessible by chemical synthesis.
4.5 Methods used for the synthesis of peptide
thioesters
Despite the applicability of native chemical ligation to whole protein chemical
synthesis (as illustrated by the examples given), a major drawback is the
difficulty in producing peptide thioesters using Fmoc SPPS. While multiple
strategies exist,142 no single method has emerged as the dominant technique.
Direct Fmoc-based solid-phase synthesis of peptide C-terminal thioesters can
be achieved using a thioester linkage to the solid support, although this linkage
is susceptible to cleavage by piperidine during the Fmoc deprotection step.142
While this can be avoided using less nucleophilic bases for Fmoc deprotection
(such as hexamethyleneimine or DBU143,144), linker aminolysis still occurs
during early synthesis cycles.142
A number of auxiliary-mediated approaches exist for the synthesis of
thioesters via intramolecular N→S or O→S acyl shift in solution following
IFor further reading on racemic protein crystallography see the review by Yeates and Kent
(2012).141
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Figure 4.2: Crystal structure of chemically synthesized topological analogue of
crambin (55). The salt bridge present in the wild type between Arg-10 and the
C-terminal carboxylate group is instead replaced by a covalent linkage. Disulfide
bridges are shown in yellow. PDB ID: 3UE7.36,140
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cleavage from the resin.142 Various auxiliaries have been reported for
this purpose, including modified thiol-containing amino acids and thiol-
functionalized aromatic backbone ‘protecting’ groups. Indeed, in some cases
so-called ‘reverse’ NCL can occur for peptides bearing internal Cys residues,
which can rearrange to the corresponding thioester fragment upon treatment
with MPAA.145 Burlina et al. reported that methylation of cysteine at the alpha
carbon allowed its use as a thioester surrogate when sited at the C-terminus
of a peptide.146
The most frequently utilized methods for thioester generation involve
synthesis on the solid phase using specially adapted linkers, such as the
‘sulfonamide safety-catch’.147–149 Safety-catch linkers are designed so as not
to be susceptible to attack unless activated by chemical modification, thus
remaining untouched during peptide synthesis cycles. The sulfonamide safety
catch and another safety-catch linker – the Dawson Dbz linker150 – are shown
in Scheme 4.4. More recently introduced strategies for the synthesis of
thioesters or thioester surrogates are also described below.
4.5.1 The sulfonamide safety-catch
The sulfonamide safety-catch is a linker that can be used for Fmoc SPPS.
After completion of the synthesis the linker nitrogen is alkylated (using
either iodoacetonitrile or trimethylsilyldiazomethane), and the desired peptide
thioester is released via attack with an appropriate thiol (Scheme 4.4). A
drawback of this method is that the final thiolysis step can be very low yielding
(as demonstrated by previous work within the group115), although the use of
2 M LiBr/THF as the solvent during this step was found to give a significant
yield increase by Quaderer et al.151
The sulfonamide linker can also be attached to the support via an acid-
labile linkage (such as Rink amide) to facilitate synthesis monitoring by small-
scale TFA test cleavages. This approach also allows direct cleavage of the
N-alkylsulfonamide (without thiolysis) which can be used in ligations directly
(see Chapter 5).152
4.5.2 The Dawson Dbz linker
After Fmoc SPPS the Dawson Dbz linker is cyclized to the reactive N-acylurea
species using p-nitrophenylchloroformate, and the peptide is released by
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Scheme 4.4: SPPS linkers used for the synthesis of peptide thioesters or N-
acylureas.142 (a) The sulfonamide safety-catch method involves synthesizing the
peptide on sulfamylbutyryl resin (56), alkylating the linker (using ICH2CN or TMS-CHN2) and releasing the peptide thioester from the activated linker via attackwith the desired thiol.142 (b) The Dawson Dbz linker (57) is used to produce
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treatment with TFA (Scheme 4.4). The resulting peptide N-acylurea can be
used directly in ligations or converted to the thioester in solution via treatment
with thiol.150 While steric and/or electronic factors normally prevent reaction
at the second linker amine, coupling can nevertheless occur – particularly
with sequences rich in sterically unhindered amino acids such as glycine –
resulting in so-called ‘overacylation’ and the formation of undesired branched
by-products.150
Previous work within the group (S. Lear, MSc thesis 2013)115 showed that
MW heating promoted overacylation of the Dbz linker, even for sequences
without glycine and containing relatively hindered amino acids. To circumvent
this problem an Alloc-protected Dbz linker77 was used (Scheme 4.5), which
was found to be effective. The use of a Di-Fmoc-Dbz linker for MW-SPPS was
recently published by Gunasekera et al.153
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Scheme 4.5: Reaction onto the second Dbz linker amine during SPPS (overacylation)
can be prevented using an Alloc-protected linker (58).77 (a) Alloc protection is
accomplished by treatment with allyl chloroformate. (b) Following SPPS, the Alloc
group is removed using Pd(0) (see Chapter 3).
76
Chapter 4. Current progress in whole protein chemical synthesis
4.5.3 Peptide hydrazides
More recently, peptide hydrazides have been found to act as suitable thioester
surrogates for NCL.154 Peptide hydrazides can be synthesized directly on a
solid support using the linker shown in Scheme 4.6. Cleavage from the resin
and global deprotection using TFA occurs as normal to release the peptide.
The activation step involves NaNO2 oxidation to the azide, with subsequent in
situ conversion to the thioester using MPAA in a one-pot fashion.155 As peptide
hydrazides are unreactive until unmasked in this manner, they can be utilized
for convergent assembly of large peptides and proteins using multiple fragment
approaches.156 The generation of peptide hydrazides via direct hydrazinolysis
of peptides attached to TentaGel® Wang resin has also been reported.157
4.5.4 SEA and SeEA peptides
Another recently reported highly versatile approach is the use of bis(2-
sulfanylethyl)amido (SEA) peptides as thioester surrogates.158 SEA peptides
can be synthesized on resin using the linker shown in Scheme 4.6 and released
using standard TFA cleavage protocols. The C-terminal SEA moiety can
undergo an N→S acyl transfer to generate the thioester in water at neutral or
mildly acidic pH, which can be used directly in NCL reactions.159 The selenium
bis(2-selenylethyl)amido (SeEA) analogue (also shown) is significantly more
reactive and therefore adds an additional layer of orthogonality, enabling
one-pot three fragment assembly under kinetic control (see section 4.4).160
The corresponding cyclic disulfide (shown) and diselenide forms of these
functional groups are unreactive towards Cys peptides, and can therefore
be used as masked intermediates in ligation reactions.162 Furthermore, the
diselenide analogue is less easily reduced – the disulfide can be reduced using
dithiothreitol (DTT) whereas the diselenide cannot and requires TCEP – which
adds yet a further orthogonal aspect the the approach.161
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Scheme 4.6: Recently developed approaches for the synthesis of peptide thioester
surrogates. (a) Peptide hydrazides can be synthesized directly on resin and the
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(see text).161
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4.6 Conclusions and future work
It can be seen that total chemical synthesis is an important tool that can be
used to answer important biological questions, not only for small bioactive
molecules but for whole proteins also. Furthermore the importance of whole
protein total chemical synthesis in addressing challenges that cannot be solved
by other means has been illustrated. The native chemical ligation reaction has
proven essential to the field, enabling the total chemical synthesis of numerous
targets of interest with those bearing precise chemical modifications (such as
PTMs) at defined sites being of particular significance. The next chapter
describes work towards the total chemical synthesis of acyl carrier protein
employing many of the techniques discussed here. The development of a
novel linker which can be used to synthesize peptide N-acylureas without
overacylation is also described.
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Chapter 5
Total chemical synthesis of E. coli
acyl carrier protein
S ubstantial amounts (>50 mg) of a protein of interest are often requiredin order to characterize its role in a biological system fully. Whilerecombinant expression is conventionally used for this purpose,163total chemical synthesis can provide a target protein bearing site-
specific incorporations of any of an almost endless array of unnatural amino
acids, typically in >100 mg quantities. The following chapter details progress
made in the total chemical synthesis of acyl carrier protein (ACP), an important
component of the cellular machinery responsible for the biosynthesis of fatty
acids.164 Chemical synthesis will provide a route to modified ACPs, which
will be used to elucidate the role of protein-protein interactions in fatty acid
biosynthesis, while offering insights into the functioning of modular synthase
systems in general.
5.1 Introduction
Multienzyme megasynthetases are large polypeptides responsible for the
biosynthesis of polyketides, nonribosomal peptides and fatty acids in living
organisms.165 The sequential action of independently folded catalytic domains
within each multienzyme results in a range of complex and highly diverse
secondary metabolites, examples of which are shown in Figure 5.1. A
schematic detailing the path of a polyketide through such a multienzyme
‘assembly line’ is shown in Scheme 5.1. Catalytic domains of various types
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are arranged into modules, each acting in turn to elongate the nascent
polyketide by a two-carbon unit bearing specific functionality. This colinearity
between the sequence of enzymatic transformations and positioning of
catalytic domains is such that features of the product structure can in some
cases be deduced from inspection of the gene sequence.165,166
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Figure 5.1: Examples of polyketide (PK) natural product structures.165
The modularity of megasynthetases makes engineering of chimeric systems
an attractive option for the biosynthesis of a diverse range of secondary
metabolites. While the combining of polyketide synthase (PKS) domains
from different systems has been demonstrated, the resulting PKS turnover
rate often suffers due to the perturbation of protein-protein interactions.167,168
Furthermore, ACP-ketosynthase (KS) domain interactions are weak but
specific, ensuring other ACPs coexisting in the same cell do not transfer their
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biosynthetic intermediates to undesignated KS partners.169 This specificity is
an issue where hybrid PKSs are concerned, and a detailed understanding of
protein-protein interactions within megasynthetases is important for effective
engineering of these systems.
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Scheme 5.1: 6-Deoxyerythronolide B synthase (DEBS). Chain elongation occurs due to the action of ketosynthase (KS) and acyl
transferase (AT) domains, while the final oxidation level of the β-carbon is controlled by the combination of ketoreductase (KR),
dehydratase (DH) and enoylreductase (ER) domains present in a given module. The nascent polyketide is bound to an acyl
carrier protein (ACP) domain at each stage before cyclization and release by the thioesterase (TE) domain at the C-terminus of
the polyketide synthase. LDD - loading didomain; KR∗ - inactive ketoreductase domain. Adapted from Khosla et al.168
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5.1.1 Fatty acid biosynthesis
Fatty acid biosynthesis is a vital process in the synthesis of structural lipids for
bacterial membranes.170 Medium-chain (4–12 carbon) fatty acids are valuable
precursors to industrial chemicals and biofuels,171 and therefore reengineering
of the fatty acid synthesis (FAS) pathway in order to produce ‘tailored’ fatty acid
metabolites is a desirable goal.172 While E. coli FAS has been used to produce
fatty acids, alcohols, esters and alkanes,171 the significance of biomolecular
interactions within megasynthetase systems – of which fatty acid synthase
(FAS) is an example – means a complete understanding of these interactions
is required. In addition, bacterial FAS is thought to be an attractive target for
new antimicrobials.170
Scheme 5.2 shows a so-called ‘type II’ FAS, a dissociated system occurring
in bacteria, plants and parasites, in which each protein is encoded by
a separate gene.173 (‘Type I’ FAS occurs in mammals and consists of a
single polypeptide.173) The fatty acid product is generated through successive
iterations of the FAS cycle, each resulting in elongation of the carbon chain by
two atoms. Acyl carrier protein (ACP) acts to shuttle fatty acyl intermediates
between enzymes in the system, as well as introducing malonate (from
malonyl-CoA,173 not shown) which is condensed with the growing fatty acid
acyl-ACP at stepÀ during each cycle. ACP also bears a 4’-phosphopantetheine
prosthetic group, which is transferred from CoA (65) to Ser-36 of apo-ACP by
ACP synthase (not shown).173,174 4’-Phosphopantetheine and related CoA are
shown in Figure 5.2.
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Scheme 5.2: Each enzyme of the Type II fatty acid synthesis (FAS II) pathway is encoded by a separate gene and exists as
a soluble protein – the elongation cycle of E. coli FAS II is shown.173 Each cycle is initiated by condensation of the growing
fatty acid acyl-ACP with malonyl-ACP, catalysed by β-ketoacyl-ACP synthase I or II, À. The product is then reduced by the
NADPH-dependent β-ketoacyl-ACP reductase, Á, and subsequently dehydrated by either β-hydroxydecanoyl-ACP dehydratase
or β-hydroxyacyl-ACP dehydratase, Â. The final reduction is carried out by the NADH-dependent enoyl-ACP reductase I, Ã.
P-Pan-SH = 4’-phosphopantetheine (Figure 5.2).
86
Chapter 5. Total chemical synthesis of E. coli acyl carrier protein
HS
N
H
O
N
H
O
OH
O P O P
O
O-
O
O-
N
NN
N
NH2
O
OHO
O
P
O-
O O-
4'-phosphopantetheine
Coenzyme A (CoA), 65
Figure 5.2: 4’-Phosphopantetheine (which is covalently attached to Ser-36 of ACP)
forms part of the structure of (and is transferred from) coenzyme A (CoA, 65).175
Enzyme-ACP interactions are of crucial importance in FAS, in addition
to the closely related sequestration of the nascent fatty acid chain by ACP
and the role of this process in substrate recognition.176 It is hoped that the
chemical synthesis of ACP will allow the generation of tools with which to
investigate enzyme-ACP and ACP-substrate interactions in order to gain a
broader understanding of FAS, as well as related modular synthase systems.
5.1.2 Acyl carrier protein (ACP)
An NMR solution structure of ACP with a bound butyryl acyl intermediate
is shown in Figure 5.3. Binding of the substrate alters the conformation of
ACP,174 and it is thought that in this way the nature of the bound substrate may
affect the stability of the ACP-enzyme complex, hence conferring substrate
specificity.176
Zornetzer et al. found that attaching either decanoate (C10:0-ACP) or
stearate (C18:0-ACP) to the pantetheine prosthetic group of spinach ACP
caused the protein to adopt a single conformer in contrast to the unacylated
protein, which interconverts between two major conformers in solution.176
A macromolecular docking study also suggested that the fatty acid was
positioned down the centre of the helix bundle, and it was hypothesized
that for longer substrate chain lengths increased solvent exposure may induce
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Figure 5.3: Ribbon representation of butyryl-ACP (butanoyl group bound to the thiol
of the 4’-phosphopantetheine prosthetic group, see text). NMR solution structure,
PDB ID: 2K94.36,174
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greater flexibility in the phosphopantetheine loop, hence facilitating protein-
protein interactions with the enzyme.
The flexibility of ACP results in crystallization of the protein being
challenging, and the importance of dynamic protein-protein interactions for
its function means that protein NMR is often a more appropriate technique for
structural characterization of ACP.164,174,176 19F NMR is a powerful technique
that can be used for investigating interactions in fluorine-labelled proteins,117
and total chemical synthesis of ACP will allow the site-specific incorporation
of fluorinated amino acids to produce analogues for use in structural 19F NMR
studies.
Perhaps most importantly, chemical synthesis will allow facile incor-
poration of a variety of amide and ester substrate-bound ACP analogues
(Figure 5.4). These can be used to study enzyme-ACP and ACP-substrate
interactions and are more resistant to hydrolysis than naturally occurring
acyl-ACPs, where the substrate is attached via a thioester linkage to the 4’-
phosphopantetheine prosthetic group.177,178
5.1.3 Previous total chemical synthesis
E. coli ACP has previously been chemically synthesized via automated Boc
SPPS (Hancock et al., 1972).179–181 The protein was synthesized in a stepwise
manner as a single peptide (no ligations used). Cleavage from the resin and
deprotection was carried out using HBr/TFA (with catalytic hydrogenation used
to remove remaining protecting groups) and the crude protein was purified
via gel filtration and ion-exchange chromatography. The resulting apo-ACP
was obtained in 42% yield, and the 4’-phosphopantetheine prosthetic group
was introduced enzymatically using ACP synthase.
An Fmoc SPPS strategy is preferred however, as repeated exposure of the
peptide to TFA during Boc SPPS can result in degradation of the product and
is not likely to be compatible with modifications such as ‘non-hydrolysable’
prosthetic group analogues (which can be installed site-specifically during
Fmoc SPPS). In addition, the use of NCL allows shorter fragments bearing
site-specific incorporations to be synthesized quickly, before attaching the
corresponding ligation partner (which can be synthesized at the same time) to
rapidly generate multiple analogues in parallel (cf. stepwise approach of the
previous synthesis).
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Figure 5.4: (a) During FAS the 4’-phosphopantetheine prosthetic group is installed
(for full structure see Figure 5.2), and the product is subsequently elongated and
released.177 (b) Substrate sequestration by ACP can be investigated using non-
hydrolysable amide substrate analogues, which have previously been enzymatically
installed (unfilled arrow).177 Chemical synthesis will allow access to a broader range
of substrate analogues of this type, as modifications such as these can be incorporated
relatively easily during Fmoc SPPS.
90
Chapter 5. Total chemical synthesis of E. coli acyl carrier protein
5.2 Synthetic strategy
The proposed strategy for the synthesis of E. coli fatty acid apo-ACP (66) using
Fmoc SPPS is given in Scheme 5.3. The whole protein is formed via native
chemical ligation (NCL) of two smaller fragments, one bearing an N-terminal
cysteine and the other with an N-alkylsulfonamide instead of a carboxyl group
at its C-terminus (see Chapter 4). The ligation reaction is carried out in
aqueous solution at neutral pH, with the addition of 4-mercaptophenylacetic
acid (MPAA, 67) as a catalyst.182 Peptide N-alkylsulfonamide 68 and acid 69
are synthesized via Fmoc SPPS and fully deprotected before NCL (see below).
The resulting product, peptide 70, contains an undesired Cys residue (shown)
which is removed via metal-free dethiylation (MFD, see Chapter 4) to give
ACP (66).
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Scheme 5.3: Strategy for total chemical synthesis of E. coli fatty acid apo-ACP (66) via ligation of N-alkylsulfonamide 68 and
peptide acid 69. Fragment 69 contains a Cys residue in place of Ala (which occurs in the final protein), enabling the use of native
chemical ligation (NCL) in the presence of 4-mercaptophenylacetic acid (MPAA, 67). The Cys thiol is removed in the final step to
generate the desired Ala residue (see text).
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5.3 Synthesis of C-terminal section
5.3.1 Initial attempts
Automated Fmoc SPPS of [A34C]ACP(34-77) (69) was carried out using a CEM
Liberty1 peptide synthesizer. Polystyrene Wang resinI was used in order to
obtain the target peptide with an acid at the C-terminus, as desired. Preloaded
resin was used to circumvent problems typically associated with loading,
such as racemization.183 A low substitution (0.33 mmole/g) was chosen in
order to minimize steric hindrance and potential aggregation, which can affect
synthesis quality for SPPS of long peptides. Double couplings were carried
out at room temperature (1 h per reaction) using 5 equivalents of Fmoc amino
acid. Deprotection of the Fmoc group was effected via treatment with 20%
piperidine twice (5 + 10 min).
Synthesis efficiency was monitored at various points by liberating a sample
of the product peptide from a test aliquot of resin. The cleavage cocktail used
consisted of 95% trifluoroacetic acid (TFA) and triisopropylsilane (TIPS) as
a scavenger, unless otherwise stated. After washing with ether to remove
cleaved protecting groups, the resulting peptide mixture was analysed using
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry. Mass spectra of test cleavages at various points during the
synthesis of 69 are shown in Figure 5.5.
Due to the fact that fragment ACP(65-74) (underlined in Figure 5.5) is
traditionally used as a ‘difficult’ sequence to test SPPS protocols, it was
anticipated that the coupling of those residues close to the C-terminus would
be problematic, particularly Val-65.185–188 No problems were encountered
in this instance however, and the use of dimethyl sulfoxide (DMSO) as the
solvent during the coupling of the valine in question (in order to disrupt
aggregation187,188) did not appear to have any effect on reaction efficiency.
The synthesis appears to proceed without problems until Asp-35 (43-mer,
spectrum E), where subsequent coupling and Fmoc deprotection of the N-
terminal cysteine results in a mass spectrum (F) containing multiple peaks
which are attributed to side products resulting from amino acid deletions. As
mass spectrometry is not ideally suited to quantifying the relative amounts
of peptide species present in a crude product mixture, chromatographic
IThe Wang linker is the most commonly used linker for the solid-phase synthesis of
peptide acids.183,184
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Figure 5.5: MALDI-TOF mass spectra from analysis of products of test cleavages
performed at various points during SPPS of [A34C]ACP(34-77) (69). It can be seen
that that the synthesis is largely unproblematic, although coupling of the final Cys
residue and deprotection of the N-terminal Fmoc protecting group results in spectrum
F, which contains multiple peaks belonging to putative deletion by-products resulting
from sequential amino acid omissions (other spectra show Fmoc-protected peptide).
‘Difficult’ sequence ACP(65-74) is underlined (see text).
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purification was attempted in order to separate the desired target 69 (m/z =
4895.5) from any deletion peptides present in the crude material. Reversed-
phase HPLC purification of 69 was hindered however by the acidic peptide’s
extremely poor solubility in conventional low pH solvent systems. Attempted
solubilization of the sample via the addition of DMF, DMSO or guanidinium
chloride was unsuccessful, and while basification using DIPEA was sufficient to
dissolve the sample before injection, elution of the product was not observed
presumably due to precipitation occurring upon introduction of the peptide
into the acidic HPLC solvent flow. Due to the large number of charged
residues present in the sequence (Asp/Glu), purification using ion-exchange
chromatography was attempted, but was also unsuccessful.
5.3.2 Addressing fragment solubility
As illustrated, attempts to synthesize 69 resulted in poor quality crude product,
and by far the most significant difficulty proved to be the extremely poor
solubility of the crude peptide and the resulting difficulties associated with
HPLC purification. In light of these difficulties, the use of pseudoproline
dipeptides during the synthesis of 69 was proposed in order to disrupt
aggregation and thus improve synthesis quality (Scheme 5.4). Pseudoprolines
revert to the parent dipeptide upon cleavage of the peptide from the resin
however, therefore this strategy does not address the issue of the poor
solubility of the fully deprotected peptide during purification and handling.
The incorporation of backbone protection is another strategy that can
be used to disrupt peptide secondary structure formation and hence improve
synthesis quality during SPPS.190–194 Furthermore, backbone protecting groups
such as 2-hydroxy-4-methoxybenzyl (Hmb) can be rendered impervious to
TFA-mediated removal via acetylation, and retained after cleavage from the
resin in order to solubilize the product peptide during subsequent purification
steps.146,195 The steps involved in an Hmb protection strategy are illustrated
in Scheme 5.5.
The automated synthesis of fragment 69 was repeated as previously carried
out. Pseudoprolines were incorporated at the positions shown in Figure 5.6,
and Val-43 was incorporated as the Hmb-protected building block (as this was
shown to be close to the point where product quality deteriorated in previous
syntheses) in a minimum volume of DMF. The leucine residue following Val-
43 was double coupled using the symmetrical anhydride (each overnight,
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Scheme 5.4: Pseudoproline dipeptides (of the form XS or XT, where X is another
amino acid) can be incorporated via Fmoc SPPS and undergo acidolysis during the
TFA cleavage step to generate the uncyclized dipeptide.189 The Fmoc-protected serine
dipeptide building block is shown (side chain of X represented by R group).
RT) due to the difficulty in acylating the phenolic Hmb hydroxyl group. This
reaction was carried out in DCM, to favour the required O→N acyl migration.II
Microwave assistance (with DIC/HOBt activation) was also used in an attempt
to increase the efficiency of the coupling and deprotection reactions.197
Figure 5.6: Sequence of ACP C-terminal fragment [A34C]ACP(34-77) (69) showing
the sites of incorporation of pseudoproline dipeptides and Hmb-protected building
block (at Val-43), bold underlined.
Boc-Cys(Trt)-OH was coupled as the N-terminal residue to prevent
reaction of the N-terminus during acetylation of the Hmb hydroxyl. The
peptide-resin was first treated with piperidine to free any Hmb hydroxyl groups
that may have become acylated during the synthesis, before acetylation with
acetic anhydride/DIPEA.146 DIPEA is required as Hmb acetylation was shown
by Quibell et al. to be unsuccessful using acetic anhydride alone.195 Cleavage
IIAcylation of the exposed Hmb hydroxyl occurs preferentially over coupling onto the
hindered secondary amine at the N-terminus of the peptide. The aryl ester intermediate then
undergoes an intramolecular acyl migration to generate the required amide bond.196
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Scheme 5.5: Hmb backbone protection can be introduced into a peptide via
incorporation of the appropriate Fmoc-protected building block.193 Acetylation of
the Hmb hydroxyl prevents loss of the protecting group during TFA-mediated
cleavage of the peptide from the resin. Hmb protection can be retained to enhance
solubility during subsequent purification/handling, and removed when required via
deacetylation in dilute hydrazine solution, followed by TFA treatment.146
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of the backbone-protected peptide from the resin was then carried out using
standard TFA cleavage conditions.
The solubility of the crude material was found to be vastly improved when
compared to that of the crude product from the previous synthesis (where
Hmb protection was not utilized). The Hmb-protected peptide dissolved
readily in a 1:1 MeCN/water solvent blend (containing 0.1% TFA), and injection
onto a preparative HPLC column resulted in a strong absorbance signal at
220 nm that was significantly higher than the baseline level. Unfortunately
however, the peptidic material observed appeared to elute as a single broad
peak assumed to be comprised of an ensemble of deletion peptides, as MALDI-
TOF MS analysis of multiple fractions taken from within the peak failed to
identify the target peptide.
It was concluded that while incorporation of backbone protection during
the synthesis did not appear to markedly improve product quality, the
assumed retention of the acetylated Hmb group appeared to drastically
improve solubility of the peptide, thus rendering HPLC purification possible.
This demonstrates that backbone protection is a hugely valuable strategy
when attempting the synthesis and purification of poorly soluble peptides.
Future work will involve resynthesis of the peptide with incorporation of Hmb
protection at multiple sites, with the aim of disrupting on-resin aggregation
(in addition to solubilization of the cleaved product) enabling synthesis of the
full target sequence. Various alternative backbone protecting groups have
recently been reported by Abdel-Aal et al. and may also prove useful, such
as 2-hydroxy-4-methoxy-5-methylsulfinyl benzyl (Hmsb)196 and 2-hydroxy-4-
methoxy-5-nitrobenzyl (Hmnb).198 Both Hmsb and Hmnb are rendered acid
labile via reduction, and can be incorporated via fully automated MW-SPPS
protocols.
5.4 Synthesis of N-terminal section
A synthesis of ACP(1-33) N-alkylsulfonamide (68, Scheme 5.3) was also
attempted via automated Fmoc SPPS using the sulfonamide linker (Chapter 4).
Aspartic acid and asparagine residues were triple coupled to remove deletion
sequences present in test cleavage samples from a preliminary synthesis (not
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shown). Boc-Ser(OtBu)-OHIII was coupled as the final amino acid to protect
the N-terminus during the subsequent linker alkylation (Scheme 5.6). The
mass spectrum for the test cleavage of 71 (unalkylated) is shown in Figure 5.7.
Figure 5.7: MALDI-TOF mass spectrum from test cleavage of unalkylated ACP(1-33)
N-acylsulfonamide (71, Scheme 5.6).
Alkylation of the linker was effected by treatment of 71 with iodoacetonitrile
and DIPEA in DMF for 24 h. A mass spectrum of the resulting test cleavage
mixture is shown in Figure 5.8. Alkylated peptide is present alongside
the corresponding peptide acid, possibly indicating that attack on the more
activated C-terminal carbonyl has occurred resulting in loss of the sulfonamide
linker (Scheme 5.7).
Cyanomethylation199 with iodoacetonitrile was used initially instead of the
more widely performed methylation200 due to the extreme toxicity201 of the
IIICommercially available as the DCHA salt, which is liberated with 10% H3PO4 beforeuse.
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Scheme 5.6: Synthesis of ACP(1-33) N-alkylsulfonamide (68) using sulfamylbutyryl
Rink amide resin. Side chain protecting groups are not shown. Reagents and
conditions: (i) Fmoc SPPS (see Experimental section); (ii) ICH2CN (10 equiv), DIPEA(10 equiv), DMF, RT, 24 h; (iii) TFA (95%, water), TIPS, RT, 4 h.
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Figure 5.8: MALDI-TOF mass spectrum from test cleavage carried out after attempted
on-resin alkylation of 71 (Scheme 5.6). While peptide bearing the alkylated linker
appears to be present, the corresponding peptide acid is also observed, suggesting
partial hydrolysis has occurred (resulting in elimination of the sulfonamide linker).
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Scheme 5.7: Suggested mechanism for hydrolysis of peptide N-
cyanomethylsulfonamides in acidic conditions (0.1% TFA solution).
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methylating agent required (trimethylsilyldiazomethane). It is thought that
peptide N-cyanomethylsulfonamides are more susceptible to hydrolysis than
their methylated counterparts however, due to the presence of the electron
withdrawing nitrile moiety.199 In light of this, the linker alkylation step was
repeated using trimethylsilyldiazomethane in order to generate the more stable
N-methylsulfonamide peptide (75, Figure 5.9) instead. This was carried out
using facilities available at the MRC National Institute for Medical Research,
London (Offer group).
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Figure 5.9: Comparison of N-alkylsulfonamides produced using the sulfonamide
safety-catch linker. Cyanomethylation using iodoacetonitrile/DIPEA produces
N-cyanomethylsulfonamides, such as fragment 68. Methylation using TMS-
diazomethane should instead generate more stable N-methylsulfonamide 75.
Unfortunately the required methylated peptide was not observed, and the
resulting MALDI-TOF MS product peak could not be assigned (potentially due
to side reactions occurring during the methylation reaction). Incorporation of
a pseudoproline into the N-terminal fragment has also been carried out, in the
hope that this will improve the solubility of the resin-bound peptide during
treatment with the methylating agent (used as the commercially available
hexane solution). Given the challenges encountered it was decided that
other strategies for the synthesis of peptide thioester equivalents should be
investigated.
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5.5 A novel nitro-modified Dawson linker
The Dawson Dbz linker can be used as an alternative method for synthesizing
C-terminal peptide thioester equivalents on the solid phase. Undesirable
overacylation can occur when using this approach however, and while the
Alloc protecting group strategy discussed in Chapter 4 (Scheme 4.5) addresses
this problem, it necessarily adds an extra protection step to the synthesis. It
was suggested that replacing one Dbz amine with a nitro group would also
stop overacylation, but without the requirement of an initial protection reaction
(Scheme 5.8). At the completion of the synthesis, reduction of the nitro group
would generate the required amine, allowing cyclization and release of the
product as illustrated in Chapter 4. An exploration of this approach is detailed
in the following sections.
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Scheme 5.8: Replacing an amine group on the Dbz linker with a nitro group would
stop overacylation during SPPS. An amine could then be generated via on-resin
reduction of the nitro group (shown in bold), allowing cyclization and release of
the product to be carried out as normal (see Scheme 4.4, Chapter 4).
5.5.1 Linker loading and MW-SPPS
Initially, attempts were made to Fmoc protect commercially available 4-amino-
3-nitrobenzoic acid (76) as illustrated in Scheme 5.9. These were unsuccessful
however, and no Fmoc-protected product was observed by LCMS after >7 h.
It was suggested that the deactivating effect of the nitro group was causing the
observed difficulties in acylation of the aniline nitrogen of 76, and consequently
Fmoc protection of the linker before loading onto the solid support was
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deemed to be unnecessary. Furthermore, undesirable multiple addition of
the linker would involve coupling of the apparently unreactive and relatively
sterically hindered amine onto a similarly hindered carboxylic acid group,
and was predicted to be unlikely. Indeed, the standard Dbz linker is loaded
routinely bearing Fmoc protection on only one of its amine groups, as steric
and electronic factors are expected to prevent reaction at the second.150
O2N
H2N
O
OH
O2N
FmocHN
O
OH
76 77
Scheme 5.9: Attempted Fmoc protection of 4-amino-3-nitrobenzoic acid (76).
No Fmoc-protected product was observed whatsoever after >7 h (by LCMS).
Reagents and conditions: Fmoc-OSu (1.0 equiv), 1:1 NaHCO3(aq) (0.1 M)/MeCN,
RT, >7 h.77,150
Linker loading and SPPS are shown in Scheme 5.10. Unprotected 76 was
loaded directly onto Rink amide polystyrene resin (0.33 mmole/g) using a
single 1 h coupling (5.0 equiv) and HATU activation. Forcing conditions were
necessary as the loading reaction was found to be relatively inefficient (see
below), presumably due to the electron withdrawing effect of the nitro group.
After capping with acetic anhydride (to acetylate remaining Rink amide resin
amine groups) the test peptide FAAA was built onto the linker using automated
MW-SPPS (double couplings). While capping was anticipated to potentially
also acetylate linker aniline groups, it was necessary to ensure all unreacted
resin amine groups were removed prior to MW-SPPS to prevent C-terminal
peptide amides being released upon cleavage.
A MALDI-TOF mass spectrum of products from the test cleavage is shown
in Figure 5.10. While target peptide 81 is present (m/z = 786.3), a larger peak
at m/z = 622.2 could be assigned to either a double alanine deletion or 81
missing the desired aryl nitro C-terminus (peptide amide only).
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Scheme 5.10: Loading of and MW-SPPS using novel nitro-Dbz linker. Reagents and
conditions: (i) Rink amide, 76 (5.0 equiv), HATU (4.8 equiv) and DIPEA (10 equiv),
DMF, RT, 1 × 1 h; (ii) 20% acetic anhydride, DMF, RT, 30 min; (iii) Fmoc-Ala-OH
(5.0 equiv), PyBOP® (10 equiv) and DIPEA (20 equiv), DMF, 75 ◦C, 2 × 10 min, MW;
(iv) Fmoc MW-SPPS (see Experimental section); (vi) TFA (95%, water), TIPS, RT, 4 h.
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Figure 5.10: MALDI-TOF mass spectrum from test cleavage of peptide 80
(Scheme 5.10). While target 81 and deletions (bearing the nitro linker) are present,
the largest peak can be assigned to 81 missing the linker (peptide amide only).
5.5.2 Linker nitro group reduction
On-resin reduction of the nitro group was attempted using the mild reducing
agent sodium hydrosulfite (Na2S2O4) under the phase-transfer conditions
developed by Kapla´nek et al. for reduction of resin-bound nitroarenes
(Scheme 5.11).202 Although Na2S2O4 has been demonstrated to effectively
reduce compounds of this type,203 the reagent suffers from poor solubility
in organic solvents and needs to be used in aqueous solution, which is
incompatible with conventional polystyrene solid supports. While attempts at
reductions using blends of water and water-miscible solvents such as NMP,
DMF and THF have met with some success,203 it was thought that a biphasic
system of DCM and water with an added phase-transfer catalyst would be
more suitable to ensure swelling of the resin and simultaneous solvation of
the reducing agent.202
The resin was agitated with Na2S2O4 and K2CO3 in a 1:1 mixture of water
and DCM to which the phase-transfer catalyst tetrabutylammonium hydrogen
sulfate (TBAHS) had been added. After 9 h the yellow colouration of the
support had disappeared, and a test cleavage was performed (mass spectra
shown in Figure 5.11). While reduction of the nitro species present appears
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to be have been partially successful, it was tentatively suggested that only a
small proportion of the aryl amine (Dbz-functionalized) peptide is present after
reaction under the conditions used. Repeating the reduction in water/DMF
with microwave heating at 40 ◦C/10 WIV was not successful. No deprotection
of the Fmoc group was observed in the presence of K2CO3.
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Scheme 5.11: On-resin reduction of the linker nitro group under phase-transfer
conditions. Reagents and conditions: Na2S2O4 (20 equiv), K2CO3 (28 equiv), TBAHS(2.0 equiv), DCM/H2O (1:1), RT, 9 h.
IVNa2S2O4 disproportionates above 50 ◦C.203
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Figure 5.11: MALDI-TOF mass spectra from test cleavages of linker nitro group
reduction after 2 h (top spectrum) and 9 h (bottom spectrum). Peaks corresponding
to peptides bearing aryl nitro C-termini are labelled with filled boxes (), while those
belonging to reduced (Dbz) peptides are marked with unfilled boxes (). The target
peptide peak is boxed. Reduction of the linker nitro group appears to be partially
successful, with an apparent increase in reduced species with prolonged reaction
time. Automated peak assignment was carried out using Peptide Calculator (see
Chapter 6).2
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5.6 Conclusions and future work
Significant progress has been made towards the total chemical synthesis of E.
coli ACP. The complete N-terminal fragment has been synthesized as the N-
alkylsulfonamide by SPPS, and while cyanomethylation was found to produce
potentially unstable peptide intermediates, attempts to produce the more
stable methylated sulfonamide analogues are ongoing. Synthesis of the C-
terminal fragment could not be completed due to solubility issues, although
these were circumvented by introduction of Hmb backbone protection,
resulting in a soluble crude product that was observed by HPLC. Further
syntheses will be trialled involving the incorporation of the Hmb group at
other positions in the sequence, with the aim of increasing the quality of the
crude product. Native chemical ligation of the two sections will be carried
out in neutral aqueous buffer in the presence of a thiol catalyst, and native
apo-ACP will be obtained via metal-free dethiylation in the final step.
The application of a novel nitro-functionalized linker based on Dawson’s
Dbz linker has also been demonstrated successfully, which should allow
overacylation-free MW-SPPS. This serves as an alternative approach for the
synthesis of peptide thioester equivalents on resin, such as the N-terminal
fragment required for the total chemical synthesis of ACP. Improvement of the
linker reduction step is necessary, and different reduction conditions should
be investigated. For example, a hydrophilic poly-ε-lysine support such as
SpheriTide® may be more suited to reactions using water-soluble reagents in
aqueous solvent.204,205 An alternative approach for the reduction of aromatic
nitro groups on resin using chromium chloride (CrCl2)206 and was also recently
demonstrated by Abdel-Aal et al. to be significantly more effective than the
Na2S2O4 reduction under phase-transfer conditions attempted here.198
However, during the period of work described Blanco-Canosa et al.
reported an improvement to their existing Dbz approach in the form of
a ‘second generation’ linker bearing a methylation on the alternate aniline
nitrogen (Figure 5.12), which was demonstrated to effectively suppress
overacylation. It is also interesting to note the use of a glycine spacer in
this study to facilitate coupling of the sterically hindered aromatic linker
to the resin, an approach which may improve linker loading for the nitro-
functionalized linker described. The ‘MeDbz’ linker represents an elegant
solution to the problem of overacylation, and while there are certainly benefits
to the method discovered here, such as rendering undesirable overacylation
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completely impossible, given the apparent poor linker loading and reduction
efficiency it is suggested that use of the MeDbz linker for the synthesis of the
N-terminal ACP fragment may be preferable.
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Figure 5.12: Comparison of Dbz linker (57) and second-generation ‘MeDbz’ linker
(83) recently reported by Blanco-Canosa et al.207
Once complete, the total chemical synthesis will enable the creation of
site-specifically modified ACP analogues which will be used to investigate the
role of ACP-subunit and ACP-substrate interactions in fatty acid synthetases,
and the identification of specific residues involved at those interfaces. The
incorporation of fluorescent probe residues116,208 will allow site-specific
labelling of the protein, offering the potential to use fluorescence resonance
energy transfer (FRET) experiments to investigate domain arrangement and
interaction distances between ACP and labelled substrate or catalytic subunit
residues. The specificity afforded will circumvent selectivity issues due to off-
site tagging encountered during previous attempts to measure intersubunit
distances in fatty acid synthetases using FRET.209,210
Labelling using fluorinated residues will enable structural characterization
via fluorine-19 NMR studies.117 The incorporation of non-hydrolysable 13C-
labelled fatty acid substrate analogues at Ser-36 will be possible during Fmoc
SPPS (see Figure 5.4). By inserting a fluorinated phenylalanine building block at
residue Phe-50, heteronuclear nuclear Overhauser effect (NOE) experiments
between 13C and 19F labels will be used to probe protein structure and
dynamics in solution. This will help to elucidate the crucial role of substrate
sequestration within the hydrophobic binding cleft of ACP,176 shedding light
on how this causes conformational changes within the protein, and the extent
to which these modulate ACP-subunit interactions and confer specificity for
designated catalytic domains.
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The introduction of residues bearing selectively reactive groups will also
allow site-specific cross-linking between ACP and catalytic subunits. Azide-
tagging, for example, would enable the use of Azide-Alkyne Cycloaddition
chemistry, whereby the tagged ACP could be covalently ‘clicked’ onto
a catalytic domain bearing a genetically encoded alkyne moiety.211 The
ability to site-specifically incorporate each tag means that the cross-linking
could be carried out with high spatial precision, with no risk of off-site
reactivity. High-resolution structural characterization of cross-linked ACP-
enzyme complexes will facilitate elucidation of synthetase protein-protein
interactions via crystallographic and NMR techniques, and cryo-electron
microscopy.
Total chemical synthesis will enable the generation of diverse libraries of
selectively modified ACPs, thus paving the way for the production of novel
tools with which the function of modular synthetases can be interrogated.
The toolkit of chemically modified ACPs will be invaluable in shedding
light on the mechanisms behind the function of FAS, PKS and multienzyme
megasynthetases in general.
111

Part III
Synthesis of dual function cancer
targeting peptides

Chapter 6
Synthesis of tumor targeting
peptides for cancer cell imaging
and tumor growth inhibition
T he inhibition of a protein target shown to be essential for tumor growthis a desirable goal for researchers seeking to understand the cellularprocesses underlying tumorigenesis. The conjugation of emissiveprobe moieties to peptides incorporating inhibitory sequences and/or
those which target cellular compartments offers the potential for selective
imaging of these processes alongside tumor growth inhibition. The following
chapter describes the synthesis of a number of peptides designed to target a
specific protein shown to be essential for tumor growth. Their incorporation
into luminescent probes and use in cancer cell imaging and tumor growth
inhibition is also described.
6.1 Introduction
Epstein-Barr virus (EBV) is a member of the herpesvirus family that infects
over 90% of humans worldwide.212 EBV has been discovered in tissues from
patients with numerous cancer types including T-cell lymphomas, Hodgkin’s
disease, non-Hodgkin’s lymphoma, Burkitt’s lymphoma and nasopharyngeal
carcinoma. In the case of the latter, tumorigenesis has been attributed
to the latent EBV infection.213 Epstein-Barr nuclear antigen (EBNA1) is a
critical component of the EBV lifecycle and has been found to directly
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contribute to the tumorigenic cell phenotype. Given that homodimerization
is required for EBNA1 to function, the development of agents that inhibit the
EBNA1 dimerization process represents a significant opportunity for potential
therapeutic targeting of EBV-associated cancers.6
While a number of EBNA1-specific protein-protein interaction inhibitors
have been reported, most cannot be easily imaged in vitro and suffer from low
bioavailability and poor water solubility.6 To overcome these disadvantages
a novel hybrid system was proposed consisting of a water-soluble EBNA1
targeting peptide conjugated to a small organic fluorophore. The approach
is illustrated in Figure 6.1, and offers the potential for simultaneous imaging
and EBV-associated tumor growth inhibition in vitro. The design, synthesis
and biological evaluation of the proposed system is described in the following
sections.
6.2 Design and synthesis of EBNA1 targeting
peptides
As EBNA1 is primarily located in the nucleus of EBV-infected cells, the targeting
peptide required both EBNA1 and nuclear targeting regions to be incorporated
into its sequence. Binding free energies of potential peptide conjugates
were evaluated in silico following molecular dynamics simulation of each
conjugate in complex with the dimerization interface of the EBNA1 DNA-
binding domain (DBD).6 The targeting sequences shown in Figure 6.2 were
proposed, incorporating an EBNA1 targeting pentapeptide taken from chain
B of the EBNA1 DBD and a polyarginine nuclear targeting sequence. Flexible
linking regions were also included between the two targeting sequences and
at the N-terminus (for attachment to the fluorophore).
116
Chapter 6. Synthesis of tumor targeting peptides
Figure 6.1: Targeting EBV-associated tumors using a dual-function probe. An
emissive inhibitor of EBNA1 dimerization can be used for tumor growth inhibition
and cancer cell killing (À and Á), with simultaneous imaging, Â. Adapted from Jiang
et al.6
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Figure 6.2: Peptide sequences synthesized incorporating EBNA1 targeting motif YFMVF (shown in blue) and nuclear localization
sequence RrRK (red). A diglycine region between the two targeting sequences and an aminohexanoic acid (Ahx) residue at the
N-terminus act as flexible linkers. Lowercase lettering indicates D-amino residues.
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Automated synthesis of peptides 84 and 85 was carried out via Fmoc
MW-SPPS using a CEM Liberty1 peptide synthesizer. Rink amide resin
(0.82 mmol/g) was used in order to install the required C-terminal amide
group. The amino acid building block was added manually to the reaction
vessel at the required point in the coupling cycle for D-Arg and Ahx residues.
Double couplings and extended Fmoc deprotection reaction times (using MW
heating) were utilized for Arg residues due to the difficulty in coupling multiple
consecutive Pbf-protected arginine building blocks. Double couplings were
also found to be necessary for Cys residues, and an extended cycle was
required for Ahx. The presence of each target peptide was confirmed by
MALDI-TOF MS after test cleavage (m/z = 1632.0 and 1631.7, for 84 and 85
respectively). Resin-bound peptides were sent to the research group of Gary
Ka-Leung Wong (Hong Kong Baptist University) for on-resin coupling of the
fluorophore shown in Figure 6.3 to the N-terminus, cleavage from the resin,
HPLC purification and biological evaluation.6
N
N
O
OH
(P)86
Figure 6.3: Structure of small organic fluorophore coupled to N-terminus of peptides
84 and 85 (to give P-84 and P-85).6
6.3 Automated assignment of peptide mass
spectra
Mass spectrometry is the principle technique used in peptide chemistry for
initial confirmation that a target molecule is present following a synthesis (as
evidenced by the work presented thus far). Where inefficient couplings occur
during syntheses of so-called ‘difficult’ sequences (such as those encountered
in Chapter 5) multiple amino acid deletion peptides are often present, which
appear as by-product peaks in the mass spectrum and can greatly complicate
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analysis. Furthermore, most of the synthetic peptides described in this and
the preceding chapters contain unnatural or non-canonical amino acids, or
chemically modified termini, which cause calculation of peptide molecular
weight to be non-trivial. These complications, in combination with the fact
that a given peptide may also appear in the mass spectrum in the form of a
metal and/or protecting group adduct, often result in the assignment of peptide
mass spectra being a challenging and time-consuming process.
To address this problem the web utility Peptide Calculator was developed
(Lear and Cobb, 2016), and has been used for the assignment of mass
spectra shown throughout this report.2 An example assignment automatically
generated by Peptide Calculator is shown in Figure 6.4 for a MALDI-TOF
mass spectrum from a synthesis of peptide 85 (Figure 6.2). Many by-product
peaks are present in the spectrum and upon initial inspection the molecular
ion for the target peptide is not found. However, through reference to the
assignment table given it is apparent that the target peptide is present as the
Pbf adduct (m/z = 1885.0), indicating that an extended TFA deprotection time
is required. During sequence input multiple non-canonical residues can be
incorporated such as Ahx (Figure 6.4), Dpr (Chapter 2), and Alloc- and allyl
ester-protected residues (Chapter 3), in addition to user-specified N- and C-
terminal modifications, including N-terminal acylation (Chapter 2), C-terminal
alkylation (Chapter 3), and the plethora of thioesters and thioester equivalents
described previously in Chapters 4 and 5.
Various other features are also available alongside molecular weight
calculation and MS assignment, including calculation of isoelectric point and
molar extinction coefficient, and ChemDraw structure file export. A plot of
β-strand propensity is also generated for sequences where an indication of
potential synthesis difficulty may be required. The MS assignment features
described are also available for peptoids through the sister utility Peptoid
Calculator, and both utilities are available online at http://www.pep-calc.com.
More information is available in the article included in Appendix D. Peptide
Calculator has greatly simplified the assignment of all mass spectral data
reported, in particular the characterization of complex mixtures of peptides
exhibiting a variety of unusual C-terminal functionality described in Chapter 5
(Figure 5.11).
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Peak (m/z) Deletion(s) Adduct(s) Loss(es) Calculated mass
1528.9 C - - 1528.87
1632.9 Ahx, C, G Na+, Pbf - 1633.75
1737.8 F Pbf - 1737.81
1781.0 C Pbf - 1781.87
1885.0 - Pbf - 1884.88
1991.0 F 2Pbf - 1990.81
2029.0 C, K, M 3Pbf - 2028.73
” M Na+, 2Pbf - 2028.82
Figure 6.4: MALDI-TOF mass spectrum from test cleavage of peptide 85 (sequence
shown in Figure 6.2) annotated with peak assignment automatically generated by
Peptide Calculator. The assignment includes deletions, unremoved protecting groups
and metal ion adducts, with support for non-canonical residues (such as Ahx). Custom
formulae can also be specified in the case of N- or C-terminal modification.
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6.4 Investigation of tumor imaging and growth
inhibition
The binding interaction of fluorescent conjugates P-84 and P-85 with EBNA1
was first characterized experimentally via luminescence titration experiments.
A significant responsive emission enhancement was observed for P-85 upon
addition of EBNA1, corresponding to an apparent binding constant log Ka
of 6.82. An enhancement was also observed for P-84 (log Ka = 5.50). A
chemical cross-linking assay was performed to evaluate the ability of the
peptide conjugates to disrupt EBNA1 dimer formation in the presence of
3-maleimidobenzoyl N-hydroxysuccinimide ester (MBS), an amine-to-thiol
crosslinker containing NHS ester and maleimide reactive groups. The
dimerization efficiency was greatly decreased upon mutation of the YFMVF
motif in the binding site, and furthermore also significantly for the wild type
in the presence of conjugates P-84 and P-85.
Fluorescence microscopy was used to image C666-1 cells (a native
nasopharyngeal carcinoma cell line with latent EBV infection) treated with
P-84 and P-85, and co-stained with a nuclear dye (Figure 6.5). Subcellular
localization of both peptides is observed in the nucleus, with P-85 exhibiting
the best cellular uptake. Nuclear localization was also observed for P-85 in
EBV-negative cancer cell lines (CNE-2 and HeLa).
The colourimetric MTT assay was used to assess cytotoxicity of P-84
and P-85 towards cancer cells in vitro. Both conjugates were found to
exhibit selective cytotoxicity against the EBV-positive C666-1 cell line (P-
85 IC50 = 15 µM), with IC50 values greater than 0.5 mM for EBV-negative
MRC-5 and HeLa cell lines. In vivo effectiveness was also investigated via
intratumoral injections of P-85 or unconjugated peptide 85 in mice carrying
C666-1 xenografts (Figure 6.6). After 21 days average tumor volumes reduced
by 65.5% when treated with the peptide alone (p < 0.005) and 92.3% when
treated with the conjugate (p< 0.001), compared to the control. After sacrifice
and tumor excision, average tumor weights were found to have decreased by
86.6% (p < 0.05) and 92.8% (p < 0.005) respctively, compared to the control.
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Figure 6.5: In vitro imaging of C666-1 cells treated with P-84 (A) or P-85 (B) for 6 h
(10 µM), then co-stained with the nuclear dye Hoechst 33342 for 1 h (1 nM). Emission
intensity profiles were plotted along the green line indicated, and were found to match
between the conjugates (found in the nucleus) and the nuclear stain (under the same
excitation).6
123
Total Synthesis of Bioactive Peptides and Whole Proteins
Figure 6.6: C666-1 mouse xenografts after 21 days of twice-weekly intratumoral
injections of DMSO control (A), or 4 µg of unconjugated 85 (B) or P-85 (C).6
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6.5 Conclusions and future work
Two peptides have been successfully synthesized incorporating both EBNA1
and nuclear targeting sequences. Couplings in the potentially difficult
polyarginine region were accomplished successfully through optimization of
the coupling and deprotection conditions. The peptides were conjugated
to a fluorescent probe and shown to bind to EBNA1 in vitro and disrupt
homodimerization, a process known to be crucial to its function as part
of its role in EBV-associated tumor growth. Tumor cell imaging was also
demonstrated using the conjugates, which were found to undergo effective
nuclear localization in a number of cancer cell lines. In addition to their imaging
potential, selective in vitro cytotoxicity against EBV-positive cancer cells was
also demonstrated, as well as in vivo tumor xenograft growth reduction for
conjugate P-85.
The results reported will allow detailed investigation into the processes
underlying tumorigenesis for EBV-associated malignancies. The conjugates
described will be used to unravel the nature of EBNA1 tethering to host
cell chromosomes, a crucial but as yet poorly understood process.6 The
insights gained will pave the way in the development of diagnostic tools and
therapeutics against EBV-associated cancers.
125

Part IV
Experimental details and
references

Chapter 7
Experimental
7.1 Peptide synthesis
All reagents were purchased from Sigma-Aldrich unless otherwise specified.
Peptide synthesis grade DMF was purchased from AGTC Bioproducts (Hessle,
UK) or Fisher Scientific, and amino acid derivatives were purchased from
CEM, Novabiochem (Merck) or AGTC. DIC and HOBt were purchased from
Fluorochem (Hadfield, UK), and PyBOP® from Apollo Scientific (Stockport,
UK). All resins were purchased from Novabiochem.
Fmoc SPPS procedures are detailed in the following sections. Fritted
polypropylene reaction vessels were used for all manual reactions and resin
swelling, with DMF as the reaction solvent. For peptide couplings DIC or
PyBOP® was used as the activator unless otherwise indicated. Amino acid
side chain functionality was protected as follows: Fmoc-Arg(Pbf)-OH, Fmoc-
Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Dpr(Boc)-OH,
Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Lys(Boc)-
OH, Fmoc-Ser(OtBu)-OH, Fmoc-Thr(OtBu)-OH, Fmoc-Trp(Boc)-OH and Fmoc-
Tyr(OtBu)-OH. Fmoc deprotections were carried out using a 20% (v/v) solution
of piperidine in DMF. Pre-swelling of the resin was carried out in DMF for a
minimum of 1 h (overnight preferred), followed by washing with DMF. The
resin was shrunk in diethyl ether to remove DMF in preparation for TFA
cleavage. Peptide-resin was stored at −18 ◦C. Peptide molecular weight
calculations and mass assignments were carried out using Pep-Calc.com.2
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7.1.1 Automated Fmoc SPPS
Automated SPPS was carried out on a CEM Liberty1 single-channel microwave
peptide synthesizer equipped with a Discover microwave unit. All reactions
were carried out at 0.1 mmol scale using the 30 mL PTFE reaction vessel,
with agitation by bubbling nitrogen. Couplings were carried out using Fmoc-
protected amino acid (5.0 equiv), PyBOP® (5.0 equiv) and DIPEA (10 equiv,
2 M solution in NMP) unless otherwise stated. For double and triple couplings
the reaction vessel was drained after each cycle and fresh reagents were added.
For DIC couplings, a 0.8 M solution of DIC in DMSO was used in the activator
base position, and a 0.5 M solution of HOBt in DMF was used in the activator
position.
Microwave-assisted
Microwave couplings were carried out for 10 min at 75 ◦C and 25 W
power unless otherwise stated. Cys and His residues were coupled at low
temperature: 10 min at room temperature followed by 10 min at 50 ◦C (25 W).
Arg residues were double coupled, with the first coupling carried out for 45 min
at RT followed by 5 min at 75 ◦C (25 W), and the second using the standard
microwave conditions given. Removal of the Fmoc group was carried out at
room temperature using two successive treatments with piperidine solution
(5 + 10 min). For DIC couplings a room temperature ‘preactivation’ period
of 30 min, 1 h or 2 h was used.
Room temperature
Reactions were carried out at room temperature using 2 × 1 h couplings
(3 × 1 h for Arg residues). The Fmoc group was removed by two successive
treatments with piperidine solution (5 + 10 min). For lassomycin, two
additional deprotections were carried out for the penultimate residue (Leu-2).
7.1.2 Manual Fmoc SPPS
Manual SPPS was carried out in fritted polypropylene reaction vessels.
Couplings and deprotections were carried out using the conditions for
automated room temperature SPPS already described (see section 7.1.1).
Efficient mixing during the synthesis was achieved using a shaker (without
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nitrogen agitation). Where indicated, capping of the peptide N-terminus was
carried out via acetylation using a 20% solution of acetic anhydride in DMF
for 30 min at RT.
For the chaiyaphumines, syntheses were carried out at 0.2 or 0.4 mmol
scale using 2 equivalents of the amino acid, with PyBOP® (2.0 equiv) as the
activator in the presence of DIPEA (4.0 equiv) (apart from Pro residues, which
used 5:5:10). N-terminal acylation was carried out according to procedure
7.1.5. The enantiomeric derivatives Fmoc-D-Ala-OH and Fmoc-D-Phe-OH
were used for the corresponding residues.
7.1.3 Cleavage of peptides from acid-labile resins
Peptide-resin was treated with 2.85 mL TFA and 0.15 mL deionized water,
with 0.15 mL TIPS as a scavenger (unless otherwise stated) for 3–4 h at room
temperature (volumes were reduced by two thirds for test cleavages). Longer
cleavage times were used for peptides containing Pbf or benzyl protecting
groups. The resin was then removed by filtration and the filtrate concentrated
in vacuo before precipitation using ether and decanting of the liquid (followed
by subsequent ether washes). For peptides bearing only protecting groups
releasing volatile products upon cleavage (such as Boc), the ether was simply
re-evaporated instead of decanting. The resulting solid peptide was dissolved
in deionized water and lyophilized. For hydrophobic sequences a small
amount of acetonitrile was added (< 50% v/v) in the event of poor solubility
(water and MeCN containing 0.1% TFA or triethylamine were also used to
improve solubility for particularly insoluble peptides).
7.1.4 Loading of 2-chlorotrityl chloride resin
2-Chlorotrityl chloride resin was pre-swelled for 1 h in DMF followed by
addition of Fmoc-Trp(Boc)-OH (1.0 equiv) and DIPEA (5.0 equiv) in DMF
(2 × 1 h). After washing with 5 portions of DMF, the linker was capped via
treatment with MeOH (15 min). Swelling was repeated in DMF for at least
1 h before continuation of the synthesis.
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7.1.5 Acylation with N-terminal capping group
For the chaiyaphumines, acylation of the N-terminal residue was carried out via
treatment of peptide-resin with 5.0 equivalents of the acyl chloride specified
(or acetic anhydride) and DIPEA (10 equiv) in DMF (2 × 1 h). The resin was
washed with 5 portions of DMF between couplings.
7.1.6 Standard solution-phase peptide cyclization
Cyclizations were carried out as follows unless otherwise stated. Fully
deprotected linear peptide was dissolved in dry DMF and added dropwise
over a period of 2 h to a further 4 volume parts of a stirred room temperature
DMF solution containing PyBOP® (3.0 equiv) and DIPEA (6.0 equiv), with a
final peptide concentration of 0.003 M. The reaction was stirred for a further
3 h before removal of the solvent using a rotary evaporator with a water bath
temperature of ∼80 ◦C. The resulting crude oil was kept at −20 ◦C until
needed for purification.
7.1.7 Pseudo-high dilution solution-phase cyclization
Pseudo-high dilution peptide cyclization conditions were used as described by
Malesevic et al.50 Fully deprotected peptide (113 µmol) and HATU (339 µmol)
were dissolved separately in 11.3 mL each of dry DMF. Both solutions were
added simultaneously using two syringe pumps at a rate of 0.01 mL/min each
to a stirred solution of HATU (11.3 µmol) and DIPEA (678 µmol) in dry DMF
(11.3 mL) over a period of∼20 h. After the addition was complete, the reaction
was stirred for a further 30 min and the solvent was removed under vacuum.
The resulting crude oil was kept at −20 ◦C until needed for purification.
7.1.8 Preparation of anhydrous methanolic HCl solution
Anhydrous HCl solution for methanolic resin cleavages was prepared by
dropwise addition of acetyl chloride to a stirred solution of methanol which
was cooled in an ice bath (final concentration 3 M). The solution was left to
stir for 1 h before use.76
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7.1.9 Allyl ester protecting group removal
Peptide-resin was swollen in DCM for 1 h and sparged with argon. PhSiH3
and Pd(PPh3)4 were added in a small amount of DCM and the reaction was
agitated under argon for 2 h at room temperature. The resin was then washed
with DCM and DMF. The procedure was repeated as needed.77
7.1.10 Coupling of Hmb building block
Fmoc-(FmocHmb)Val-OH (3.0 equiv) was coupled manually overnight at room
temperature (DIC/HOBt, 3.0 equiv each) in a minimum volume of DMF. The
Fmoc group was removed using the conditions described. The symmetrical
anhydride214 of Fmoc-Leu-OH was preformed via addition of DIC (5.0 equiv)
to a solution of Fmoc-protected leucine (10 equiv) in dry DCM (3 mL) that
had been sparged with argon gas. The mixture was stirred at 0 ◦C in a flask
fitted with a calcium chloride drying tube. After 20 min the anhydride solution
was added directly to the resin, which had been washed with DCM to remove
residual DMF. After 24 h the resin was drained and the coupling repeated.
7.1.11 Acetylation of Hmb group
Peptide-resin was first treated with piperidine solution followed by washing
with 5 portions of DMF. The resin was then agitated with a solution of acetic
anhydride (10 equiv) and DIPEA (5.0 equiv) (1:1 volume) in a minimum volume
of DMF at RT.146 After 30 min the solvent was drained and the resin washed
with 5 further portions of DMF.
7.1.12 Liberation of Boc-amino acid from DCHA salt
Boc-Ser(OtBu)-OH·DCHA was suspended in ice-cold ethyl acetate (30 mL/g)
and 10% phosphoric acid was added until all the solid had dissolved. The
aqueous layer was separated and the pH checked using pH paper (2–3). The
organic layer was washed with 2 volume parts phosphoric acid (10%) and 3× 2
volume parts water. The pH of the final aqueous wash should be 4. Complete
conversion of the starting material was confirmed by TLC (1:1 hexane/ethyl
acetate). The organic layer was dried (MgSO4) and concentrated in vacuo to
afford Boc-Ser(OtBu)-OH as a colourless oil.215
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7.1.13 Alkylation of sulfonamide linker
Peptide-resin was cyanomethylated via treatment with iodoacetonitrile (10
equiv) and DIPEA (10 equiv) in DMF (1 mL) for 24 h with agitation in a
foil-wrapped reaction vessel.216,217 The solvent was removed and the resin
washed with DMF (3 × 5 mL), THF (3 × 5 mL) and DMF again. Alternatively,
methylation was carried out by treatment of peptide-resin with 2.0 M
trimethylsilyldiazomethane in hexane for 24 h. The resin was drained and
washed with DCM and DMF. TMS-diazomethane residues were destroyed
using base.
7.1.14 On-resin reduction of nitro linker
Peptide-resin was swollen for 1 h in DMF. The solvent was exchanged for DCM
and a solution of Na2S2O4 (20 equiv), K2CO3 (28 equiv) and TBAHS (2.0 equiv)
in a 1:1 mixture of DCM/H2O was added to the resin (2 mL total).202 After
agitating for 9 h at room temperature, the solvent was removed and the resin
washed (3 × H2O/3 × DCM/3 × DMF).
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7.2 Purification and characterization
7.2.1 Preparative high-performance liquid chromatography
(HPLC)
Samples were dissolved in deionized water (with MeCN for insoluble
peptides), centrifuged and injected in ∼30 mg amounts (0.5–1 mL) per run
onto a Speck and Burke Analytical C18 Column (5.0 µm, 10.0 × 250 mm)
attached to a PerkinElmer Series 200 LC Pump and 785A UV/Vis Detector.
A linear gradient of 0-50% B (solvent A = 5:95:0.1 MeCN/H2O/TFA; B =
95:5:0.1 MeCN/H2O/TFA) over 60 min, followed by 50-100% B over 15 min,
with a flow rate of 2 mL/min was used for separations unless otherwise stated.
Absorbance data were collected at 220 nm. For chaiyaphumines the gradient
was started at 10% B and absorbance recorded at 280 nm. For lassomycin
(and analogues) a gradient of 10-36% B over 40 min, followed by 36-100%
B over 20 min was used. Selected fractions were lyophilized and a mass
assigned using MALDI-TOF MS or ESI-MS, and peak fractions of interest were
pooled and lyophilized.
7.2.2 Analytical chromatography (HPLC)
10µL of sample solution was injected using a PerkinElmer Series 200 Autosam-
pler onto a Waters XBridge BEH C18 Column (3.5 µm, 4.6 mm × 100 mm)
attached to a PerkinElmer Series 200 LC Pump and Series 200 UV/Vis Detector.
The column temperature was maintained at 40 ◦C using a PerkinElmer Series
200 Peltier Column Oven. A linear gradient of 0-100% B (solvent A =
5:95:0.05 MeCN/H2O/TFA; B = 95:5:0.03 MeCN/H2O/TFA) over 30 min with
a flow rate of 1 mL/min was used for all analyses. Solvents were degassed
using an in-line vacuum degasser. Absorbance data were collected at 220 nm
and processed using the TotalChrom software (version 6.3.1).
7.2.3 Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS)
MALDI-TOF and LIFT-TOF/TOF spectra were acquired on an Autoflex II
ToF/ToF mass spectrometer (Bruker Daltonik GmBH) equipped with a 337 nm
nitrogen laser. Peptides were dissolved in 1:1 deionized water/MeCN
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(solvents containing 0.1% TFA or triethylamine were used for particularly
insoluble analytes). Sample solution (1 mg/mL) was mixed with matrix solution
(α-cyano-4-hydroxy-cinnamic acid, ∼50 mg/mL) in a ratio of 1:9, and 1 µL of
the resulting solution spotted onto a metal target and placed into the MALDI
ion source. Reflectron mode was used for molecules with m/z < 4000.
MS data was processed using FlexAnalysis 2.0 (Bruker Daltonik GmBH) or
MestReNova 10.0 (Mestrelab Research S.L.). MALDI MS/MS was performed
using LIFT technology, which enables detection of product ions that result
from elevating the laser power.
7.2.4 Analytical liquid chromatography mass spectrometry
(LCMS)
Analytical LCMS was carried out using an Acquity UPLC system (Waters Ltd,
UK) equipped with a photodiode array detector. Samples were injected onto
an Acquity UPLC BEH C18 column (1.7 µm, 2.1 × 50 mm) and a gradient
of 5–95% B (solvent A = H2O, 0.1% formic acid; B = MeCN) was run over
3.8 min with a flow rate of 0.6 mL/min. The flow of solvent from the UPLC
system was introduced into the electrospray ion source of an Aquity TQD or
QToF Premier mass spectrometer, and positive ions were measured.
7.2.5 Ion-mobility (IM) mass spectrometry
Ion-mobility mass spectrometry was carried out using a Synapt G2S mass
spectrometer equipped with an Acquity UPLC (Waters Ltd, UK). 1 µL of sample
was injected onto a BEH C18 column (1.7 µm, 2.1 × 100 mm) and a gradient
of 5-95% B (solvent A = H2O, 0.1% formic acid; B = MeCN, 0.1% formic
acid) was run over 6.0 min with a flow rate of 0.4 mL/min. A photodiode
array detector provided absorbance data from 200 nm to 500 nm. The solvent
flow was introduced into the electrospray ion source, and full scan MS carried
out for positive ions. IM separation was performed with nitrogen as the gas.
MS and photodiode array absorbance data was processed using MassLynx 4.1
(Waters Ltd, UK). IM results are represented as a plot of m/z against drift time
in Bins (mobiliogram).
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7.2.6 Nuclear magnetic resonance (NMR) spectroscopy
NMR spectra were recorded on a Bruker Avance 400 MHz or Varian VNMRS
700 MHz. Multiplicities: s = singlet, d = doublet, dd = doublet of doublets,
ddd = doublet of doublet of doublets, dq = doublet of quartets, t = triplet,
quint = quintet, m = multiplet. Chemical shifts are reported in δ units and
are referenced to residual solvent peaks: CHCl3 (1H 7.26 ppm, 13C 77.0 ppm)
and DMSO (1H 2.50 ppm, 13C 39.5 ppm). Chaiyaphumine NMR spectra
were recorded on a Varian VNMRS 600 spectrometer operating at a proton
frequency of 599.7 MHz and a 13C-carbon frequency of 150.8 MHz. The
instrument was equipped with a 5 mm OneNMR probe head. The experiments
were carried out with compounds dissolved in 500 µL d6-DMSO at 298 K.
For structure elucidation and complete assignment of proton and carbon
resonances 1H-1H COSY, 1H-13C multiplicity edited-HSQC, 1H-13C HMBC
and 1H-1H NOESY (mixing time 500 ms) spectra were acquired.
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7.3 Biological testing
Parasitic and mammalian cytotoxicity screening was carried out by Marcel
Kaiser (Swiss Tropical and Public Health Institute). Testing against Mycobac-
terium tuberculosis was performed by Tim Bull (St. George’s University of
London).
7.3.1 Activity against Trypanosoma brucei rhodesiense
This stock was isolated in 1982 from a human patient in Tanzania and after
several mouse passages cloned and adapted to axenic culture conditions.218
Minimum Essential Medium (50 µL) supplemented with 25 mM HEPES, 1 g/L
additional glucose, 1% MEM non-essential amino acids (100x), 0.2 mM 2-
mercaptoethanol, 1 mM Na-pyruvate and 15% heat inactivated horse serum
was added to each well of a 96-well microtiter plate. Serial drug dilutions
of eleven 3-fold dilution steps covering a range from 100 to 0.002 µg/mL
were prepared. 4 × 103 bloodstream forms of T. b. rhodesiense STIB 900 in
50 µL was added to each well and the plate incubated at 37 ◦C under a 5% CO2
atmosphere for 70 h. 10 µL Alamar Blue (resazurin, 12.5 mg in 100 mL double-
distilled water) was then added to each well and incubation continued for a
further 2–4 h.219 The plates were read with a Spectramax Gemini XS microplate
fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an
excitation wavelength of 536 nm and an emission wavelength of 588 nm. The
IC50 values were calculated by linear regression220 from the sigmoidal dose
inhibition curves using SoftmaxPro software (Molecular Devices Cooperation,
Sunnyvale, CA, USA). Melarsoprol (Arsobal Sanofi-Aventis, received from
WHO) is used as control.
7.3.2 Activity against T. cruzi
Rat skeletal myoblasts (L6 cells) were seeded in 96-well microtitre plates
at 2000 cells/well in 100 µL Roswell Park Memorial Institute (RPMI) 1640
medium with 10% fetal bovine serum and 2 mM L-glutamine. After 24 h the
medium was removed and replaced by 100 µL per well containing 5000
trypomastigote forms of T. cruzi Tulahuen strain C2C4 containing the β-
galactosidase (Lac Z) gene.221 After 48 h the medium was removed from
the wells and replaced by 100 µL fresh medium with or without a serial
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drug dilution of eleven 3-fold dilution steps covering a range from 100 to
0.002 µg/mL. After 96 h of incubation the plates were inspected under an
inverted microscope to assure growth of the controls and sterility. Then the
substrate chlorophenol red-β-D-galactopyranoside (CPRG)/Nonidet (50 µL)
was added to all wells. A color reaction developed within 2–6 h and could
be read photometrically at 540 nm. Data were analyzed with the graphic
programme Softmax Pro (Molecular Devices), which calculated IC50 values by
linear regression220 from the sigmoidal dose inhibition curves. Benznidazole
is used as control (IC50 0.5 ± 0.2 µg/mL).
7.3.3 Activity against L. donovani axenic amastigotes
Amastigotes of L. donovani strain MHOM/ET/67/L82 were grown in axenic
culture at 37 ◦C in SM medium222 at pH 5.4 supplemented with 10%
heat-inactivated fetal bovine serum under an atmosphere of 5% CO2 in
air. 100 µL of culture medium with 105 amastigotes from axenic culture
with or without a serial drug dilution were seeded in 96-well microtitre
plates. Serial drug dilutions of eleven 3-fold dilution steps covering a
range from 90 to 0.002 µg/mL were prepared. After 70 h of incubation
the plates were inspected under an inverted microscope to assure growth
of the controls and sterile conditions. 10 µL of Alamar Blue (12.5 mg
resazurin dissolved in 100 mL distilled water)223 were then added to each
well and the plates incubated for another 2 h. Then the plates were read
with a Spectramax Gemini XS microplate fluorometer (Molecular Devices
Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of 536 nm
and an emission wavelength of 588 nm. Data were analyzed using the software
Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA). Decrease
of fluorescence (= inhibition) was expressed as percentage of the fluorescence
of control cultures and plotted against the drug concentrations. From the
sigmoidal inhibition curves the IC50 values were calculated.
7.3.4 Activity against P. falciparum
In vitro activity against erythrocytic stages of P. falciparum was determined
using a 3H-hypoxanthine incorporation assay,224,225 using the drug sensitive
NF54 strain (Schipol Airport, The Netherlands226) or the chloroquine and
pyrimethamine resistant K1 strain that originates from Thailand227 and the
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standard drug chloroquine (Sigma C6628). Compounds were dissolved
in DMSO at 10 mg/mL and added to parasite cultures incubated in RPMI
1640 medium without hypoxanthine, supplemented with HEPES (5.94 g/L),
NaHCO3 (2.1 g/L), neomycin (100 U/mL), AlbumaxR (5 g/L) and washed human
red cells A+ at 2.5% haematocrit (0.3% parasitaemia). Serial drug dilutions of
eleven 3-fold dilution steps covering a range from 100 to 0.002 µg/mL were
prepared. The 96-well plates were incubated in a humidified atmosphere
at 37 ◦C; 4% CO2, 3% O2, 93% N2. After 48 h 50 µL of 3H-hypoxanthine
(=0.5 µCi) was added to each well of the plate. The plates were incubated for
a further 24 h under the same conditions. The plates were then harvested with
a BetaplateTM cell harvester (Wallac, Zurich, Switzerland), and the red blood
cells transferred onto a glass fibre filter then washed with distilled water.
The dried filters were inserted into a plastic vial with 10 mL of scintillation
fluid, and counted in a BetaplateTM liquid scintillation counter (Wallac, Zurich,
Switzerland). IC50 values were calculated from sigmoidal inhibition curves by
linear regression220 using Microsoft Excel. Chloroquine and artemisinin are
used as control.
7.3.5 In vitro cytotoxicity with L6 cells
Assays were performed in 96-well microtiter plates, each well containing
100 µL of RPMI 1640 medium supplemented with 1% L-glutamine (200 mM)
and 10% fetal bovine serum, and 4000 L6 cells (a primary cell line derived from
rat skeletal myoblasts228,229). Serial drug dilutions of eleven 3-fold dilution
steps covering a range from 100 to 0.002 µg/mL were prepared. After 70 h of
incubation the plates were inspected under an inverted microscope to assure
growth of the controls and sterile conditions. 10 µL of Alamar Blue was then
added to each well and the plates incubated for another 2 h. Then the plates
were read with a Spectramax Gemini XS microplate fluorometer (Molecular
Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength
of 536 nm and an emission wavelength of 588 nm. The IC50 values were
calculated by linear regression220 from the sigmoidal dose inhibition curves
using SoftmaxPro software (Molecular Devices Cooperation, Sunnyvale, CA,
USA). Podophyllotoxin (Sigma P4405) is used as control.
140
Chapter 7. Experimental
7.3.6 Activity against Mycobacterium tuberculosis
The MICs of the compounds were determined using standard liquid-broth
and solid-agar based methods. Briefly, serial dilutions of each compound
were made between 100 mg/L and 0.78 mg/L with MB7H9/oleic albumin
dextrose catalase (OADC) (BD Biosciences) media in 96-well U-bottom plates.
Mycobacterium tuberculosis H37Rv was grown to log phase (OD600 = 1.0)
and 104 cells were added to all wells. Solid-agar based method was carried
out as previously described230 using a 48-well plate format. Compounds
were tested in triplicate by adding serial dilutions into separate wells overlaid
with MB7H11/OADC (BD Biosciences) agar based media. Mycobacterium
tuberculosis culture (5 µL containing 104 cells) was then inoculated into
the centre of each well on top of the solidified media. Plates were
sealed and incubated at 37 ◦C in 5% CO2 for 10 days. Each plate also
contained standardised serial dilution controls of first line tuberculosis drugs
isoniazid (INH [Sigma, UK]; concentration range 8, 4, 2, 1, 0.5, 0.25, 0.125,
0.0625 µg/mL) and rifampicin (RIF [Sigma, UK]; concentration range 16,
8, 4, 2, 1, 0.5, 0.25, 0.125 µg/mL), in addition to negative (media only)
controls. The MICs were determined as the first dilution to show complete
growth inhibition as determined by a total lack of colony formation within
the test period. It was not possible to obtain an authentic sample of naturally
isolated lassomycin to compare in this assay because the Lentzea kentuckyensis
subspecies from which lassomycin was originally prepared is the property of
NovoBiotic Pharmaceuticals and was unavailable.
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7.4 NMR structure calculation
1H-1H NOESY NMR data were processed separately using vnmrJ (version 4.2)
and imported into CcpNmr Analysis58 (version 2.4) for manual peak picking
and assignment to a molecular system. Custom residue definitions were
created using CcpNmr ChemBuild (version 1.0). Initial distance restraints
were calculated from assigned peaks using the Analysis software and split into
ambiguous and unambiguous restraint lists. Complete peak lists including
unassigned peaks were also generated. The inbuilt graphical interface was
used to export peak and restraint lists to ARIA53 (version 2.3), and set up the
run directory tree.
Structure refinement was carried out by ARIA using CNS54,55 (version 1.2
at patch level 1) and a modified version of the PARALLHDG force field56
(version 5.3). New force field topology definitions were added manually
for D-amino acid residues, the phenylacetyl capping group and the ester
linkage in topallhdg5.3.pro. Parameters for new bond length, angle,
dihedral and improper torsion angle types were added to parallhdg5.3.pro.
Bond lengths and angles for similar cyclic depsipeptides were taken from
the literature231–233 and dihedrals were generated using SwissParam.234
Phenylacetyl group parameters were taken from HIC-Up.235 Greater flexibility
was introduced into the force field by dividing all force constants for bond
angles and impropers by 10, as described by Mareuil et al.236 Topology and
parameter files were modified in both the run and ARIA distribution directories.
The CNS generate.inp script was modified to include the sequence
(declared manually within the chain statement, incorporating nonstandard
residues) and topology patch for the side-chain-to-tail ester bond. The linkage
definitions in topallhdg5.3.pep were also modified to prevent terminal
hydrogens being added to the capping residue, as an N-terminal amine group
is not present in this case.
Simulated annealing was carried out using Cartesian dynamics only (torsion
angle dynamics disabled) on an ensemble of 20 structures over 8 iterations
each (without final refinement in explicit solvent). The Cartesian high
temperature value was increased to 10 000 K (default value for torsion angle
annealing) and the default simulation total time period was quadrupled (step
length kept the same). The 10 lowest energy structures were chosen for the
final ensemble.
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7.5 Chaiyaphumines
7.5.1 Natural ester series
Chaiyaphumine 10a
a
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H
N
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H
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The linear sequence was synthesized as
described in section 7.1.2 and capped
with 2-phenylacetyl chloride (procedure
7.1.5), before undergoing resin cleavage
and deprotection as described in proce-
dure 7.1.3. Solution-phase cyclization of
224 mg of the linear precursor according
to procedure 7.1.6, followed by HPLC
purification (procedure 7.2.1) yielded 10a
(16 mg, 7%), HPLC Rt = 20.3 min (procedure
7.2.2); HRMS m/z (ESI) 721.3364, consistent
with empirical formula C40H45N6O7 with an
accuracy of 1.9 ppm (accepted as [M + H]+).
Chaiyaphumine 10b
b
N
H
H
N
NH
N
O
H
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O
O
O
OO
HN
10
The linear sequence was synthesized as
described in section 7.1.2 and capped with
butyryl chloride (procedure 7.1.5). Resin
cleavage was carried out using a 1% TFA
solution in DCM (5 × 30 s).237 The resulting
combined filtrates were concentrated in
vacuo and lyophilized. Global deprotection
was carried out on the crude solid as
described in procedure 7.1.3. A modification
of solution-phase cyclization procedure 7.1.6
was carried out whereby the linear precursor
was added under syringe pump control at a rate of 0.35 mL/h using EDCI as
the activator (1.3 equiv) in the presence of DMAP (1.3 equiv) with HOBt
(1.3 equiv).50,238 The procedure was carried out on 66 mg of the linear
precursor, followed by HPLC purification (procedure 7.2.1), to yield 10b (5 mg,
8%), HPLC Rt = 5.0 min (procedure 7.2.2, 10 min gradient); HRMS m/z (ESI)
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673.3353, consistent with empirical formula C36H45N6O7 with an accuracy of
0.4 ppm (accepted as [M + H]+).
Chaiyaphumine 10c
c
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The linear sequence was synthesized as
described in section 7.1.2 and capped with
propionyl chloride (procedure 7.1.5), before
undergoing resin cleavage and deprotection
as described in procedure 7.1.3. Solution-
phase cyclization of 27 mg of the linear
precursor according to procedure 7.1.6,
followed by HPLC purification (procedure
7.2.1) yielded 10c (2 mg, 8%), HPLC Rt =
18.3 min (procedure 7.2.2); HRMS m/z (ESI)
659.3174, consistent with empirical formula
C35H43N6O7 with an accuracy of 2.9 ppm
(accepted as [M + H]+).
Chaiyaphumine 10d
d
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H
H
N
NH
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The linear sequence was synthesized as
described in section 7.1.2 and capped with
acetic anhydride (procedure 7.1.5), before
undergoing resin cleavage and deprotection
as described in procedure 7.1.3. Solution-
phase cyclization of 10 mg of the linear
precursor according to procedure 7.1.6 using
HATU as the activator, followed by HPLC
purification (procedure 7.2.1) yielded 10d
(2 mg, 21%), HPLC Rt = 16.8 min (procedure
7.2.2); HRMS m/z (ESI) 645.3044, consistent
with empirical formula C34H41N6O7 with an
accuracy of 1.1 ppm (accepted as [M + H]+).
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7.5.2 Amide-linked analogues
Chaiyaphumine 11a
a
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The linear sequence was synthesized as
described in section 7.1.2 and capped
with 2-phenylacetyl chloride (procedure
7.1.5), before undergoing resin cleavage
and deprotection as described in procedure
7.1.3. Solution-phase cyclization of 18 mg of
the linear precursor according to procedure
7.1.6, followed by HPLC purification (proce-
dure 7.2.1) yielded 11a (4 mg, 23%), HPLC
Rt = 16.3 min (procedure 7.2.2); HRMS m/z
(ESI) 706.3355, consistent with empirical
formula C39H44N7O6 with an accuracy of
0.3 ppm (accepted as [M + H]+).
Chaiyaphumine 11b
b
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H
N
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N
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The linear sequence was synthesized as
described in section 7.1.2 and capped with
butyryl chloride (procedure 7.1.5), before
undergoing resin cleavage and deprotection
as described in procedure 7.1.3. Solution-
phase cyclization of 12 mg of the linear
precursor according to procedure 7.1.6,
followed by HPLC purification (procedure
7.2.1) yielded 11b (1 mg, 9%), HPLC Rt =
16.3 min (procedure 7.2.2); HRMS m/z (ESI)
658.3358, consistent with empirical formula
C35H44N7O6 with an accuracy of 0.8 ppm
(accepted as [M + H]+).
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Chaiyaphumine 11c
c
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The linear sequence was synthesized as
described in section 7.1.2 and capped with
propionyl chloride (procedure 7.1.5), before
undergoing resin cleavage and deprotection
as described in procedure 7.1.3. Solution-
phase cyclization of 15 mg of the linear
precursor according to procedure 7.1.6,
followed by HPLC purification (procedure
7.2.1) yielded 11c (1 mg, 7%), HPLC Rt =
15.3 min (procedure 7.2.2); HRMS m/z (ESI)
644.3176, consistent with empirical formula
C34H42N7O6 with an accuracy of 3.3 ppm
(accepted as [M + H]+).
Chaiyaphumine 11d
d
N
H
H
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The linear sequence was synthesized as
described in section 7.1.2 and capped with
acetic anhydride (procedure 7.1.5), before
undergoing resin cleavage and deprotection
as described in procedure 7.1.3. Solution-
phase cyclization of 23 mg of the linear
precursor according to procedure 7.1.6,
followed by HPLC purification (procedure
7.2.1) yielded 11d (2 mg, 9%), HPLC Rt =
14.1 min (procedure 7.2.2); HRMS m/z (ESI)
630.3034, consistent with empirical formula
C33H40N7O6 with an accuracy of 1.0 ppm
(accepted as [M + H]+).
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7.6 Lassomycin and lassomycin-amide
Fmoc-Asp(OtBu)-Ile-OMe (30)
FmocHN
O
OtBu
O
H
N
O
OMe
30
Fmoc-Asp(OtBu)-OH (1.14 g, 2.8 mmol), H-Ile-OMe
(0.40 g, 2.8 mmol) and PyBOP® (1.44 g, 2.8 mmol)
were suspended in DCM (30 mL) and stirred at
room temperature. N-Methylmorpholine (0.91 mL,
8.3 mmol) was added and the reaction was stirred
at room temperature for 18 h. The crude reaction
mixture was evaporated under reduced pressure and
purified via column chromatography (SiO2; 98/2% hexane/EtOAc → 50/50%
hexane/EtOAc) to yield Fmoc-Asp(OtBu)-Ile-OMe (30) as a white powder
(0.93 g, 63%), δH (700 MHz, CDCl3) 0.88–0.93 (3H, m, Ile-δCH3), 0.88–
0.93 (3H, m, Ile-γCH3), 1.15–1.23 (1H, m, Ile-γCH2), 1.38–1.44 (1H, m,
Ile-γCH2), 1.46 (9H, s, OtBu), 1.89–1.95 (1H, m, Ile-βCH), 2.64 (1H, dd,
J 17.3 and 7.3 Hz, Asp-βCH2), 2.93 (1H, dd, J 17.3 and 4.1 Hz, Asp-βCH2),
3.71 (3H, s, CO2CH3), 4.23 (1H, t, J 7.1 Hz, Fmoc-CH), 4.41 (2H, d, J 7.1 Hz,
Fmoc-CH2), 4.53 (1H, dd, J 8.6 and 4.8 Hz, Ile-αCH), 4.58–4.63 (1H, m,
Asp-αCH), 6.08 (1H, d, J 8.2 Hz Asp-NH), 7.16 (1H, d, J 8.6 Hz, Ile-NH),
7.31 (2H, t, J 7.5 Hz, FmocArH), 7.40 (2H, t, J 7.5 Hz, FmocArH), 7.59 (2H,
d, J 7.5 Hz, FmocArH), 7.76 (2H, d, J 7.5 Hz, FmocArH); δC (176 MHz,
CDCl3) 11.6, 15.6, 25.1, 28.1, 37.6, 47.2, 50.9, 52.1, 56.9, 67.4, 82.0, 120.1,
125.1, 127.2, 127.8, 141.4, 143.7, 143.9, 156.0, 170.6, 171.6, 171.9; HRMS
m/z (ESI) 539.2756, consistent with empirical formula C30H39N2O7 with an
accuracy of 0.2 ppm (accepted as [M + H]+).
Fmoc-Asp(OH)-Ile-OMe (34)
FmocHN
O
OH
O
H
N
O
OMe
34
Fmoc-Asp(OtBu)-Ile-OMe (30, 0.33 g, 0.6 mmol)
was treated with 20 mL of TFA solution (40% in
DCM) for 30 min. Complete removal of the t-
butyl group was confirmed using TLC. The reaction
mixture was evaporated under reduced pressure to
give Fmoc-Asp(OH)-Ile-OMe (34) as a white powder
(quantitative yield, 0.29 g) which was used without
further purification, δH (700 MHz, CDCl3) 0.86–0.91 (3H, m, Ile-δCH3), 0.86–
0.91 (3H, m, Ile-γCH3), 1.11–1.20 (1H, m, Ile-γCH2), 1.35–1.44 (1H, m,
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Ile-γCH2), 1.85–1.96 (1H, m, Ile-βCH), 2.78 (1H, dd, J 17.4 and 6.4 Hz, Asp-
βCH2), 3.03 (1H, d, J 17.4 Hz, Asp-βCH2), 3.72 (3H, s, CO2CH3), 4.22 (1H,
t, J 6.6 Hz, Fmoc-CH), 4.43 (2H, d, J 6.6 Hz, Fmoc-CH2), 4.53 (1H, dd, J 8.4
and 4.7 Hz, Ile-αCH), 4.60–4.69 (1H, m, Asp-αCH), 5.97 (1H, d, J 8.0 Hz,
Asp-NH), 7.09 (1H, d, J 8.4 Hz, Ile-NH), 7.31 (2H, t, J 7.5 Hz, FmocArH),
7.40 (2H, t, J 7.5 Hz, FmocArH), 7.57 (2H, d, J 7.5 Hz, FmocArH), 7.76 (2H,
d, J 7.5 Hz, FmocArH); HRMS m/z (ESI) 483.2115, consistent with empirical
formula C26H31N2O7 with an accuracy of 3.3 ppm (accepted as [M + H]+).
Lassomycin (24)
The dipeptide Fmoc-Asp(OH)-Ile-OMe (34) was coupled manually to Rink
amide AM resin (0.77 mmol/g substitution, 0.10 mmol scale) using two
1 h couplings at RT. The sequence GLRRLFADQLVGRR was then built
onto the resin-supported dipeptide via automated RT SPPS (as described in
section 7.1.1). Resin cleavage (procedure 7.1.3) and pseudo-high dilution
cyclization (procedure 7.1.7) were carried out as described, and the crude cy-
clization product was dissolved in 2.5 mL deionized water/acetonitrile, filtered
and centrifuged. Purification by high-performance liquid chromatography
(procedure 7.2.1) afforded lassomycin (26 mg, 14%), HPLC Rt = 12.6 min
(procedure 7.2.2); MALDI-TOF mass: found m/z 1881.1 [M + H]+, calcd
1881.2 [M + H]+; HRMS m/z (ESI) 940.55785, consistent with empirical
formula C83H144N30O20 with an accuracy of 0.3 ppm (accepted as [M + 2H]2+).
Lassomycin-amide (35)
Linear peptide GLRRLFADQLVGRRNI-amide was synthesized via automated
SPPS at room temperature (section 7.1.1) on Rink amide AM resin (0.79 mmol/g
substitution, 0.10 mmol scale). Resin cleavage (procedure 7.1.3), cyclization
(procedure 7.1.7) and purification by high-performance liquid chromatogra-
phy (procedure 7.2.1) were carried out as detailed above to afford lassomycin-
amide (4 mg, 8%), HPLC Rt = 13.0 min (procedure 7.2.2); MALDI-TOF mass:
found m/z 1866.2 [M + H]+, calcd 1866.2 [M + H]+; HRMS m/z (ESI)
933.06000, consistent with empirical formula C82H143N31O19 with an accuracy
of 1.8 ppm (accepted as [M + 2H]2+).
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Lassomycin(1-9) (36)
Linear peptide GLRRLFADQ-amide was synthesized via automated MW-
SPPS (section 7.1.1) on Rink amide AM resin (0.79 mmol/g substitution,
0.10 mmol scale), using DIC as the activator. Resin cleavage (procedure
7.1.3), cyclization (procedure 7.1.6) and purification by high-performance
liquid chromatography (procedure 7.2.1) afforded lassomycin(1-9) (31 mg,
29%), HPLC Rt = 12.4 min (procedure 7.2.2); MALDI-TOF mass: found
m/z 1056.6 [M + H]+, calcd 1057.2 [M + H]+; HRMS m/z (ESI) 1056.6082,
consistent with empirical formula C47H78N17O11 with an accuracy of 1.4 ppm
(accepted as [M + H]+).
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7.7 ACP fragments
[A34C]ACP(34-77) (69)
Sequence CDSLDTVELVMALEEEFDTEIPDEEAEKITTVQAAIDYINGHQA synthe-
sized via automated SPPS at room temperature (section 7.1.1) on Fmoc-Ala-
Wang resin LL (0.33 mmol/g substitution, 0.10 mmol scale). Double couplings
were used for all residues. For the final 11 couplings the reaction volume was
doubled (equivalents also doubled to maintain concentration). Resin cleavage
and deprotection using TFA was carried out according to procedure 7.1.3 to
afford fragment 69 (101 mg from half resin, 41%), MALDI-TOF mass: found
m/z 4895.5 [M + H]+, calcd 4895.3 [M + H]+.
ACP(1-33) N-acylsulfonamide (unalkylated) (71, cleaved)
Synthesis of sequence STIEERVKKIIGEQLGVKQEEVTNNASFVEDLG carried
out via automated SPPS at room temperature (section 7.1.1) on Fmoc-Gly-
4-Sulfamylbutyryl Rink amide AM resin (0.26 mmol/g substitution, 0.10 mmol
scale). Double couplings were used for all residues except Asn and Asp,
which were triple coupled. For the final 13 couplings the reaction volume
was doubled (equivalents also doubled to maintain concentration). Boc-
Ser(OtBu)-OH was liberated from the commercially available DCHA salt
according to procedure 7.1.12 and coupled manually as the N-terminal amino
acid under the conditions used for previous couplings. Resin test cleavage
and deprotection using TFA was carried out according to procedure 7.1.3 to
afford ACP(1-33) N-acylsulfonamide (unalkylated), MALDI-TOF mass: found
m/z 3808.9 [M + H]+, calcd 3807.9 [M + H]+.
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7.8 Nitro-functionalized linker
Fmoc-FAAA-[76]-amide (81)
Linker 76 (5.0 equiv) was coupled manually (section 7.1.2) to Rink amide
AM resin (0.79 mmol/g substitution, 0.10 mmol scale) for 1 h using HATU
(4.8 equiv) with DIPEA (10 equiv). Unreacted amine groups were capped
according to the procedure given in section 7.1.2, and the Fmoc group
removed using the conditions given previously. The sequence FAAA was then
built on-resin via automated MW-SPPS (section 7.1.1) using double couplings.
Resin cleavage and deprotection using TFA was carried out according to
procedure 7.1.3 to afford 81, MALDI-TOF mass: found m/z 786.3 [M + Na]+,
calcd 786.3 [M + Na]+.
Fmoc-FAAA-diaminobenzamide (82, cleaved)
Resin-bound 81 (80) was reduced using Na2S2O4 according to procedure
7.1.14. Resin cleavage and deprotection using TFA was carried out according
to procedure 7.1.3 to afford Fmoc-FAAA-diaminobenzamide, MALDI-TOF
mass: found m/z 756.4 [M + Na]+, calcd 756.3 [M + Na]+.
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7.9 EBNA1 targeting peptides
C-Ahx-RrRKGGYFMVF-amide (84)
Synthesized via automated MW-SPPS (section 7.1.1) on Rink amide AM resin
(0.82 mmol/g substitution, 0.10 mmol scale), using DIC as the activator. A 1 h
preactivation period was used for all residues except Ahx, which required 2 h.
Double couplings were used for Arg and Cys residues, with extended Fmoc
deprotection times for Arg (3 min MW + 20 min). Resin-bound peptide was
sent directly to the collaborator for fluorophore conjugation and biological
characterization. MALDI-TOF mass: found m/z 1632.0 [M + H]+, calcd
1631.9 [M + H]+.
C-Ahx-YFMVFGGRrRK-amide (85)
Synthesized via automated MW-SPPS (section 7.1.1) on Rink amide AM resin
(0.82 mmol/g substitution, 0.10 mmol scale), using DIC as the activator. A 1 h
preactivation period was used for all residues except Ahx, which required 2 h.
Double couplings were used for Arg and Cys residues, with extended Fmoc
deprotection times for Arg (3 min MW + 20 min). Resin-bound peptide was
sent directly to the collaborator for fluorophore conjugation and biological
characterization. MALDI-TOF mass: found m/z 1631.7 [M + H]+, calcd
1631.9 [M + H]+.
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Part V
Appendices

Appendix A
Chaiyaphumine NMR spectra
The following NMR characterization is included for chaiyaphumine 10a
(Chapter 2)
A.1 Chaiyaphumine 10a 1H NMR spectrum 174
A.2 Chaiyaphumine 10a 13C NMR spectrum 175
A.3 Chaiyaphumine 10a 1H-1H COSY NMR spectrum 176
A.4 Chaiyaphumine 10a 1H-13C HSQC NMR spectrum 177
A.5 Chaiyaphumine 10a 1H-13C HMBC NMR spectrum 178
A.6 Chaiyaphumine 10a 1H-1H NOESY NMR spectrum 179
NOE-derived distance restraints for the final molecular dynamics energy
minimization run are also included (Table A.1, page 180).
173
Figure A.1: 1H NMR spectrum of chaiyaphumine 10a, d6-DMSO, 298 K, 600 MHz.
174
Figure A.2: 13C NMR spectrum of chaiyaphumine 10a, d6-DMSO, 298 K, 150 MHz.
175
Figure A.3: 1H-1H COSY NMR spectrum of chaiyaphumine 10a, d6-DMSO, 298 K, 600 MHz.
176
Figure A.4: 1H-13C HSQC NMR spectrum of chaiyaphumine 10a, d6-DMSO, 298 K, 600 MHz.
177
Figure A.5: 1H-13C HMBC NMR spectrum of chaiyaphumine 10a, d6-DMSO, 298 K, 600 MHz.
178
Figure A.6: 1H-1H NOESY NMR spectrum of chaiyaphumine 10a, d6-DMSO, 298 K, 600 MHz.
179
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Table A.1: NOE-derived distance restraint list following final molecular dynamics
energy minimization run.
Atom 1 Atom 2 Lower Upper Av dist Viol
1-Thr α 1-Thr NH 1.7 3.2 2.90 0
1-Thr α 2-Phe NH 1.5 2.4 2.24 0
1-Thr α 1-Thr γ 1.7 3.2 2.20 0
1-Thr α 2-Phe β 1.9 4.6 4.41 0
1-Thr α 1-Thr NH 1.7 3.1 2.90 0
1-Thr α 2-Phe NH 1.4 2.3 2.24 0
1-Thr α 1-Thr γ 1.7 3.4 2.20 0
1-Thr α 1-Thr γ 1.7 3.2 2.20 0
1-Thr α 2-Phe β 1.9 4.7 4.41 0
1-Thr α 1-Thr NH 1.7 3.1 2.90 0
1-Thr α 2-Phe NH 1.4 2.3 2.24 0
1-Thr β 1-Thr NH 1.8 3.9 2.68 0
1-Thr β 1-Thr γ 1.5 2.6 2.09 0
1-Thr β 1-Thr α 1.6 2.9 2.96 0.07
1-Thr β 1-Thr NH 1.8 3.5 2.68 0
1-Thr β 2-Phe NH 1.9 4.2 4.25 0.03
1-Thr β 1-Thr γ 1.6 2.9 2.09 0
1-Thr β 1-Thr γ 1.6 2.7 2.09 0
1-Thr β 1-Thr α 1.6 2.9 2.96 0.11
1-Thr β 1-Thr NH 1.8 3.6 2.68 0
1-Thr β 2-Phe NH 1.9 4.3 4.25 0
1-Thr γ 2-Phe NH 1.9 4.3 3.20 0
1-Thr γ 5-Trp δ 1.9 4.5 4.53 0.06
1-Thr γ 2-Phe NH 1.9 4.3 3.20 0
1-Thr γ 1-Thr NH 1.8 3.7 3.74 0.05
1-Thr γ 1-Thr NH 1.8 3.5 3.74 0.21
1-Thr γ 5-Trp δ 1.9 4.6 4.53 0
1-Thr γ 2-Phe NH 1.9 4.4 3.20 0
1-Thr γ 1-Thr γ 1.1 1.5 1.31 0
1-Thr NH 5-Trp NH 1.5 2.4 2.42 0.03
1-Thr NH 5-Trp NH 1.5 2.5 2.42 0
1-Thr NH 5-Trp NH 1.5 2.5 2.42 0
1-Thr NH 5-Trp NH 1.5 2.4 2.42 0
1-Thr NH 3-D-Ala α 1.9 4.7 4.69 0
2-Phe α 2-Phe NH 1.8 3.7 2.78 0
2-Phe α 2-Phe β 1.7 3.0 2.31 0
2-Phe α 2-Phe β 1.8 3.4 2.98 0
2-Phe α 2-Phe β 1.9 4.0 2.31 0
2-Phe α 2-Phe β 1.8 3.6 2.31 0
2-Phe α 2-Phe NH 1.7 3.4 2.78 0
2-Phe α 2-Phe β 1.9 4.6 2.98 0
2-Phe α 2-Phe β 1.9 4.7 2.98 0
2-Phe α 2-Phe β 1.7 3.1 2.31 0
2-Phe α 2-Phe β 1.8 3.5 2.98 0
2-Phe α 2-Phe NH 1.8 3.4 2.78 0
2-Phe β 2-Phe NH 1.8 3.6 2.82 0
2-Phe β 2-Phe NH 1.6 2.9 2.19 0
2-Phe β 2-Phe NH 1.9 4.1 2.82 0
2-Phe β 2-Phe NH 1.8 3.7 2.82 0
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2-Phe β 2-Phe NH 1.7 3.3 2.19 0
2-Phe β 2-Phe NH 1.7 3.1 2.19 0
2-Phe β 2-Phe NH 1.8 3.6 2.19 0
2-Phe β 1-Thr γ 1.9 4.6 4.70 0.07
2-Phe β 2-Phe NH 1.8 3.6 2.82 0
2-Phe β 2-Phe NH 1.6 3.0 2.19 0
2-Phe β 1-Thr γ 1.9 4.7 4.70 0.01
2-Phe β 1-Thr γ 2.0 4.8 4.96 0.21
2-Phe NH 1-Thr NH 1.9 4.3 4.05 0
2-Phe NH 1-Thr NH 1.9 4.0 4.05 0.06
2-Phe NH 1-Thr NH 1.9 4.1 4.05 0
3-D-Ala α 5-Trp NH 1.9 4.5 4.12 0
3-D-Ala α 5-Trp NH 1.9 4.6 4.12 0
3-D-Ala β 3-D-Ala α 1.6 2.7 2.12 0
3-D-Ala β 4-Pro δ 1.7 3.2 3.21 0.03
3-D-Ala β 3-D-Ala α 1.6 3.0 2.12 0
3-D-Ala β 4-Pro δ 1.7 3.2 3.21 0.02
3-D-Ala β 2-Phe β 1.9 4.6 4.04 0
3-D-Ala β 4-Pro δ 1.9 4.7 4.06 0
3-D-Ala β 3-D-Ala α 1.6 2.8 2.12 0
3-D-Ala β 4-Pro δ 1.9 4.0 4.06 0.11
3-D-Ala β 4-Pro δ 1.7 3.2 3.21 0
3-D-Ala β 2-Phe β 1.9 4.7 4.04 0
3-D-Ala β 3-D-Ala β 1.1 1.5 1.31 0
4-Pro α 5-Trp NH 1.9 4.1 3.58 0
4-Pro α 5-Trp NH 1.9 4.0 3.58 0
4-Pro α 4-Pro β 1.7 3.2 2.64 0
4-Pro α 4-Pro β 1.6 2.7 2.31 0
4-Pro α 5-Trp NH 1.8 3.5 3.58 0.05
4-Pro α 4-Pro β 1.8 3.9 2.64 0
4-Pro α 4-Pro β 1.7 3.2 2.31 0
4-Pro α 4-Pro β 1.7 3.3 2.64 0
4-Pro α 4-Pro β 1.6 2.7 2.31 0
4-Pro α 5-Trp NH 1.8 3.6 3.58 0
4-Pro β 5-Trp NH 1.9 4.6 4.14 0
4-Pro β 5-Trp δ 2.0 4.9 4.66 0
4-Pro β 5-Trp NH 1.8 3.9 3.41 0
4-Pro β 5-Trp NH 1.8 3.9 3.41 0
4-Pro β 5-Trp NH 1.8 3.8 3.41 0
4-Pro β 4-Pro β 1.5 2.6 1.77 0
4-Pro β 4-Pro β 1.5 2.6 1.77 0
4-Pro β 5-Trp NH 1.9 4.7 4.14 0
4-Pro β 5-Trp δ 2.0 5.0 4.66 0
4-Pro β 5-Trp NH 1.8 3.8 3.41 0
4-Pro β 4-Pro β 1.5 2.6 1.77 0
4-Pro β 3-D-Ala β 1.9 4.6 4.60 0
4-Pro δ 5-Trp NH 1.8 3.7 2.06 0
4-Pro δ 5-Trp NH 1.8 3.7 2.06 0
4-Pro δ 4-Pro β 1.9 4.4 4.04 0
4-Pro δ 4-Pro β 1.9 4.0 3.94 0
4-Pro δ 4-Pro β 1.9 4.5 3.89 0
4-Pro δ 4-Pro β 1.9 4.6 3.22 0
4-Pro δ 4-Pro β 1.9 4.6 3.22 0
4-Pro δ 3-D-Ala α 1.6 2.8 1.95 0
4-Pro δ 4-Pro δ 1.4 2.2 1.77 0
4-Pro δ 3-D-Ala α 1.5 2.5 2.52 0.01
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4-Pro δ 4-Pro δ 1.4 2.3 1.77 0
4-Pro δ 3-D-Ala α 1.7 3.0 1.95 0
4-Pro δ 5-Trp NH 1.8 3.8 2.06 0
4-Pro δ 4-Pro β 1.9 4.6 3.22 0
4-Pro δ 5-Trp NH 1.8 3.7 2.06 0
4-Pro δ 4-Pro β 1.9 4.5 4.04 0
4-Pro δ 4-Pro β 1.9 4.1 3.94 0
4-Pro δ 4-Pro β 1.9 4.6 3.89 0
4-Pro δ 3-D-Ala α 1.6 2.9 1.95 0
4-Pro δ 4-Pro δ 1.4 2.3 1.77 0
4-Pro δ 3-D-Ala α 1.5 2.6 2.52 0
4-Pro δ 4-Pro β 1.9 4.6 3.22 0
5-Trp α 1-Thr NH 1.9 4.4 3.33 0
5-Trp α 5-Trp NH 1.8 3.5 2.89 0
5-Trp α 5-Trp NH 1.8 3.7 2.89 0
5-Trp α 5-Trp δ 1.9 4.3 4.36 0.06
5-Trp α 1-Thr NH 1.9 4.2 3.33 0
5-Trp α 1-Thr NH 1.9 4.1 3.33 0
5-Trp α 5-Trp NH 1.7 3.3 2.89 0
5-Trp α 5-Trp NH 1.7 3.4 2.89 0
5-Trp α 5-Trp δ 1.9 4.4 4.36 0.01
5-Trp α 1-Thr NH 1.9 4.2 3.33 0
5-Trp α 5-Trp NH 1.7 3.4 2.89 0
5-Trp δ 5-Trp NH 1.9 4.2 2.74 0
5-Trp δ 5-Trp NH 1.9 4.2 2.74 0
5-Trp Indole 1 (ArNH) 5-Trp α 1.9 4.2 2.83 0
5-Trp Indole 1 (ArNH) 5-Trp Indole 5,7 1.7 3.3 2.44 0
5-Trp Indole 1 (ArNH) 5-Trp Indole 5,7 1.7 3.4 2.44 0
5-Trp Indole 1 (ArNH) 5-Trp α 1.9 4.7 2.83 0
5-Trp Indole 1 (ArNH) 5-Trp δ 1.5 2.5 2.56 0.08
5-Trp Indole 1 (ArNH) 5-Trp δ 1.6 2.8 2.56 0
5-Trp Indole 1 (ArNH) 5-Trp α 1.8 3.8 2.83 0
5-Trp Indole 1 (ArNH) 5-Trp Indole 5,7 1.6 3.0 2.44 0
5-Trp Indole 1 (ArNH) 5-Trp δ 1.5 2.5 2.56 0.04
Average restraint violation: 0.01
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Lassomycin NMR and MALDI LIFT
spectra
The following NMR and MS characterization is included for lassomycin
(Chapter 3)
B.1 Fmoc-Asp(OtBu)-Ile-OMe (30) 1H NMR spectrum 184
B.2 Fmoc-Asp(OtBu)-Ile-OMe (30) 13C NMR spectrum 185
B.3 Fmoc-Asp(OH)-Ile-OMe (34) 1H NMR spectrum 186
B.4 Lassomycin (24) MALDI LIFT-TOF/TOF mass spectrum 187
B.5 Linear (uncyclized) lassomycin (25) MALDI LIFT-TOF/TOF mass
spectrum 188
B.6 Overlay of lassomycin 1H-13C HSQC NMR spectra 189
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Figure B.1: 1H NMR spectrum of Fmoc-Asp(OtBu)-Ile-OMe (30) recorded at 700 MHz (CDCl3).
184
Figure B.2: 13C NMR spectrum of Fmoc-Asp(OtBu)-Ile-OMe (30) recorded at 176 MHz (CDCl3).
185
Figure B.3: 1H NMR spectrum of Fmoc-Asp(OH)-Ile-OMe (34) recorded at 700 MHz (CDCl3).
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Appendix B. Lassomycin NMR and MALDI LIFT spectra
Figure B.4: MALDI LIFT-TOF/TOF mass spectrum showing fragmentation of
lassomycin (24) with ions labelled.
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Figure B.5: MALDI LIFT-TOF/TOF mass spectrum showing fragmentation of linear
(uncyclized) lassomycin (25) with ions labelled.
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Appendix B. Lassomycin NMR and MALDI LIFT spectra
Figure B.6: Overlay of 1H-13C HSQC (heteronuclear single-quantum correlation)
NMR spectra of naturally isolated [13C, 15N]lassomycin at 40 ◦C (green), and synthetic
lassomycin (24) at 25 ◦C (blue) and 40 ◦C (red).
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Appendix C
Synthesis of the POLARIS peptide:
A regulator of ethylene signalling
in Arabidopsis
S ynthetic peptides can be useful in elucidating the role of a given geneproduct in a biological system in order to complement genetic studies.The following chapter describes the synthesis of a peptide found toregulate ethylene signalling in the plant Arabidopsis, and the effect of
the synthetic peptide on root length in both wild type and mutant seedlings.
C.1 Introduction
Food security is a pressing issue facing societies worldwide.239 With the global
population projected to rise to over 9 billion by 2050, it is vitally important
to ensure sufficient food crops can be grown in increasingly drought-affected
or nutrient-stressed environments.240 Genetic engineering offers a potential
solution to this problem, as it can be used to create plant lines which produce
deeper root systems or make more efficient use of available water.241,242 A
detailed genetic understanding of plant physiology is therefore crucial, and
much of the current research effort is focused on elucidating the processes
governing root growth and the mechanisms by which root shape and structure
are regulated.
Root growth is controlled by a number of plant hormones including auxin
and ethylene. Although the molecular mechanisms behind this interplay are
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not well understood, ethylene is thought to regulate growth by achieving local
activation of the auxin signalling pathway.243 A summary of ethylene signalling
and the receptors involved is given in the following section.
C.1.1 Ethylene signalling
Ethylene is perceived by a family of receptor complexes which are associated
with or lie within the endoplasmic reticulum (ER) membrane.244 As a gaseous
hormone, ethylene diffuses into and out of cells and so can be detected at
the ER, which is not a typical site for receptor-ligand binding. A five-member
family of ethylene receptors is responsible for ethylene sensing in the model
organism Arabidopsis thaliana, composed of ETR1, ERS1, ETR2, ERS2, and
EIN4.245 The C-terminal half of ETR1 has been shown to be important as a
docking site for the kinase CTR1, a downstream negative regulator of the
ethylene pathway.245
A three-state model for ETR1 receptor signalling, including the involvement
of CTR1, is shown in Figure C.1. As indicated, the presence of copper
is important – the copper transporter RAN1 has been demonstrated to be
essential for ethylene-binding activity, and is thought to play a role in the
delivery of copper to ethylene receptors.246
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Figure C.1: A three-state model for ETR1 receptor signalling. The ethylene binding domain of ETR1 is shown as a disulfide-
stabilized homodimer anchored in the ER membrane by three α-helical domains on each monomer. Copper(I) and ethylene
are shown binding to regions demonstrated to be important in mutation studies. Upon ethylene binding the receptor adopts
an intermediate conformation in which it is still transmitting a signal. The third equilibrium state, where the receptor is turned
off, leads to diminished activity of CTR1. CTR1 negatively regulates the ethylene response, thus in the third state inhibition of
downstream signalling is released. Adapted from Mudge and Lacey et al.247,248
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C.1.2 The Arabidopsis POLARIS (PLS) peptide
The POLARISI (PLS) gene from Arabidopsis thaliana is required for correct
root growth (cell division and elongation) and root architecture (lateral root
formation).249 PLS encodes a peptide of 36 amino acids in length, and
pls mutants exhibit a phenotype with reduced root length. Furthermore,
PLS is required for correct control of several ethylene-mediated responses,
including growth in the dark, microtubule dynamics and auxin transport and
homeostasis.
A model proposed by Chilley et al. for the interaction of PLS with the
ethylene and auxin signalling pathways, and its function in root growth, is
shown in Figure C.2. According to the model, treatment with ethylene results
in a decrease in the concentration of auxin in the root tip which in turn leads to
a reduction in PLS transcription, allowing ethylene to alter root architecture (for
example leading to the production of thicker roots and fewer lateral roots).249
Auxin signalling from the shoot would act antagonistically by increasing PLS
transcription, thus PLS is suggested to act as a modulator of the auxin-ethylene
interaction. This interaction is thought to affect root cell division and shape –
and therefore root growth – through effects on the cytoskeleton.
Due to the importance of PLS in the mediation of crosstalk between auxin
and ethylene signalling, and by extension for the regulation of root growth
and architecture, it was decided that direct action of the PLS peptide upon
Arabidopsis root growth should be investigated. For this reason a chemical
synthesis of PLS was proposed, in order that sufficient quantities of PLS
could be produced for use in root growth assays. Crucially, access to the
synthetic peptide also allows the facile generation of mutant and truncated PLS
analogues, with which regions of the sequence or specific residues essential
for activity can be identified. Synthesis and testing of PLS and PLS analogues
is described in the following sections.
C.2 Synthesis of PLS, truncations and mutants
The full length PLS sequence (87a, Figure C.3) was synthesized via automated
MW-SPPS on polystyrene Wang resin preloaded with the C-terminal amino
acid histidine. Truncated sequences (also shown) were synthesized in order to
INomenclature used in this chapter as follows: POLARIS (PLS) refers to the peptide
product of the POLARIS (PLS) gene, polaris (pls) refers to the mutant (short-root phenotype).
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Figure C.2: Model for PLS interaction with ethylene and auxin signalling, and its
function in root growth. Auxin plays a role in cytoskeleton dynamics, cell division, and
cell expansion, while ethylene suppresses these effects. Auxin is a positive regulator of
PLS expression, and PLS suppresses the effects of ethylene. The relationship between
the inhibitory effects of ethylene on cytoskeleton dynamics (dotted line) and auxin
transport are unclear mechanistically. Adapted from Chilley et al.249
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investigate which sections of the sequence are essential for biological function.
Truncations 87d and 87e were synthesized using Rink amide resin to give
an amide instead of an acid group at the C-terminus. A C-terminal amide
was assumed to be more similar to the internal amide bond present at the
corresponding point in the parent sequence, in contrast to an carboxylic acid,
which would carry a negative charge. In a similar manner, truncation peptides
87b and 87c were N-terminally acetylated via on-resin treatment with acetic
anhydride in order to remove the charge on the N-terminal amine group. Ser
and Ala mutants (peptides 87f and 87g) were also synthesized to investigate
the effect of removing cysteine residues (and any associated potential for
disulfide bonding or coordination to metal centres) from the peptide (see
below). Correct masses for the PLS peptides were confirmed by MALDI-TOF
MS.
Figure C.3: The sequence of the PLS peptide (87a), in addition to those of the
truncations 87b–e and mutant 87f (in which the Cys residues have been replaced by
Ser) that were synthesized. Peptides 87b and 87c are acetylated at the N-terminus,
and 87d and 87e are C-terminally amidated.
C.3 Effect of synthetic peptides on root growth
The synthetic peptides were tested on both wild type (C24) Arabidopsis
seedlings, and the loss-of-function pls mutant (in which the PLS peptide is
absent) to investigate their effects on root growth (Anna Mudge, Durham).247
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Seedlings were grown for 10 days in liquid growth medium supplemented
with full length PLS (87a), truncation peptides 87b–e, or no peptide. Mean
primary root length after 10 days is plotted in Figure C.4.
Figure C.4: Mean primary root length of wild type and pls mutant seedlings treated
with peptides 87a–e (50 nM final concentration, 0.01% DMSO v/v) at 10 days after
germination. Error bars show ±1 standard error.
The primary root length of the wild type does not change significantly with
the addition of full length PLS (87a) or any of the truncated peptides (87b–e).II
In contrast, there is a significant effect on the pls mutant upon addition of PLS
peptides,III with 87a and PLS(1-22) (87d) significantly increasing the primary
root length (Tukey’s HSD test).247
Both full length 87a and PLS(1-22) (87d) were shown to rescue root length
in the pls mutant, whereas PLS(1-9) (87e) and PLS(13-36) (87c) were not. As
almost all of the sequence of 87d is overlapped by both 87c and 87e (see
Figure C.3), it was suggested that the presence of both Cys residues may be
important for activity, a characteristic shared by all peptides found to rescue
root growth.
To investigate the role of the Cys residues, the effect of Ser mutant 87f on
root growth was examined. (Ala mutant 87g was not available at the time the
IIAnalysis of variance F(5, 121) = 1.6, p = 0.16.247
IIIAnalysis of variance F(5, 112) = 6.13, p = 4.65 × 10−5.247
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assay was carried out and will be tested in the future.) Mean primary root
length after 10 days is plotted in Figure C.5.
Figure C.5: Mean primary root length of wild type and pls mutant seedlings treated
with full length PLS (87a) and mutant 87f (100 nM final concentration, 0.01% DMSO
v/v), at 10 days after germination. Error bars show ±1 standard error.
The PLS peptide lacking the two Cys residues (87f) did not exhibit the
same activity in Arabidopsis roots as the unmodified peptide (87a). While the
mean primary root length did not change significantly for the wild type when
treated with either 87a or 87f,IV the pls seedlings were significantly affected.V
However, only the unmodified full sequence (87a) significantly affected the
mean pls root length (Tukey’s HSD test).247 The presence of both Cys residues
is therefore required for PLS function.
C.4 Conclusions and future work
PLS, a peptide found to be important in the regulation of root growth and
architecture in Arabidopsis thaliana, was chemically synthesized, and sufficient
IVAnalysis of variance F(2, 58) = 2.42, p > 0.05.247
VAnalysis of variance F(2, 51) = 9.48, p = 3.15 × 10−4.247
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quantities were obtained to evaluate its effect on Arabidopsis seedlings in a
root growth assay. The synthetic route to full length PLS (87a) also allowed
access to a number of truncation peptides (87b–e), which were used to look
for regions in the PLS sequence important for activity. Both 87a and the
truncation 87d were shown to rescue root growth in the pls mutant, and due
to a lack of activity for all other peptides, it was suggested that the two cysteine
residues present only in the active sequences were responsible for their ability
to rescue root growth.
Mutants 87f and 87g, in which the cysteines were replaced by Ser or Ala
respectively, were synthesized. Peptide 87f was found to lack any ability
to rescue root growth, supporting the hypothesis that the Cys residues are
essential. (The activity of 87g will be evaluated in future assay work.) These
results suggest that the presence of both Cys residues in the sequence of
PLS is necessary for its function, which may be related to cysteine’s ability
to coordinate metal ions. Considering the importance of copper binding in
ethylene receptor signalling (discussed previously), is it suggested that PLS
may potentially modulate the availability of copper at the ethylene receptor,
and further work is underway in the Lindsey group to investigate this.247
PLS may exert its effect on ethylene signalling by decreasing the availability
of copper at the ETR1 receptor in order to prevent ethylene binding, thus
maintaining the receptor in its ‘on’ state and negatively regulating the
downstream ethylene response (see Figure C.1).247 Future work will involve
investigation of the interaction between copper(I) and PLS using circular
dichroism spectroscopy and crystallization studies.
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Pep-Calc.com J. Comput. Aid. Mol.
Des. article
The following article describing the web utility presented in Chapter 6 was
published in the Journal of Computer-Aided Molecular Design.
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Pep-Calc.com: a set of web utilities for the calculation of peptide
and peptoid properties and automatic mass spectral peak
assignment
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Abstract The ability to calculate molecular properties
such as molecular weights, isoelectric points, and extinc-
tion coefficients is vital for scientists using and/or synthe-
sizing peptides and peptoids for research. A suite of two
web utilities: Peptide Calculator and Peptoid Calculator,
available free at http://www.pep-calc.com, are presented.
Both tools allow the calculation of peptide/peptoid chem-
ical formulae and molecular weight, ChemDraw structure
file export and automatic assignment of mass spectral
peaks to deletion sequences and metal/protecting group
adducts. Peptide Calculator also provides a calculated
isoelectric point, molar extinction coefficient, graphical
peptide charge summary and b-strand contiguity profile
(for aggregation-prone sequences), indicating potential
regions of synthesis difficulty. In addition to the unique
automatic spectral assignment features offered across both
utilities, Peptoid Calculator represents a first-of-a-kind
resource for researchers in the field of peptoid science.
With a constantly expanding database of over 120 amino
acids, non-natural peptide building blocks and peptoid
building blocks, it is anticipated that Pep-Calc.com will act
as a valuable asset to those working on the synthesis and/or
application of peptides and peptoids in the biophysical and
life sciences fields.
Keywords Peptide  Peptoid  Calculated properties 
Automatic mass assignment  ChemDraw export 
Calculator
Introduction
Convenient and rapid access to calculated molecular
properties is essential for researchers using and/or synthe-
sizing peptides and peptidomimetics for biophysical or life
sciences applications. Furthermore, the process of assign-
ing peptide byproducts in mass spectra resulting from
residue deletions or incomplete protecting group removal
during a synthesis can be a laborious and time consuming
process, and access to freely available automatic assign-
ment tools is necessary to improve workflow and increase
research efficiency. While a plethora of peptide and protein
property calculation tools are accessible online, very few
offer mass spectral peak assignment functionality, and for
those that do this is often extremely limited.
While the ExPASy portal [1] acts as the most compre-
hensive protein property calculation resource for molecular
biology, other more specific tools exist, such as ChemCalc
[2], PredictProtein [3], IMSPeptider [4], POTAMOS [5],
Top Pred [6], CheckMyMetal [7], AFAL [8] and a host of
other peptide property calculation utilities [9–16]. Few of
these are designed specifically with the synthetic peptide
chemist in mind however, and furthermore, to the best of
our knowledge, no freely available web services exist for
the calculation of peptoid molecular properties or assign-
ment of peptoid synthesis mass spectra.
We present a pair of web tools: Peptide Calculator and
Peptoid Calculator, for chemical formula and molecular
weight calculation of peptides and peptoids. In addition,
both sites offer automatic assignment of mass spectral
peaks to deletion sequences, metal ion adducts and pro-
tected byproducts, as well as the option to download
structures in ChemDraw format for the sequences entered.
Peptide Calculator can also give calculated values for
isoelectric point and molar extinction coefficient (at
& Sam Lear
contact@pep-calc.com
1 Department of Chemistry, Durham University, South Road,
Durham DH1 3LE, UK
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280 nm), as well as a plot of calculated b-strand propensity
for the sequence. Both utilities are available at http://www.
pep-calc.com.
Features summary
Sequence input
Peptide and peptoid sequences up to 150 residues in length
can be entered, containing any combination of amino acids
or peptoid building blocks present in the database. For
peptides, the input string may include any of the standard
single-letter amino acid codes in addition to a number of
‘nonstandard’ residues (such as phosphoserine, pS), which
must appear in parentheses within the string. An equivalent
set of single-letter codes does not exist for peptoid building
blocks, therefore Peptoid Calculator instead accepts a
string of residue codes separated by dashes, without the
requirement for multiple-letter codes to be enclosed in
brackets. As peptoids can often consist of repeating motifs,
Peptoid Calculator additionally allows parentheses to be
used to indicate repeat sequences within the input string.
Peptide and peptoid sequence input options are summa-
rized in Fig. 1.
Both utilities also offer the option of specifying for-
mulae for the N- and C-termini of the input sequence.
These can be entered as a custom molecular formula string,
or selected from lists of predefined formulae (Fig. 1). A full
list of available residue types (showing residue code,
molecular formula and molecular structure) and predefined
termini available on Peptide Calculator and Peptoid Cal-
culator is given on each site’s Help page.
Afinal (optional) inputfieldcanbeused to specifym/zvalues
belonging to singly-charged species in mass spectra, for auto-
matic assignment to peptide or peptoid deletion sequences and/
or adducts (described below).
Fig. 1 Summary of input options available for Peptide Calculator and
Peptoid Calculator. Sequences can be specified using a large variety
of residue types, and Peptoid Calculator also accepts input strings
containing repeating sequence motifs indicated by nested
parentheses. Termini formulae can be selected from available options
and are also fully customizable. Optionally, m/z values can be
specified for automatic peak assignment
J Comput Aided Mol Des
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Calculated parameters
Both utilities will provide a molecular formula and calcu-
lated molecular weight for peptide/peptoid sequences
entered, in addition to an automatically generated Chem-
Draw structure in .cdxml format (Fig. 2). A spectral
assignment for the peptide/peptoid will also be given if
m/z values were provided as part of the input.
An example of an automatic peak assignment is illus-
trated in Fig. 3 (assignment output shown in Table 1). A
number of peaks are present in the spectrum and have been
assigned to either deletion sequences (where one or more
residues are missing from the target sequence), sequences
with unremoved protecting groups, metal adducts or a
combination of two or more of the conditions described.
Peptide Calculator and Peptoid Calculator will attempt to
assign any m/z values provided to either the target sequence
or a formula containing single or multiple residue dele-
tions, metals, unremoved protecting groups or any combi-
nation thereof.
A number of calculated parameters specific to peptides
are also available. Peptide Calculator will provide esti-
mated values for sequence isoelectric point and molar
extinction coefficient (at 280 nm), as well as a pie
chart summarizing proportions of acidic, basic and
uncharged residues in the sequence (Fig. 2). For sequences
that are 10 residues or longer in length, a b-strand conti-
guity profile is calculated (Fig. 2). This provides an
ab initio prediction of the location of b-strand forming
regions within the sequence, and hence may offer an
indication of aggregation-prone sequences, or those which
are likely to present difficulties during synthesis.
Methods
Peptide Calculator and Peptoid Calculator make use of a
database each containing either amino acids or peptoid
building blocks defined by residue codes (single- or mul-
tiple-letter) and accompanying molecular formulae.
Molecular weights are calculated by reference to a table of
atomic masses (most abundant isotope). Methods used to
generate other calculated parameters are described below.
All Pep-Calc.com functionality is scripted using an
extensible framework written in the Python programming
language, and the site is accessed using an HTML web
interface. Residue formulae can be added to either database
upon request.
Isoelectric point and molar extinction coefficient
calculation
Theoretical peptide isoelectric points are calculated using
the bisection method described by Kozlowski [17–19]. The
net charge of the peptide can be found using the Hender-
son–Hasselbalch equation, taking into account
Fig. 2 Both Peptide Calculator
and Peptoid Calculator will
output a number of basic
calculated properties, in
addition to a peak assignment
and ChemDraw structure file for
the sequence. A number of
additional parameters are also
provided for peptides, including
estimated isoelectric point and
molar extinction coefficient, as
well as a graphical residue
charge summary and b-strand
contiguity profile
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contributions from negatively and positively charged
groups (first and second terms in Eq. (1) respectively,
where Ka is the acid dissociation constant of the amino
acid).
charge ¼
X 1
1þ 10pKapH þ
X 1
1þ 10pHpKa ð1Þ
As the isoelectric point (pI) represents the pH at which
the net charge of the peptide equals zero, finding the root of
this equation (in this case numerically, using the bisection
method) gives the pI (or pH at zero charge).
Peptide Calculator takes into account side chain charge
contributions from Arg, Asp, Cys, Glu, His, Lys and Tyr
residues, in addition to the N-terminal amine and C-ter-
minal carboxyl groups (only if the terminus types are set to
‘Unmodified’ and ‘Acid’ respectively). Other residue side
chains are not taken into account for pI estimation, and are
designated ‘Other’ in the charge summary pie chart.
Molar extinction coefficients are estimated using
Eq. (2), described by Pace et al. [20]. The formula takes
into account numbers of Trp and Tyr residues in the pep-
tide (nTrp and nTyr respectively), in addition to the number
of cystine residues (ncystine) formed via disulfide bond for-
mation between pairs of cysteine side chains (reduced
cysteine residues do not contribute significantly to the
absorbance above 275 nm [20]).
e280 M
1cm1 ¼ 5500nTrp þ 1490nTyr þ 125ncystine ð2Þ
Peptide Calculator outputs two values for e280, calcu-
lating the theoretical molar extinction coefficient based on
either formation of the maximum number of disulfide
bonds possible (ncystine equal to the number of cysteine
residue pairs), or complete reduction resulting in the
absence of disulfides (ncystine ¼ 0).
Automatic mass spectral peak assignment
User-entered m/z values are assigned through the process
summarized in the flowchart given in Fig. 4. Pep-Calc first
compiles lists of possible single-amino-acid deletions and
single modifications (metal adducts and unremoved pro-
tecting groups), including null entries for no deletion or no
modification. A complete set of combinations of these lists
is then generated, and the molecular weight of the peptide/
peptoid sequence incorporating each combination of single
deletion and/or single modification calculated. Each input
peak is then compared against the list of molecular
weights, and a peak is assigned to a particular peptide if it
falls within ±1.0 u of the calculated molecular weight of
the peptide.
In the event that all the input peaks are not assigned on
the first pass, Pep-Calc calculates the molecular weights for
all peptide/deletion/modification combinations incorporat-
ing single or double deletions and single or double modi-
fications, and checks remaining peaks against these
(omitting already assigned peaks). This process is repeated
until all peaks are assigned, or until up to the maximum
allowed number of deletions/modifications have been
checked. To prevent excessive computation times the
Fig. 3 Example spectrum automatically assigned by Peptide Calcu-
lator (assignment is also available for Peptoid Calculator). A number
of single- and multiple-residue deletions have been identified, in
combination with sodiation and/or unremoved 2,2,4,6,7-pen-
tamethyldihydrobenzofuran-5-sulfonyl (Pbf) protecting groups. The
ethyl 3-mercaptopropionate thioester is available as a predefined
C-terminus and can be selected during sequence input
Table 1 Example peak assignment output (sequence and mass
spectrum shown in Fig. 3). For each peak specified by the user, a set
of all possible combinations of residue deletions and/or adducts
agreeing with that m/z value are provided, in addition to a calculated
mass for each suggestion
Peak (m/z) Deletion(s) Adduct(s) Calculated mass
1063.7 R, S Na? 1063.52
1197.8 S – 1197.64
1315.9 R, S Na?, Pbf 1316.52
1450.0 S Pbf 1450.64
1537.0 – Pbf 1537.67
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maximum number of deletions/modification depends on
the sequence length, and is set at 5 iterations for sequences
up to 30 residues in length, 4 for 60-mers and 3 up to the
maximum 150 residue sequence input.
Calculation of sequence b-strand propensity
b-Strand contiguity profiles for peptides greater than 9
residues in length are calculated using an implementation
of the simple algorithm for sliding averages (SALSA)
described by Zibaee et al. [21]. A window of size 4 resi-
dues is scanned across the input sequence and each frag-
ment within the window scored using Eq. (3), where Pa; Pb
and Pt are the Chou–Fasman secondary structure proba-
bility parameters (for a-helix, b-strand and reverse turn
preference, respectively) [22]. This process is repeated for
all window sizes up to 20 residues or the sequence length
(whichever is reached first), and all fragments with scores
lower than 1.2 are discarded.
fragment score ¼
P
Pb
1
2
P
Pa þ
P
Ptð Þ
ð3Þ
b-Strand propensity values are then calculated for each
residue in the sequence by summing the scores of all
remaining windows which contain the residue. These final
values are then plotted to produce a b-strand contiguity
profile for the peptide. Chou–Fasman parameters are only
available for the 20 canonical amino acids and hence only
these are taken into account when calculating b-strand
propensity values.
It should be noted that b-strand propensity alone may
not be indicative of aggregation likelihood or sequence
difficulty. In addition, ab initio secondary structure pre-
diction methods based on probability parameters alone can
START, N = 1
Make list of possible
0, 1, ..., N deletions and
list of possible 0, 1, ..., N
modifications for the sequence
Find all combinations possible
choosing one item from each list
Calculate the molecular weight
(MW) of each combination of
deletion(s) and modification(s)
when applied to the sequence
(Re)input
unassigned
peaks
Compare peaks to MW
list, assign peak to
peptide if MW is within ±1.0 u
All peaks assigned?
N at maximum limit?
Output
assigned
peaks
N = N + 1
END
yes
no
yes
no
Fig. 4 Flowchart summarizing the mass spectral peak assignment
algorithm used by Peptide Calculator and Peptoid Calculator.
Residues missing from the expected full sequence are termed
‘deletions’ and any other atom or group that causes a change in the
molecular weight of the sequence (including metal adducts and
unremoved protecting groups) is termed a ‘modification’. Which
deletions and modifications are allowed depends on the residues
present in the sequence (unremoved Pbf protecting groups, for
example, are only permitted for Arg residues). Only sequences
bearing a single deletion and/or a single modification are considered
on the first iteration (N = 1), increasing to two of each on the second
etc. The maximum allowed value for N depends on the length of the
input sequence, and is set at 5 iterations for sequences up to and
including 30 residues in length, 4 up to 60 residues and 3 up to the
maximum 150 residues
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in some cases give false predictions or fail to predict
regions of a given secondary structure. SALSA was chosen
with speed in mind, and for this reason the calculated
profile is intended to serve only as a guide.
Conclusions
Peptide Calculator and Peptoid Calculator form a set of full
featured, freely available web utilities for peptide and
peptoid molecular property calculation and mass spectral
peak assignment. Modern peptide research demands tools
that can handle residue types beyond the canonical amino
acids (such as phosphorylated peptide building blocks [23–
25]), and with unique spectral assignment capabilities and
an expanding amino acid database Peptide Calculator
offers a service beyond that of current freely available web
utilities. Furthermore, similar services for peptoid research
are non-existent, and Peptoid Calculator represents a first-
of-a-kind resource for researchers in the field of peptoid
science. The tools described have found broad application
in our lab, and are used frequently in peptide and peptoid
research activities [26–28]. It is anticipated that Pep-
Calc.com (http://www.pep-calc.com) will act as a valuable
asset to those synthesizing and/or using peptides or pep-
toids as part of their research in the biophysical and life
sciences fields.
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